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Purpose.  5-HMF is a potential antisickling agent forming a Schiff-adduct with 
hemoglobin (Hb). In-vitro studies were designed to identify the metabolic pathways of 5-
HMF in human hepatic cytosol, to assess inter-species differences in its hepatic 
metabolism, and to predict in-vivo PK properties. Moreover, metabolism of 5-HMF in 
human RBCs was investigated. Finally, in-vitro studies were done to characterize 5-HMF 
binding kinetics with human Hb and albumin (HSA). 
 
 xxx 
 
Methods. NAD+ reduction was monitored at 340 nm in human hepatic cytosol for 5-HMF 
(26 mM) and prototypical ADH and ALDH substrates in the presence or absence of their 
inhibitors. Furthermore, concentration-dependency studies were performed for 5-HMF 
(1.5-96 mM) in mouse, rat, dog, and human hepatic cytosol and fitted by Michaelis 
Menten (MM) model. In-vitro-in-vivo-extrapolation (IVIVE) was performed using the 
well-stirred model. Moreover, metabolic studies of 5-HMF (12-142 mM) in human RBCs 
were done under similar conditions. 
Time- and concentration-dependent binding studies were conducted for 5-HMF (5 µM-5 
mM), in Hb (217 μM) and  HSA (6 3 and 202 μM) solutions. Ultrafiltered 5-HMF 
concentrations were measured by a validated HPLC-UV assay. After correction for 
nonspecific binding, rate constants, binding affinity, and capacity were estimated by 
nonlinear regression. 
 
Results.  In human hepatic cytosol, 5-HMF followed MM kinetics with Km: 218(±74) mM 
and was mainly inhibited by the ALDH inhibitor. In all animal species, 5-HMF exhibited 
millimolar Km values and is expected to have low hepatic extraction, high oral 
bioavailability, and first-order PK for relevant blood concentrations. The IVIVE-predicted 
in-vivo half-lives for 5-HMF were adequate for the mouse and dog but overestimated for 
humans. In RBCs, 5-HMF had Clintin-vitro of 0.34(± 0.02) ml/min/ml RBCs scaled-up to 9.9 
ml/min/kg.  
Time-dependent binding of 5-HMF was demonstrated for both Hb and HSA. Steady-state 
studies revealed saturable Hb binding and non-saturable HSA binding.   
 xxxi 
 
Conclusions. 5-HMF is an ALDH/ADH substrate in hepatic cytosol. Across animal 
species, 5-HMF is expected to be a low-hepatic-extraction-ratio drug with high oral 
bioavailability. 5-HMF is subject to RBCs metabolism in human. 5-HMF is expected to 
show fast association with, but slow dissociation from its drug target, Hb, which may lead 
to a prolonged in-vivo PD effect. 
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CHAPTER 1 
1  
INTRODUCTION 
 
 
1.1 Sickle Cell Disease 
 
1.1.1 Prevalence  
 
Sickle cell disease (SCD) is one of the most common inheritable genetic diseases 
worldwide (Niscola 2009) (Wahl 2009). SCD is affecting 1 in every 375 African-American 
births in the USA, 100,000 patients in the general USA population, and it has an estimate of 20-
25 million patients in the world (Aliyu 2008) (Driscoll 2007) (Bolaños-Meade 2009) (Field 
2009). The frequency of SCD is becoming more uniform through the world because of the 
immigration of patients to countries with low SCD incidence history (Niscola 2009).  
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1.1.2 Pathogenesis 
 
The pathogenesis of the disease reveals a substitution of the normal GAG codon with 
GTG resulting in the expression of sickled hemoglobin (HbS) rather than adult hemoglobin 
(HbA), where glutamic acid amino acid is replaced by valine amino acid at the sixth position of 
β-globin protein in patients with SCD (Niscola 2009) (Smiley 2008) (Wahl 2009). The resultant 
HbS is less stable and less soluble than the normal HbA (Niscola 2009). Consequently, the 
typically flexible doughnut shape of red blood cells (RBCs) is altered to stiff crescent-like RBCs, 
in which Hb is likely to polymerize upon uploading its oxygen content (Vekilov 2007). 
Furthermore, patients with SCD might be affected by other hemoglobin abnormalities, such as 
thalassemia, and the resultant syndrome is dependent of the accompanying defect (Niscola 
2009).  
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1.1.3 Complications 
 
The quality of life of SCD patients ranges from normal asymptomatic life to one with 
frequent hospitalization (Niscola 2009). Besides leading to anemia as a result of abnormal RBCs 
destruction, SCD is associated with other complications due to the abnormal shape of RBCs. 
Infection is an important problem faced by SCD patients and can be severe enough to cause 
death, e.g. pulmonary infections. Furthermore, the tendency of HbS to polymerize upon 
deoxygenation results in vascular occlusion (Driscoll 2007). Because of that, acute 
manifestations like acute splenic sequestration and vaso-occlusive pain crises occur, which is the 
predominant symptom in SCD patients (Niscola 2009). Niscola and co-workers reported that 
while 39% of SCD patients had no pain crises, 5.2% of the patients had 3-10 annual pain 
episodes (Niscola 2009). The pain crises were found more frequent in adults than in children and 
were associated with higher hematocrit and lower fetal hemoglobin (HbF) percentage (Field 
2009). Overall, approximately 90% of SCD patients’ hospitalizations are due to the pain 
episodes that they encounter (Niscola 2009). Other consequences of RBC deformation are 
chronic organ damage, cerebrovascular disease, and pulmonary hypertension (Smiley 2008) 
(Driscoll 2007). Because of the chronic nature of SCD and frequent hospitalization, some 
patients suffer from psychological illnesses as well (Niscola 2009).    
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1.1.4 Sickle Cell Disease Treatments  
 
1.1.4.1 Non-Opioid Analgesics 
 
Mild to moderate pain is managed by acetaminophen and non-steroidal anti-inflammatory 
drugs (NSAIDs) in a pathway that leads to desensitizing of the nociceptors responsible for pain, 
with an advantage of the latter in having an anti-inflammatory effect (Niscola 2009). In severe 
pain cases, these are combined with opioids to decrease the dose that would be required if 
opioids were used alone (Field 2009) (Niscola 2009). On the other hand, NSAIDs inhibit the 
basal levels of prostaglandin and may lead to renal and cardiovascular toxicity (Niscola 2009). 
Moreover, aspirin is avoided in children due to the risk of Reye’s syndrome (Niscola 2009).   
 
1.1.4.2 Opioids  
 
Opioids represent an approach for providing an immediate relief of acute pain episodes 
(Field 2009). The presence of multiple choices in this class acting on different opioid receptors, 
ranging from weak agonists, e.g. codeine, to strong agonists, e.g. morphine, and formulated in 
different dosage forms offers an advantage that encourages clinicians to prescribe them for SCD 
patients (Niscola 2009) (Field 2009). However, the misuse of these drugs leading to drug 
dependence is an immense disadvantage in their therapy (Niscola 2009). In addition, if not 
cautiously administered, opioids may cause death by respiratory depression (Niscola 2009).  
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1.1.4.3 Hydroxyurea  
 
Currently, hydroxyurea is the only Food and Drug Administration (FDA) approved 
therapeutic agent for the treatment of SCD (Charache 1997) (Lanzkron 2008). Its disease-
modifying properties are a result of its ability to induce HbF production by unclear mechanism 
of action (Lanzkron 2008). HbF has a higher oxygen affinity than that of HbA (Lanzkron 2008). 
The protective effect of a relatively higher fraction of HbF in some SCD patients is demonstrated 
in lower pain episode rates, as discussed in Section 1.1.3 (Niscola 2009). In addition, a two-year 
study with a maximum hydroxyurea daily dose of 35 mg/kg resulted in 3.5% increase in HbF 
and a decrease in the annual rate of pain crises (Lanzkron 2008). Upon a seven-year follow-up, it 
was observed that the mortality rate decreased by 40% (Lanzkron 2008). Unfortunately, 
hydroxyurea was associated with reproductive toxicity in male mice and developmental toxicity 
in rat and mice fetuses (Lanzkron 2008). In addition, chronic administration of this agent was 
associated with leukemia, lymphoma, and skin hyperpigmentation (Lanzkron 2008).  
 
  
 6 
 
1.1.4.4 Stem Cell Transplant 
 
Other therapeutic approaches are mainly supportive and do not cure the disease with the 
exception of hematopoietic stem cell transplant, which is hindered by its eligibility criteria and 
the availability of suitable donors (Lanzkron 2008) (Driscoll 2007). The age of the ideal 
candidate for a bone marrow transplant is usually not more than 16 years and he should have 
suffered a major complication of SCD, such as stroke, neuropathy, and retinopathy. In addition, 
the donor should be a sibling having a matching lymphocyte antigen (Bolaños-Meade 2009). 
Besides, considering that children are the ones who are undergoing this surgery, families are 
often  worried about the mortality rates and morbidities affecting their growth and development 
(Bolaños-Meade 2009).  
 
1.1.4.5 Blood Transfusion:  
 
Blood transfusion is indicated for the management of anemia in SCD. The aim of blood 
transfusion is to dilute HbS with normal blood and increase the life span of circulating RBCs 
(Wahl 2009). Yet, many complications are associated with this procedure, such as 
alloimmunization, infection, acute lung injury, and iron overload (Wahl 2009) (Porter 2007).  
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1.1.4.6 Non-Pharmacological Interventions 
 
Non-pharmacological and behavioral interventions constitute an important part in SCD 
treatment. Massage and relaxation were reported to decrease the pain rate (Niscola 2009). In 
addition, optimism and cognitive strategies are used to cope with pain and alter its perception in 
SCD patients (Niscola 2009).     
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1.2 5-HMF 
 
 
1.2.1 Exposure to 5-HMF  
 
5-HMF is a versatile ubiquitous compound, to which humans are exposed in industry, 
food, and pharmaceutical formulations. As shown in Figure 1-1, 5-HMF is a small (MW: 126 D) 
molecule with a pKa value of 12.8 (ACS 2009) that behaves as a neutral molecule at 
physiological pH range.    
 
The following are major areas, in which 5-HMF is involved:  
 
1.2.1.1 5-HMF in Industry 
 
As part of its utility, 5-HMF is used in the synthesis of resins, solvents, polymers, and 
plant protective agents (NTP 1994). In addition, 5-HMF is produced from biomass and is 
investigated as an alternative biofuel (Yong 2008). On the other hand, 5-HMF has a negative 
industrial interaction since it is considered as a potent inhibitor for ethanologenic bacteria growth 
and fermentation, which are used to produce ethanol (Liu 2006).  
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Figure  1-1. 5-HMF structure 
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1.2.1.2 5-HMF in Drug Formulations  
 
Human exposure to 5-HMF can occur through cigarette smoke and pharmaceutical 
syrups (NTP 1994). In addition, 5-HMF is found in pharmaceutical products mainly as a 
degradation product. As a review for its inadvertent presence, 5-HMF concentration in parenteral 
preparations was reported by Ulbricht et al. In this review, 5-HMF was detected at a 
concentration of 10 mg/l (Ulbricht 1984) and at a range of 0.2-200 mg/l of 5-HMF in parenteral 
solutions (Germond 1987). In addition, 5-HMF was identified in a study investigating impurities 
in a morphine sulfate formulation as a result of including the carboxylate salt of opioids and/or 
having an acidic formulation (Kelly 2003).  
Surprisingly enough, 5-HMF is an active ingredient of a microsupplement product, 
Sanopal (Matzi 2007). Currently, this product is marketed as a preoperative support for lung 
resection. Moreover, 5-HMF was identified as a therapeutic moiety in traditional Chinese 
medicines (Lin 2008) (Li 2005) (Xu 2007). 
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1.2.1.3 5-HMF in Food 
 
1.2.1.3.1 5-HMF FORMATION  
 
5-HMF can be found in foods as a result of Maillard reaction, which is a non-enzymatic 
reaction between free amino groups in protein and reducing sugars that is enhanced by high 
temperature. Moreover, caramelisation (dehydration) of reducing sugars catalyzed by high 
temperature and an acidic environment produces 5-HMF (Delgado-Andrade 2007) (M. P. 
Murkovic 2006) (Gaspar 2009).  
5-HMF consumption is affected by food selection and cooking processes (Delgado-
Andrade 2007). In a study conducted by Delgado-Andrade et. al., 5-HMF levels were correlated 
with thermal processing (frying vs. boiling) and sugar content (Delgado-Andrade 2007). It was 
found that the long heating time and temperature over 90 °C favor the production of furfurals, 
including 5-HMF (Cocchi 2008).  
Along with 5-HMF, 5-methylfurfural (5-MF) and 2-furfural (2-F) are found in food as a 
result of the Maillard reaction (Gaspar 2009). These compounds were identified as structural 
analogs for 5-HMF by the National Toxicology Program (NTP) at NIH (NTP 1994). In addition, 
5-hydroxymethyl-2-furoic acid (HMFA), which is an identified major metabolite of 5-HMF, was 
found in food along with 5-HMF (M. B. Murkovic 2007). A peak concentration of around 0.2 
mg/g and 0.9 mg/g coffee of HMFA and 5-HMF, respectively, were formed during a roasting 
process. The fact that HMFA levels peaked after the 5-HMF peak suggested that HMFA is a 
degradation product of 5-HMF (M. B. Murkovic 2007). However, further investigations 
proposed an alternative for the production of HMFA (M. B. Murkovic 2007).  
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1.2.1.3.2 5-HMF CONSUMPTION IN FOOD 
 
5-HMF is found in various types of food such as coffee, honey, biscuits, bread, juice, 
dried fruits, honey-wines, and cereals (Janzowski 2000) (Gaspar 2009) (Kahoun 2008) (Fallico 
2008) at concentrations ranging between 300-1900 mg/kg (M. P. Murkovic 2006). Moreover, 5-
HMF is present in traditional drinks such as barley tea, which is a common drink in Japan 
(Kulkarni 2008). Table 1-1 lists a number of foods with the estimated concentrations of 5-HMF 
and its primary metabolite (if data available). Considering its abundant presence, it is estimated 
that the daily consumption of 5-HMF ranges between 30-150 mg (Husøy 2008), which is within 
the reported acceptable daily intake of 2.5 mg/kg (Germond 1987). Furthermore, 5-HMF levels 
have been monitored in honey as an indicator for its quality with respect to overheating and 
aging (Gaspar 2009) (Fallico 2008). In addition, a limit of 0.08 mg/g of 5-HMF was reported to 
indicate potential adulteration (M. B. Murkovic 2007). Moreover, 5-10 mg/l and 25 mg/l are the 
recommendations by the International Federation of Fruit Juice Processors for 5-HMF 
concentration in fruit juice and fruit concentrate, respectively (Gaspar 2009).  
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Table  1-1. 5-HMF and HMFA concentrations in food. 
ND: not detected 
Food 5-HMF Content ( mg/kg) 
HMFA Content 
( mg/kg) Reference 
Dried apricot 30-780 - (M. P. Murkovic 2006) 
Dried pear 100 - (M. P. Murkovic 2006) 
Dried Peach 40 - (M. P. Murkovic 2006) 
Dried plum 1600-2200 - (M. P. Murkovic 2006) 
Dried plum jam 1100-1200 - (M. P. Murkovic 2006) 
Dried date 1000 - (M. P. Murkovic 2006) 
Dried fig 1 - (M. P. Murkovic 2006) 
Dried pineapple 280 - (M. P. Murkovic 2006) 
Dried apple 80 - (M. P. Murkovic 2006) 
Bread with dried fruits 450 - (M. P. Murkovic 2006) 
Baby food 22 - (M. P. Murkovic 2006) 
Coffee (ground, roasted) 300-1900 - (M. P. Murkovic 2006) 
Whole wheat biscuit 0.16 0.18 (Husøy 2008) 
Biscuits with chocolate and 
nuts 0.07 0.08 (Husøy 2008) 
Cappuccino with added 
sugar, instant powder 1.72-143 0.23-17.2 (Husøy 2008) 
Coffee instant 91.3-3060 5.6-174 (Husøy 2008) 
Ground coffee 262-547 40.3-130 (Husøy 2008) 
Bread 0.06-0.14 ND.07 (Husøy 2008) 
Narwegian brown cheese 0.08-0.21 ND (Husøy 2008) 
Rasberry jam 0.08 ND (Husøy 2008) 
Honey 0.34 0.05 (Husøy 2008) 
Dark beer 13.3 ND (Husøy 2008) 
Chocolate with nuts ND ND (Husøy 2008) 
Wine 0.84 g/l - (M. B. Murkovic 2007) 
Dried plum juice 1.6 g/l - (Gaspar 2009) 
Balsamic vinegar 1.2- 4.6 g/l - (Gaspar 2009) 
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1.2.2 5-HMF Mechanism of Action and Pharmacodynamics in Sickle Cell Disease 
 
Safo reported that 5-HMF is a potent agent in reducing the sickling of RBCs containing 
HbS (SS cells) (Safo 2004). The antisickling action of 5-HMF originates from its ability to form 
a Schiff base adduct through binding to the N-terminal α-valine amino acid (Abdulmalik 2005) 
(Safo 2004).  
Upon preincubation of 5-HMF in SS cells suspension (haematocrit= 20%), a left-shift in 
oxygen equilibrium curve (OEC) was observed, shown in Figure 1-2, as a result of increased 
affinity to oxygen (O2) in a dose-dependent manner (Abdulmalik 2005) (Safo 2004). 
1, 2, and 5 mM of 5-HMF were added to suspensions of RBCs containing HbS (SS cells) 
(the concentration of SS cells was not specified) and incubated for an hour under air, after which 
they were exposed to hypoxic conditions for 5 hours. Samples were taken at 0, 1, 2, 3, and 5 
hours to investigate the percentage of sickled cells using computer analysis (Abdulmalik 2005). 
5-HMF added immediately before exposing the cells to the hypoxic conditions was associated 
with lower survival of cells in comparison to those pre-incubated with 5-HMF, as shown in 
Figure 1-3. This might be attributed to the notion that Hb adduct with aldehydes takes 
approximately an hour to form (Abdulmalik 2005).  
The adduct formation in an in-vivo system was indicated by the appearance of a new peak 
in transgenic mice blood using anion-exchange chromatography at 215 nm after an oral 
administration of 5-HMF. 100% and 70% of Hb-adduct were formed in the transgenic mice after 
an hour of the oral administration of 100 and 50 mg/kg of 5-HMF, respectively. The peak 
remained for 3 hours followed by a gradual decrease. The peak was finally disappeared at 6 
hours (Abdulmalik 2005). It should be noted that for in-vitro determination of Hb-adduct, cation 
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exchange chromatography along with detection at 410 nm were used, as shown in Figure 1-4 
(Abdulmalik 2005).  
Further analysis was performed on the data reported by Abdulmalik et. al. in transgenic 
mice (Abdulmalik 2005). Concentrations of free hemoglobin, 5-HMF plasma concentrations, and 
the adduct formed over time were combined in a semi-quantitative plot, as shown in Figure 1-5. 
It is observed that there was a lag-time between the peak plasma concentration and that for the 
adduct.  
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Figure  1-2. Left-shift in oxygen equilibrium curve upon incubation with 5-HMF. (Abdulmalik 
2005) 
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Figure  1-3. In-vitro increased survival of RBCs with 5-HMF preincubation. (Abdulmalik 2005) 
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Figure  1-4. Hb-adduct formation. (Safo 2004) 
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Figure  1-5. Hb-adduct concentration vs 5-HMF plasma concentration. Data taken from 
(Abdulmalik 2005) 
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Figure 1-6 shows a linear regression analysis that was performed on 5-HMF 
pharmacological effect versus the reported concentration. The pharmacological effects were the 
inhibition of in-vitro RBCs sickling (6A) and the change in oxygen affinity (pO50) (6B). These 
effects were reported in suspensions of RBCs containing HbS that were pre-incubated for one 
hour with 0, 1, 2, and 5 mM of 5-HMF and exposed to hypoxic conditions (4% O2) for 5 hours 
(Abdulmalik 2005). The inhibition of sickling and the change in pO50 were proportional to the 
concentration of 5-HMF in the RBCs suspension. Thus, if a shift of 5-10 mmHg in pO2 is 
therapeutically targeted, a blood concentration of 1-2 mM (120-240 µg/ml) of 5-HMF would be 
required. This is supported by the results reported by Safo for in-vitro experiments,  where 1 mM 
and 2 mM of 5-HMF were used and resulted in a shift of -6.6 mmHg and -10.8 mmHg in pO2, 
respectively (Safo 2004). In concordance with that, a preliminary projection of a therapeutic 5-
HMF IV dose was made as 0.8-1.5 g achieving 100-200 µg/ml blood concentration (Venitz 
2006). 
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Figure  1-6. Blood PD after pre-incubation with 5-HMF. Estimated from (Abdulmalik 2005) (Safo 2004). 
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1.2.3 1.2.3 Other 5-HMF Pharmacological Activities 
 
Although 5-HMF occurs in herbs and fruits known to exhibit antioxidant effects, 5-HMF 
was reported not to have antioxidant activity (Prior 2006). On the other hand, a micronutrient 
supplement that contains 5-HMF along with α-ketoglutaric acid (α-KG) was reported to decrease 
oxidative stress and increase exercise capacity of athletes though they were declared to have no 
doping effect (Matzi 2007). Hence, its effectiveness as a pre-operative support for lung resection 
surgeries indicated by lung cancer was investigated (Matzi 2007). The pharmacological 5-HMF 
effect in this aspect was attributed to its ability to consume and interact with oxygen, hydroxyl, 
and superoxide radicals (Matzi 2007).  
It was reported that 5-HMF inhibits interleukins-1 β expression together with the tumor 
necrosis factor α (Michail 2007). Consequently, 5-HMF was involved in phase II clinical studies 
in combination with other substances as a cytostatic agent (Michail 2007). This might be related 
to the ability of 5-HMF to selectively inhibit terminal deoxynucleotidyltransferase (TdT) with an 
IC50 of 5 .5  µM and  DNA p oly merase λ with an IC50 of 26.1 µM in a competitive manner 
(Mizushina 2006). Mizushina et. al. reported that all of the investigated changes in the structure 
of 5-HMF resulted in activity loss (Mizushina 2006). This pharmacological activity of 5-HMF is 
relevant as an anticancer agent knowing that the inhibition of DNA polymerases is targeted by 
antitumor drugs (Miura 2004) and that TdT overexpression is reported in acute lymphocytic and 
myelocytic leukemias (Di Santo 2006). TdT is mainly expressed by the developing T and B-
lymphocytes in bone marrow and thymus (Di Santo 2006). On the other hand, DNA polymerase 
λ is expressed mainly in human ovaries, testis, and fetal liver (Di Santo 2006).  
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5-HMF was extracted from Dictyophora indusiata mushroom and proved to have anti-
tyrosinase activity. The mode of action was found through non-competitive inhibition of the 
enzyme with an ID50 of 0.98 mM that might be related to the formation of Schiff-base (Sharma 
2004). In this study, mushroom tyrosinase was used for this assay (Sharma 2004). Tyrosinase 
enzymes are involved in many important functions as melanin synthesis and undesired enzymatic 
browning of vegetables and fruits upon post harvest damage (Sharma 2004).  
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1.2.4 5-HMF Pharmacokinetics 
 
Following is an elaborate summary of the ADME properties for 5-HMF as described in 
the literature: 
 
1.2.4.1 Oral Absorption and Bioavailability 
 
Only 17% of a 100 mg/kg oral dose of 5-HMF was detected in mice intestine after 5 
minutes of administration, which rapidly decreased to 1% by 60 minutes (Czok, Tolerance of 5-
hydroxymethylfurfural (HMF). 2d communication: pharmacologic effects. 1970). This rapid 
disappearance indicated a rapid and complete absorption of 5-HMF assuming negligible 
chemical and metabolic degradation.   
The intestinal absorption of 5-HMF was investigated using Caco-2 cell lines. Breakfast 
cereals were used as a source of 5-HMF in addition to a 5-HMF standard (Delgado-Andrade 
2008). 5-HMF was subjected to stomach and intestinal digestion through continuous in-vitro 
mixing with gastric juice followed by intestinal enzymes and bile acids. This process was 
followed by assessment of 5-HMF concentration in the solution before adding it to the apical 
chamber of Caco-2 cell lines. It was found that only 13-56% of the 5-HMF content in the cereals 
was detected in the soluble fraction of the digest. When the digestion process was applied to 5-
HMF standard, only 61% of the initial 5-HMF concentration was detected in the soluble fraction 
of the digest. Then, the concentration of 5-HMF in the basolateral side was measured after 2 
hours of incubation. It was observed that 5-HMF did not affect the integrity of Caco-2 
monolayer. 17-68% of the 5-HMF spiked test solutions was detected in the basolateral side. 
Breakfast cereals had only 24-32% transported through the cell lines. In this study, 5-HMF was 
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suggested to be transported in the intestine through passive diffusion and transporters (Delgado-
Andrade, Estimation of hydroxymethylfurfural availability in breakfast cereals. Studies in Caco-
2 cells 2008).  
High oral bioavailability was pointed out by Abdulmalik et al. (Abdulmalik 2005), 
implying high fraction absorbed (fabs) and low first-pass effect. In addition, the low value of the 
apparent clearance (CLTot/Foral), estimated in that study, indicated a high Foral value and low first-
pass effect unless the actual clearance value was so low. The absolute Foral is calculated with 
reference to an IV administration of the drug, as illustrated by Equation 1-1, for the same dose 
(Hurst, 2007):  
 Foral = AUCoralAUCIV ...............................................................................................................Equation 1-1  
 
Where, Foral is a composite of the drug fraction absorbed through the GI (not metabolized, 
degraded, and/or subject to efflux transporters) (fg) and the fraction that escapes the pre-systemic 
hepatic metabolism (fh). Thus, Foral can also be described by Equation 1-2 (Hurst, 2007):  
 Foral =  fg  ×  fh….…………………………………..……..………..………………Equation 1-2  
 
5-HMF is probably a low hepatic-extraction ratio drug. Thus, fh is probably high (>80%). 
The structure 5-HMF seems to be relatively stable to degradation in the GI and appears to be 
highly permeable. Unfortunately, the role of transporters in 5-HMF disposition has not yet been 
characterized. However, considering the structure of 5-HMF and assuming that 5-HMF can be 
classified as a class I BCS drug, transporters should not play a major part in its disposition. 
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Hence, we postulate that fg is around 90%. Consequently, 72% is the value projected for the oral 
bioavailability (Foral) of 5-HMF. 
 
 
1.2.4.2 Distribution 
 
5-HMF distribution in the body was investigated by assessing the concentration-time 
profiles of 5-HMF related radioactivity in rodent tissues studied by Godfrey et al (Godfrey 
1999): it was observed that 5-HMF peak levels in various tissues were achieved before 2 hours 
post-administration of 100 and 500 mg/kg doses, suggesting a rapid distribution into most 
physiological compartments. In addition, liver and kidney had the largest tissue/blood partition 
coefficient (AUC48 ratio) in rats and mice, as evident in Table 1-2. This might be attributed to the 
fact that these organs not only act as distribution compartments, but also are elimination sites 
with relatively high blood supply. 
Germond and co-workers investigated the distribution of 5-HMF using whole animal 
autoradiography in rats after oral and intravenous administration of [14C]5-HMF (Germond 
1987). After one hour of oral administration, most of the radioactivity was found in the bladder, 
kidney, and liver with little radioactivity detected in the stomach and small intestines and the 
lowest radioactivity detected in the nervous system (Germond 1987). Again, this supports the 
conclusion of rapid distribution and emphasize the importance of kidney and liver in the 
elimination of 5-HMF. On the other hand, a higher concentration was observed in the nervous 
system after intravenous administration (0.1% of the administered dose) and the radioactivity in 
the stomach, but not in the small intestine, was absent (Germond 1987). The radioactivity was 
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distributed uniformly in other organs (1-2% of radioactivity). Another point, the authors pointed 
out the discrepancy in almost complete recovery of 5-HMF related-radioactivity observed in this 
study and what was reported in earlier studies, summarized in by Ulbricht et al., in which only 
around 50% of 5-HMF was recovered and the unrecovered  part was assumed to undergo 
covalent protein binding (Germond 1987). Germond et al. attributed this discrepancy to the 
ineffectiveness of the extraction method used in the previous studies, in which the glycine 
conjugate was not extractable (Germond 1987).  
Further analysis of a study carried-out by Czok (Czok, Tolerance of 5-
hydroxymethylfurfural (HMF). 2d communication: pharmacologic effects. 1970) observed a 
bixeponential decline of 5-HMF in rat plasma after an IV injection of 100 mg/kg. The volume of 
distribution (Vdcc) of 6.6 L/kg estimated for Czok is 10 fold higher than the anticipated 5-HMF 
Vd that is equivalent to total body water. The volume of distribution at pseudosteady-state 
(Vdpss), 7.2 L/kg, was similar to Vdcc.  The same biphasic pattern was observed in mice after 
IV bolus injection of 100 mg/kg (Monien 2009). The Vdcc was estimated to be 0.55 L/kg 
(Monien 2009). This is equivalent to total body water as would be expected considering 5-HMF 
polar structure. On the other hand, the Vdpss was 7.7 L/kg (Monien 2009).   
As far as plasma protein binding is concerned, in-vitro interaction of 5-HMF with 
intracellular Hb was similar when 5-HMF was incubated in plasma or RBC suspension in saline 
(Abdulmalik 2005). Therefore, the fraction of 5-HMF bound to plasma protein is anticipated to 
be low. Furthermore, the small molecular size and hydrophilic characteristics of 5-HMF support 
the notion of low plasma protein binding.  
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Table  1-2. AUC48 tissue/blood ratio of 5-HMF in rats and mice. Estimated from (Godfrey 
1999). 
   Mice   
Dose (mg/kg) Blood Liver Kidney Muscle Skin Adipose Brain Testes 
5 1 2.4 1.4 0.1 0.2 0.1 0.1 0.1 
100 1 2.4 5.6 0.6 0.8 0.4 0.4 0.6 
500 1 1.8 4.8 0.6 0.9 0.4 0.3 0.6 
   Rats   
10 1 3.5 3.0 1.4 2.2 1.7 0.4 1.2 
100 1 4.0 6.3 2.6 2.2 5.1 0.6 2.5 
500 1 2.2 6.6 1.5 1.5 1.1 0.4 1.0 
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1.2.4.3 Metabolism 
 
On the other hand, Godfrey and co-workers reported in a mass balance study conducted 
in rodents (mouse and rat) that the total radioactivity recovery within 48 hours after 5-HMF 
administration (5-500 mg/kg) by oral gavage was 80-92%, mostly (>70%) eliminated as 
metabolites in the urine (Godfrey 1999).  
N-(5-hydroxymethyl-2-furoyl)glycine (HMFG), 5-Hydroxmethyl-2-furoic acid (HMFA), 
and 2,5-Furan dicarboxylic acid (FDCA), shown in Figure 1-7, were identified as metabolites in 
the urine of rodents, with HMFA accounting for approximately 80% of the metabolites (Godfrey 
1999).  
These results are concurred by the fact that two major metabolites were identified by 
Germond et al. as HMFA and HMFG, with the ratio of HMFA to HMFG increased from 1 to 18 
with increasing the administered doses (Germond 1987). The ratio decreased when glycine was 
administered indicating the importance of its availability in the formation of HMFG (Germond 
1987). The conjugation of glycine was proposed to occur in kidney, since this metabolite was 
only found in kidney homogenate (Germond 1987). Its note worthy, that HMFA, but not 5-HMF 
or HMFG, was extracted from liver homogenate (Germond 1987) and that 44-67% of 5-HMF 
administered to dogs, rabbits, and chickens were excreted as HMFA in the urine (NTP 1994).  
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Figure  1-7. Major metabolites of 5-HMF in rodents (Godfrey 1999). 
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In humans, it was reported that the total recovery of 5-HMF in urine was 46% and 14% 
after 6 hours of oral administration of dried plum juice and dried plums as metabolites (Prior 
2006). Likewise, 74% and 38% of the administered dose was recovered in the urine as HMFA 
and FDCA of parenterally fed human neonates exposed to 5-HMF as a hydrolysis product of 
fructose upon sterilization process of fructose solutions (E. B. Jellum 1973).  
The above-mentioned study involved six healthy women volunteers who administered 
dried plum juice and dried plums after an overnight fast in a randomized cross-over clinical 
study (Prior 2006).  The amount of 5-HMF was estimated as 497 mg (3.9 mmol) and 61.2 mg 
(0.5 mmol) in the dried plum juice and dried plums, respectively. In addition to the baseline 
sample, blood was sampled at 0.25, 0.5, 1, 2, 3, 4, and 6 hours post administration. Moreover, 
urine was collected at the baseline and every two-hour period up to six hours. Bioanalysis was 
performed using HPLC-MS/MS and HPLC-UV (Prior 2006). The analysis was focused on peaks 
that appeared in the plasma of those administered the dried plum products and was not in the 
control group (Prior 2006). 
HMFA, compound I in Figure 1-7, was identified as the major metabolite of 5-HMF 
excreted in the urine accounting for 36.9% of 5-HMF dose (1.5 mmol/6 hrs). In addition, HMFA 
was detected in the urine of controls at levels of 0.006 mmol/6 hrs. The area under the curve of 
the plasma concentration-time profile for HMFA was 0.32 mmol/l.hr (Prior 2006). The reported 
plasma concentration-time profile for HMFA was used in the estimation of the pharmacokinetics 
parameters, as summarized in Table 1-3.  
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Figure  1-8. Potential metabolites of 5-HMF. (Prior 2006)        
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Table  1-3. Pharmacokinetics parameters of HMFA in humans. 
Parameter Value 
AUC6hrs  (mM.hr) 0.316 
AUC∞ (μM.hr) 0.328, reported 0.318 
t1/2  (min) 69 
Ke  (min-1) 0.01 
Urinary clearance of unchanged drug (ml/min) 80 
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(5-Carboxylic acid-2-furoyl)glycine, compound IV in Figure 1-8, was identified as a 
metabolite of 5-HMF in urine with 0.168 mmol excreted in 6 hours (4.2% of 5-HMF dose). This 
compound was also found in one of the control urine (Prior 2006). This metabolite was not 
detected in murine studies after oral administration of 5-HMF (Germond 1987) (Godfrey 1999). 
Moreover, N-(5-hydroxymethyl-2-furoyl)glycine, compound III in Figure 1-7, was  
identified as a metabolite in the urine accounting for 3.6% of 5-HMF dose (0.137 mmol/6 hrs). 
This metabolite was observed in urine earlier after oral administration of 5-HMF in rats and mice 
(Germond 1987) (Godfrey 1999). 
Furthermore, 5-hydroxymethyl-2-furoylaminomethane, compound V in Figure 1-8, was 
identified as a metabolite for 5-HMF with small amounts excreted, which was 1.8% of 5-HMF 
dose. This compound was also detected in 50% of the controls excreted urine (Prior 2006). This 
metabolite was not detected in murine studies after oral administration of 5-HMF (Germond 
1987) (Godfrey 1999). 
In this study, the ratio of compound I to III was twofold higher with the administration of 
dried plum juice compared to dried plums, which is supported by Germond et al. observation that 
the proportion of excreted compound III decreased with the increase in the administered dose 
(Germond 1987) (Godfrey 1999). 
Although compound II in Figure 1-7 was not detected in the study (Prior 2006), Godfrey 
et al. observed this metabolite in rats and mice (Godfrey 1999).  
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All of the above suggests that oxidation is the main biotransformation pathway of 5-
HMF, is most likely by oxidoreductase enzymes; ALDH and ADH. The major metabolite, 
HMFA, implies that ALDH plays a crucial rule in 5-HMF detoxification. Besides the liver, these 
enzymes are found in stomach, kidney, erythrocytes, etc (Satre 1994) (Sládek 2003).  
Recently, 5-sulfoxymethylfurfural (SMF) was detected in mice plasma after the I.V. 
bolus administration of 100 mg/kg 5-HMF (Monien 2009).  SMF was reported as a carcinogenic 
and mutagenic compound, however, the AUC ratio of SMF to 5-HMF was 0.017% (Surh 1994) 
(Monien 2009). 
ADH involvement in the formation of a primary metabolite was reported to happen only 
by yeast. 5-HMF was metabolized by ethanolgenic yeast to 2,5-bis-hydroxymethyl furan,  shown 
in Figure 1-9, with a preference to the presence of NADPH as a cofactor in the redox reaction, 
which was observed at 222 nm with a total disappearance of 5-HMF after 48 hours of incubation 
(Liu 2006).   
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Figure  1-9. 2,5-bis-hydroxymethyl furan (Lin 2008) 
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In general, a drug is considered a low hepatic extraction-ratio drug if less than 20% of 
what enters the liver, through the hepatic artery and portal vein, is lost upon leaving the liver. As 
mentioned above, 5-HMF is highly metabolized with the metabolic clearance (Clmet) accounting 
for more than 70% of total clearance (Cltot) in rats (Godfrey 1999). Stating that 5-HMF had high 
oral bioavailability in mice indicates that it is a low hepatic extraction-ratio drug (Abdulmalik 
2005). The apparent clearance (Cltot/F) of less than 5 ml/min/kg in mice, reported by Abdulmalik 
and co-workers, is much less than the liver blood flow in mice (around 280 ml/min/kg) (Davies 
1993). Knowing that this value as a clearance might have been overestimated, because of the 
unknown oral bioavailability (Foral), provides us with more confidence in considering 5-HMF as 
a low hepatic extraction-ratio drug. When this apparent value was allometrically scaled to 
human, assuming it represents the true clearance, it was around 5% of the hepatic blood flow. 
However, this allometric scaling did not account for the differences in the metabolic enzymes 
expression and activity between human and animals (Venitz 2006).  
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1.2.4.4 Excretion 
 
As a small molecule with a neutral structure at physiological pH range, it was anticipated 
that 5-HMF is freely filtered in the kidney and that it is subject to tubular reabsorption (Venitz 
2006). However, only 12 mg of unchanged 5-HMF was excreted in urine after administration of 
1 g of 5-HMF to rabbits (Lang 1970). This is in agreement with detecting 0.73% of the 5-HMF 
amount consumed by healthy volunteers in their urinary excretion as unchanged 5-HMF (M. P. 
Murkovic 2006). This study was conducted in seven healthy volunteers, in whom the urinary 
excretion of unchanged 5-HMF was investigated after administering 24 mg of 5-HMF in plum 
jam after an overnight fast (M. P. Murkovic 2006). Figure 1-10 shows the amount excreted in 
urine over time. The total of the average amounts of unchanged 5-HMF excreted over the 6 
hours was 176 µg. Unfortunately, the metabolites were not investigated in this study. However, 
the presence of the sulfated metabolite was investigated but it was not detected in urine (M. P. 
Murkovic 2006).  
  More than 60% of the 5-HMF dose was eliminated in rodents urine, mainly as 
metabolites (~90%) (Godfrey 1999). In the studies performed by Germond, Jellum, and Godfrey, 
the urinary excretion of unchanged 5-HMF was not reported. Both Godfrey et al. and Jellum et 
al. stated clearly that 5-HMF was not detected in the urine (Godfrey 1999) (E. B. Jellum 1973). 
Germond and co-workers suggested that the kidney might contribute to the metabolism of 5-
HMF by adding the glycine moiety to its carboxylic metabolite. Blood concentrations, reported 
by Godfrey et al. for the oral administration of 5-HMF in rodents, were used to estimate the 
exposure parameters of 5-HMF by non-compartmental analysis, as shown in Table 1-4.          
The  values for the   apparent clearance (Cltot/F)   indicated  higher  bioavailability and/or   lower  
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Figure  1-10. Unchanged 5-HMF excretion in human urine over time after administering 24 mg 
of 5-HMF in plum jam. 
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elimination rate of 5-HMF in rat compared to that in mice. The estimated parameters were 
compared to those reported by Abdulmalik et al. for the 100 mg/kg dose in mice, as shown in 
Table 4. In this study, the blood sampling schedule included seven time-points after the pre-dose 
sample from 30 minutes to 6 hours (Abdulmalik 2005), while Godfrey reported concentrations 
for four time points from 2 hours to 48 hours (Godfrey 1999). A discrepancy was noted in the 
estimate of the apparent clearance and the AUC reported by Abdulmalik et al.. Hence, the 
trapezoidal AUC (AUCtrap) was re-estimated for the concentration-time profile. The estimated 
AUCtrap was not similar to the reported value, as shown in Table 1-5.  
Czok reported lower 5-HMF plasma concentrations in rats after I.V. injection of 100 
mg/kg (Czok, Tolerance of 5-hydroxymethylfurfural (HMF). 2d communication: pharmacologic 
effects. 1970). Using non-compartmental analysis, the initial t1/2 was estimated as 4.8 minutes 
and the terminal t1/2 was 11 minutes with a total clearance of 446 ml/minute/kg, which is 10 fold 
higher than the apparent clearance estimated for Godfrey study. The findings are concurred by a 
recent study carried-out by Monien and co-workers (Monien 2009). The distribution t1/2 after an 
I.V. bolus of 100 mg/kg in mice, was 1.7 minute and the terminal t1/2 was 28 minutes with a total 
clearance of 190 ml/minute/kg after HPLC-MS/MS analysis of mice plasma (Monien 2009). In 
beagle dogs, 5-HMF was administered as 5 g/hour infusion (Klimmek 1978), and the 
pharmacokinetic parameters for it were summarized in Table 1-6. 
In addition, in a mass balance study, 0-330 mg/kg of [C14]5-HMF was administered to 
rats by both stomach tube and tail vein injection (Germond 1987). When 5-HMF administered 
through stomach tube, less than 1% was recovered as radioactivity in the expired air. The 
remaining activity, which accounted for around 85% of the radioactivity, was recovered in the 
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urine after 8 hours of administration (Germond 1987). Hence, it is postulated that at least 70% of 
5-HMF is orally absorbed and is subject to extensive metabolism.  
Table  1-4. Comparison of exposure parameter estimates in rats and mice in blood (n= 4). 
Estimated from (Godfrey 1999) 
 Dose (mg/kg) 
 Rats Mice 
 5 100 500 10 100 500 
AUC48hrs (µg/ml*min) 2071 8679 52005 159 2109 22877 
ClTot/F (ml/min/kg) 2.4 11.5 9.6 62.8 47.4 21.9 
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Table  1-5. Comparison of the exposure parameters for oral administration of 100 mg/kg in mice. 
 
Estimated from 
Godfrey et al., 
1999 
Estimated from 
Abdulmalik et al., 
2005 
Reported by 
Abdulmalik et al., 
2005 
AUC∞ 
(µg/ml*min) 2,109 22,680 412 ± 25 
Cltot/F 
(ml/min/kg) 47.4 4.4 4.2 ± 0.3 
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Table  1-6. Pharmacokinetics parameters for IV infusion of 5 g/hour infusion to beagle dogs 
(n=7). 
Parameter Value 
AUC120min (μg/ml.min) 3503 
AUC∞ (μg/ml.min) 7959 
t1/2 (min) 123.5 
Ke (min-1) 0.006 
CL (ml/min) 628.2 
Vd (l) 112.0 
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As a conclusion, renal elimination contributes mainly to the elimination of drug 
metabolites. However, the kidney contribution to the unchanged drug elimination is minimal in 
the light of evidence that 5-HMF is highly metabolized and no 5-HMF was detected in the urine.  
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1.2.4.5 BCS Classification 
 
The Biopharmaceutics Classification System (BCS) classifies drugs according to their 
solubility, dissolution, and permeability properties of the drug substance in the highest strength 
of their immediate release drug product (Wu 2005). The calculated solubility of 5-HMF, shown 
in Figure 1-1, is 48 g/l at 25 °C (ACS 2009), which means that up to 12 g of 5-HMF can be 
dissolved in 250 ml of aqueous media (pH 1-7.5 at 37 °C) as defined by the FDA (Wu 2005). 
This estimated solubility is based on the assumption that the solubility of 5-HMF is constant 
between 25-37 °C. 12 g is much larger than the proposed human dose of around 1.5 g 5-HMF 
(Venitz 2006) and probably the highest strength dose will be less than 12 g. Thus, 5-HMF can be 
considered as a highly soluble drug substance. 
It is assumed in this case that other components in the formulation will not significantly 
decrease the dissolution of the dosage form. Hence, it is predicted that ≥ 85% of the labeled 
amount of 5-HMF will be dissolved in 900 ml buffer using apparatus I or II (FDA 2000). As far 
as permeability is concerned, a drug is considered to be highly permeable if it was proven that at 
least 90% of the administered dose is orally absorbed in humans. The intravenous (IV) reference 
dose or mass balance study can prove that (FDA 2000). Unfortunately, except for what was 
reported by Jellum et al. (E. B. Jellum 1973), where 5-HMF was administered intravenously, no 
in-vivo human study had 5-HMF administered intravenously. However, 46% recovery of HMFA 
in urine of healthy volunteers after administering dried plum juice (Prior 2006) indicates that at 
least 46% was absorbed through the gastrointestinal tract. If this value is compared to what was 
reported by Jellum regarding 36-73% recovery of 5-HMF metabolites in urine after parenteral 
administration of 5-HMF, it indicates that 5-HMF has high oral bioavailability.  
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The calculated log D value of 5-HMF equals -0.45 (ACS 2009) over a pH range of 1-10 
and its small molecular weight (MW: 126 D) makes it a candidate for passive diffusion in the 
gastrointestinal tract (Hurst 2007). Germond and co-workers reported that 95-100% of the 
radioactivity was recovered in urine within 24 hours of oral and intravenous [14C]-5-HMF 
administration to rats (Germond 1987). The doses ranged between 0.8-330 mg/kg administered 
for two rats at each dose level (Germond 1987). This indicates that ≥90% is orally absorbed in 
rats. If a similar absorption behavior is found in human, 5-HMF can be classified as a class I 
drug according to the BCS. However, although it was mentioned in this study that 5-HMF was 
administered both orally and intravenously; the AUC after IV administration was not reported. 
This prevents from calculating the absolute bioavailability in order to draw any informed 
conclusion regarding 5-HMF oral bioavailability. Abdulmalik et al. stated that 5-HMF had high 
oral bioavailability and achieved high levels in whole blood samples of mice (Abdulmalik 2005).  
A mass balance study by Godfrey et al. reported 61-77% and 70-82% recovery of 
cumulative radioactivity in urine in mice and rats, respectively, after oral gavage of doses 
ranging between 5-500 mg/kg (Godfrey 1999). This indicates that at least 61% and 70% of 5-
HMF is absorbed mice and rats, respectively. Assuming that there is no significant difference in 
the disposition of 5-HMF between human and rodents, 5-HMF might be classified as 
intermediate to high permeability drug in human. As a conclusion, 5-HMF was recognized to be 
highly metabolized in the above studies indicating that 5-HMF can be classified as a class I drug 
according to the Biopharmaceutics Drug Disposition Classification System (BDDCS) (Wu 
2005). Thus, 5-HMF can be classified as either class I (high solubility, high permeability) or 
class III (high solubility, low permeability) drug according to the BCS. 
The following points summarize the preclinical findings in rodents: 
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• A rapid distribution to physiological compartments was observed with the highest AUC 
tissue-to-blood ratios achieved in the kidney and liver. Plasma protein did not affect 5-
HMF interaction with Hb.  
• Metabolism was recognized as the major route of elimination for 5-HMF. Three 
metabolites were identified in the urine with HMFA as the primary one.  
• There is a variation in the apparent clearance estimated for animals in the discussed 
studies. This complicates drawing any conclusion regarding bioavailability and clearance 
mechanism of 5-HMF.  
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1.2.5 5-HMF Toxicity 
 
There is no epidemiological study relating 5-HMF to cancer, in neither a positive nor in a 
negative direction (NTP 1994).  
 
1.2.5.1 In-vitro  
 
Incubation of 5-HMF with RBCs did not cause any toxicity, when investigated through 
morphology, pumps, and transporters function of RBCs (Abdulmalik 2005). In another study, 
0.07, 0.74, and 7.4 mM of 5-HMF were incubated with blood cells to investigate changes in the 
metabolic activity (Nässberger 1990). While the heat output increased by 60% in RBCs, a 
significant reduction in the heat output was observed in the granulocytes. On the other hand, no 
adverse effects were observed in thrombocytes (Nässberger 1990).  
5-HMF present in light colored caramel resulted in colonic aberrant cryptic foci initiation 
and promotion in rats (X. C. Zhang 1993). However, upon conducting a statistical study on this 
work carried-out by Zhang et. al, it was found that 5-HMF had only a borderline significant 
effect in producing the aberrant cryptic foci (Minkin 1994).  
Moderate carcinogenicity was induced by incubation of 5-HMF in cell lines for an hour 
at a concentration of 115 mM (Janzowski 2000). Also, at a high 5-HMF concentration (120 
mM), a weak mutagenic effect was observed in-vitro (Janzowski 2000). However, DNA damage 
was not observed (Janzowski 2000). In addition, 5-[(sulfooxy)-methyl]furfural, a chemically 
synthesized derivative of 5-HMF was mutagenic adverse events, while another derivative, 5-
(chloromethyl)furfural, was mutagenic and cytotoxic (Surh 1994).  
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1.2.5.2 In-vivo 
 
1.2.5.2.1 HUMAN 
 
 5-HMF was administered in a clinical regimen as 720 mg/day subdivided into three doses 
to preoperative patients for 10 days with no apparent side effects (Matzi 2007). Furthermore, 5-
HMF at concentrations normally encountered in parenteral solutions are not considered toxic 
(Ulbricht 1984).  
   
 
1.2.5.2.2 DOG 
 
 5 g/hour and 50 mg/hour of 5-HMF were infused to beagle dogs in 0.9% sodium chloride 
(Klimmek 1978). An increase in lactate concentration, pO2, and heart rate and a decrease in 
pCO2, and pH to around 7.06 was observed with the infusion of 5 g/hour. On the other hand, no 
changes were observed in the haematocrit, electrolytes, creatinine, bilirubin, and enzyme 
activities (Klimmek 1978). 
 
1.2.5.2.3 RABBIT 
 
When 400 mg of 5-HMF was given twice daily for a week through subcutaneous 
injection to rabbits, no adverse effects were observed (Rasmussen 1982).   
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1.2.5.2.4 RAT  
 
The LD50 in rats ranged between 2.5-5 g/kg when 5-HMF was administered through oral 
route (NTP 1994) (Janzowski 2000). 250 mg/kg of 5-HMF was fed to rats for 40 weeks without 
affecting their weights or the histological characteristics of liver, kidney, heart, spleen, and testes 
(Lang 1970). On the other hand, it was reported that 5-HMF showed some evidence of 
carcinogenicity in female mice at gavage doses of 188 and 375 mg/kg/day, while no evidence of 
carcinogenicity was reported for similar doses in rats or male mice up to 750 mg/kg doses in a 
two-year toxicity study. In addition, respiratory and olfactory epithelium degeneration was 
observed in this study (NTP, TR-554 Toxicology and Carcinogenesis Studies of 5-
(Hydroxymethyl)-2-Furfural (CAS No. 67-47-0) in F344/N Rats and B6C3F1 Mice (Gavage 
Studies) 2008).  
In a study aimed to find an association between the erectile dysfunction in renal failure 
and the increase in the glycation products, the levels of 5-HMF were measured in the penile 
tissue as an indicator of glycation products, which resulted from non-enzymatic reaction between 
sugars and free amino groups in proteins. A significant increase in 5-HMF levels was found in 
rats with induced renal failure in comparison to the control (Usta 2002).  
In addition, 5-HMF is used as a measure of glycated proteins in diabetes and cataracts 
after being released by acid hydrolysis of the glycated proteins. A significant higher level of the 
released 5-HMF was estimated in diabetic rats with cataracts in comparison to non-diabetic rats 
(Turk 1997).  
 
 
 
 51 
 
 
1.2.5.2.5 MICE  
 
No lethal effects were observed upon oral administration of 5-HMF up to 2 g/kg (Czok, 
Tolerance of 5-hydroxymethylfurfural (HMF). 2d communication: pharmacologic effects. 1970). 
On the other hand, the LD50 was 0.84 g/kg through an intraperitoneal route (Czok, Tolerance of 
5-hydroxymethylfurfural (HMF). 2d communication: pharmacologic effects. 1970). A slightly 
lower LD50 of 0.75 g/kg was estimated when 5-HMF was administered through an I.V. route 
(Czok, Tolerance of 5-hydroxymethylfurfural (HMF). 2d communication: pharmacologic effects. 
1970). Gastrointestinal movements and bile secretion were increased with the increase in 5-HMF 
oral dose administered (50, 100, 200 mg/kg). In addition, 5-sulfoxymethylfurfural (SMF), a 
carcinogenic and mutagenic compound, accounted for 17 ppm of 5-HMF AUC in mice plasma 
after an I.V. bolus administration of 100 mg/kg 5-HMF (Monien 2009) (Surh 1994).  
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1.2.6 5-HMF in Humans 
 
Despite the fact that 5-HMF is reported to be involved in clinical trials as anticancer 
agent and micronutrients, a shortage of literature for studies characterizing or predicting its PK in 
human is apparent. Moreover, the variation in the estimated in-vivo animal exposure parameters 
emphasizes the need for preclinical studies exploring the PK of 5-HMF.  
720 mg/day of 5-HMF along with α-ketoglutaric acid (α-KG) divided into three doses 
were given to a study group (n=16) in a randomized prospective study involving 32 lung cancer 
patients undergoing lung resection surgery (Matzi 2007). The micronutrient supplement was 
given for 10 days before the surgery. The study group had a significant improvement in their 
exercise capacity and did not suffer from oxidative stress after the surgery as indicated by their 
carbonyl protein and isoprostane levels (Matzi 2007). 
A study in seven healthy volunteers investigated the urinary excretion of unchanged 5-
HMF after administering 1.2 mg/g of 5-HMF in 20 g of plum jam after an overnight fast. 
Volunteers were three females and four males with a wide age range between 18-45 years (M. P. 
Murkovic 2006).  
Another study involved six healthy women volunteers aged between 65-70 years who 
administered dried plum juice and dried plums after an overnight fast in a randomized cross-over 
clinical study (Prior 2006).  The amount of 5-HMF was estimated to be 497 mg (3.9 mM) and 
61.2 mg (0.5 mM) in the dried plum juice and dried plums, respectively (Prior 2006). 
Moreover, a study investigated the presence of furan compounds in the urine of healthy 
volunteers using gas chromatography and mass spectroscopy (Mrochek 1972). 2,5-
furandicarboxylic acid with a total amount between 3-5 mg/24 hours, 2-Furoylglycine, 5-
hydroxymethyl-2-furoic acid with a total amount between 1-25 mg/24 hours, were identified in 
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the urine of these healthy human. On the other hand, 5-hydroxymethyl-2-furoyl glycine was 
identified in a patient with chronic lymphocytic leukemia. Moreover, enhanced urinary excretion 
of the above compounds were observed in two patients with lymphocytic leukemia. The excreted 
amount of 2,5-furandicarboxylic acid in these patients reached 214 and 300 mg/24 hours 
(Mrochek 1972).  
In a paper presented by Michail et. al., it was stated that 5-HMF is under phase II clinical 
studies in combination with other compounds for its anticytostatic activity (Michail 2007). In 
addition, it was mentioned that a dose of 3 g 5-HMF/day was given to cancer patients in a pilot 
study. 300 ng/ml was reported to be the approximate minimum concentration to characterize the 
pharmacokinetic profile of 5-HMF considering the required number of half-lives (Michail 2007).  
The only systemic exposure to 5-HMF was reported in parenterally fed human neonates 
(n=2), who were exposed to 5-HMF as a hydrolysis product of fructose upon sterilization process 
of fructose solutions (E. B. Jellum 1973).  
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1.3 Aldehyde Dehydrogenase (ALDH) 
 
ALDH is a potential enzyme in the metabolism of 5-HMF. Below is a description of its 
structure, function, substrates, isoenzymes, expression, polymorphism, and pharmacogenetics.  
 
1.3.1 1.3.1 Structure  
 
ALDH1 and ALDH2 are the main ALDH isoenzymes studied in the liver. Both of these 
are homotetramers with a total molecular weight of ~220-240 kDa (C. D. Cheung 2003) (A. R. 
Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in 
acetaldehyde metabolism 1996) (Agarwal 1992). In general, other ALDH isoenzymes are 
homotetramers with few present as homodimers. Table 1-7 summarizes the quaternary structures 
of ALDH isoenzymes.  
Based on human ALDH1, Cys-302 and Glu-268 were reported to be involved in the 
catalytic site, while Lys-192, Gly-245, Gly-250, Glu-399, and Phe-401 are important amino 
acids for the binding of the cofactor NAD(P)+ (Manzer 2003). Consequently, inactive 
isoenzymes were characterized by the presence of arginine amino acid in their active site instead 
of cysteine (Manzer 2003).   
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Table  1-7. Quaternary protein structure of ALDH isoenzymes (Marchitti 2008) (V. P. Vasiliou 
2000) 
Quaternary 
Protein 
Structure 
Isoenzyme 
Tetramer ALDH1A1, ALDH1A2, ALDH1B1, ALDH1L1, ALDH1L2, ALDH2, ALDH5A1, ALDH6A1, ALDH7A1, ALDH9A1 
Dimer ALDH1A3, ALDH3A1, ALDH3A2, ALDH4A1 
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1.3.2 Function  
 
In general, ALDH catalyzes an irreversible oxidation of aliphatic and aromatic aldehydes 
into acids (C. D. Cheung 2003) (V. P. Vasiliou 2000). In conjunction with this irreversible 
oxidation of aldehydes, the enzymatic reaction involves the reduction of a cofactor, nicotinamide 
adenine dinucleotide, (NAD+) into NADH.  
The main isoenzymes studied are ALDH1 and ALDH2 because of their well-known 
function in acetaldehyde detoxification and converting it into acetic acid (Liao 1991) (Agarwal 
1992) (Ricciardi 1983) (Klimmek 1978). Consequently, ALDH1A1 deficiency was associated 
with alcohol injury in mice while increased expression of ALDH1A1 in brain contributed to 
alcohol avoidance (Marchitti 2008). ALDH activity was proposed as an alcohol consumption 
indicator since the activity of ALDH in RBCs was found to be significantly less in alcoholics 
than teetotalers (Johnson 1992). 
Hence, the role of ALDH is very important in detoxification processes. Besides alcohol, 
this includes many compounds causing skin sensitization and present in flavors and fragrances, 
such as cinnamaldehyde (C. D. Cheung 2003). While cinnamaldehyde might be present in the 
fragrance, it can be formed because of cinnamic alcohol activation through metabolism (C. D. 
Cheung 2003). Moreover, the cytosolic ALDH1A1 is involved in cyclophosphamide 
detoxification (V. P. Vasiliou 2000) (Beedham 1997). While ALDH1A1 decreases the toxicity of 
cyclophosphamide, it also causes resistance of tumors to cyclophosphamide in the case of its 
high expression in targeted tumor tissue (Marchitti 2008). Hence, the metabolism of anticancer 
drugs by ALDH  contributes  to the development of resistance to these drugs, especially where 
there is an increase expression of ALDH in the tumor tissue (Beedham 1997) (V. N. Vasiliou 
2005). 
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In particular, it was fond that antineoplastic resistance is associated with an enhanced 
expression of ALDH3A1 (V. P. Vasiliou 2000). While ALDH3A1 has low expression level in 
healthy liver tissue, its expression increases in liver cancer cells since it contributes to cell 
regulation by downregulating transcription factors (Marchitti 2008). Relevant to this aspect, 
ALDH1A2 was reported to act as a tumor suppressor (Marchitti 2008). 
On the other hand, the ALDH enzyme is essential for development and growth as they 
catalyze the oxidation of retinal to retinoic acid, which is an essential compound for gene 
expression (V. N. Vasiliou 2005). An ALDH1A2 knockout mice, dies in the early embryonic 
stages due to its key role in retinoic acid metabolism and its function as an important regulator in 
the development of organs including kidney, pancreas, forebrain, spinal cord, retina, spleen, and 
lung (Marchitti 2008) (V. P. Vasiliou 2000). ALDH decreased activity is observed in cirrhosis 
and can result in feminization due to its importance in retinal oxidation and androgen binding 
role in testis (Marchitti 2008) (Ricciardi 1983).  
Besides detoxicification, ALDH plays a role in the bioactivation of GABA 
neurotransmitter and is involved in DNA repair and replication through catalyzing the formation 
of tetrahydrofolate that is required for purine synthesis (Marchitti 2008) (V. N. Vasiliou 2005).  
In addition, ALDH1 and ALDH3 were proposed to have a role in the transparency of 
cornea since a reduced level of these enzymes was observed in cataract (Manzer 2003) (Marchitti 
2008). It is thought that ALDH1A1 protects the eye from cataracts by oxidizing lipid 
peroxidation products, thus decreasing oxidative stress caused by aging and UVB exposure 
(Marchitti 2008) (Manzer 2003). This is supported by the notion that lipid peroxidation products, 
such as malondialdehyde and 4-hydroxynonenal, are substrates for ALDH (Manzer 2003). 
Moreover, ALDH acts as an antioxidant by producing NAD(P)H and scavenging free radicals 
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through its cysteine, sulfhydryl, and methionine groups (Marchitti 2008). On the other hand, 
some of the ALDH isoenzymes, which are present in the cornea have no metabolic capacity and 
thought to contribute only structurally to the transparency of cornea (Manzer 2003) (Sophos 
2003) (V. N. Vasiliou 2005). 
Other than its famous role in aldehydes oxidation, ALDH catalyzes ester hydrolysis and 
ALDH2 acts as a nitrate reductase, thus activating nitroglycerine (Marchitti 2008). Furthermore, 
in addition to their catalytic activity, ALDH function as binding proteins for endogenous 
moieties as androgen in human genital tissues and exogenous substances as acetaminophen 
(Sophos 2003) (V. N. Vasiliou 2005). 
An advantageous outcome for the absence of ALDH1A1 was noticed in knockout mice, 
where a protection against insulin resistance and diet-induced obesity was observed (Marchitti 
2008). 
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1.3.3 Substrates 
 
Aldehydes are known to be very reactive compounds due to the presence of the highly 
electrophilic carbonyl group, for which they are related to carcinogenicity (Beedham 1997) (V. 
N. Vasiliou 2005). Inside the human body, they are generated from carbohydrates, amino acids, 
lipids, and neurotransmitters (Marchitti 2008). On the other hand, human exposure to aldehyde 
might be through exogenous sources, such as environmental acetaldehyde and formaldehyde and 
through intended exposure while ingesting ethanol, food flavors, and anticancer medications 
(e.g. cyclophosphamide and ifosfamide) (Marchitti 2008). Consequently, some aldehydes are 
essential for biological process in the body while others are toxic (Marchitti 2008). 
Generally, aliphatic aldehydes with longer carbon chains have higher affinity toward 
ALDH than those with shorter chains (A. R. Klyosov, Possible role of liver cytosolic and 
mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism 1996). Some aromatic 
aldehydes were also shown to have high affinity for ALDH with Km values less than 100 nM (A. 
R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in 
acetaldehyde metabolism 1996). In this aspect, naphthaldehydes have Km values in the single nM 
range (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde 
dehydrogenases in acetaldehyde metabolism 1996). A substitution on benzaldehydes and 
naphthaldehydes did not significantly affect their affinity to ALDH whether the addition was an 
electropositive or electronegative group (A. R. Klyosov, Possible role of liver cytosolic and 
mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism 1996). On the other hand, 
modification in the structure to make it more hydrophilic especially at the ortho-position, 
decreased the affinity toward ALDH with around 10 fold or more activity (A. R. Klyosov, 
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Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde 
metabolism 1996).  
High affinity substrates for liver ALDH, such as cinnamaldehyde and benzaldehyde, have 
been identified with a Km values less than 100 nM (A. R. Klyosov, Possible role of liver 
cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism 1996). While 
hyperbolic non-linear regression using the Michaelis Menten equation is usually used to estimate 
the metabolic parameters, these low Km values make it difficult to determine the metabolic 
parameters accurately (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial 
aldehyde dehydrogenases in acetaldehyde metabolism 1996). Even with known substrates as 
acetaldehyde and retinal, different affinity values were reported that vary as much as 100 fold 
difference (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde 
dehydrogenases in acetaldehyde metabolism 1996). In addition, the Km value for certain 
substrates was difficult to determine although the activity was observed (A. R. Klyosov, Possible 
role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism 
1996).  
Consequently, for substrates having affinities in the nanomolar or subnanomolar range, a 
more complicated procedure that involved the addition of another substrate to the reaction was 
reported (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde 
dehydrogenases in acetaldehyde metabolism 1996). However, this procedure was deemed 
complicated and does not provide an advantage over measuring the kinetics using the substrate 
alone (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde 
dehydrogenases in acetaldehyde metabolism 1996).   
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Acetaldehyde is a prototypical substrate for ALDH. In human, the Km value of cytosolic 
ALDH toward acetaldehyde is 180 µM (A. R. Klyosov, Possible role of liver cytosolic and 
mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism 1996). In mice, 
acetaldehyde Km was reported to be 0.9-5 µM and 0.8-1.4 mM in the mitochondrial fraction, 
while it was 10-50 µM and 0.1-0.6 mM in the cytosol (Tomita 1990). This variation in the Km 
values in addition to what was reported with more than a 20 fold range (22-483 µM) estimated as 
the Km value for acetaldehyde in humans is attributed to difficulties in measuring the initial 
velocities for low concentrations or variations in the enzyme or cell fraction purification 
processes (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde 
dehydrogenases in acetaldehyde metabolism 1996). Likewise, acetaldehyde experiments are 
difficult to carry on since the acetaldehyde boiling point is 21 °C. In addition, acetaldehyde 
oxidation products formed in the presence of air interferes with oxidoreductase activity 
measurement. Hence, redistillation of acetaldehyde under anaerobic conditions is recommended 
before conducting the experiments to remove interfering substances (Yan 1987). Moreover, 
acetaldehyde is not a high affinity substrate for all ALDH isoenzymes. Acetaldehyde is primarily 
metabolized by ALDH2 with a Km< 1 µM (Marchitti 2008). ALDH1A1 is another isoenzyme 
that contributes to acetaldehyde metabolism, for which the Km was estimated to be between 50-
180 µM (Marchitti 2008). Besides, ALDH1B has high affinity toward acetaldehyde with a Km of 
30 µM (Marchitti 2008). On the other hand, the affinity of acetaldehyde toward ALDH3 is less 
than that for ALDH1 and ALDH2, hence, its role in the metabolism of ingested ethanol is 
minimal (Liao 1991). Likewise, ALDH1A2 does not seem to play an important role in 
acetaldehyde oxidation since it has a relatively low affinity with a Km value of 650 µM 
(Marchitti 2008).   
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Other than acetaldehyde, retinal is an endogenous substrate for ALDH1 and an inhibitor 
for ALDH2 (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde 
dehydrogenases in acetaldehyde metabolism 1996). Furthermore, lipid peroxidation products, 
such as malondialdehyde and 4-hydroxynonenal, are substrates for ALDH enzyme (Manzer 
2003). γ-aminobutyric acid represents another example of endogenous substrate for ALDH5A1 
and ALDH9A1 (V. P. Vasiliou 2000). Table 1-8 lists some ALDH substrates.   
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Table  1-8. ALDH substrates. 
Substrates Km (mM) 
vmax 
(nmol/min/mg 
protein) 
Species ALDH Enzyme Source Reference 
Ethanol 
4.7 20.2 Rat Hepatic cytosol (Gupta 2006) 
6 8.4 Rabbit Hepatic cytosol (Gupta 2006) 
1.7 33 Dog Hepatic cytosol (Gupta 2006) 
0.7 32.5 Human Hepatic cytosol (Gupta 2006) 
Propylene glycol 
19.7 9 Rat Hepatic cytosol (Gupta 2006) 
15.7 4.8 Rabbit Hepatic cytosol (Gupta 2006) 
13 24.5 Dog Hepatic cytosol (Gupta 2006) 
5.8 37.2 Human Hepatic cytosol (Gupta 2006) 
Ethanol 1 to 2 - Human Liver purified enzyme (Wagner 1983) 
Methanol 6 to 150 - Human Liver purified enzyme (Wagner 1983) 
Ethylene glycol 13 to 220 - Human Liver purified enzyme (Wagner 1983) 
Benzyl  alcohol 0.004 to 0.12 - Human Liver purified enzyme (Wagner 1983) 
Octanol 0.005 to 0.017 - Human Liver purified enzyme (Wagner 1983) 
16-HHA 0.007 to 0.026 - Human Liver purified enzyme (Wagner 1983) 
Cyclohexanol 0.005 to 23 - Human Liver purified enzyme (Wagner 1983) 
5-Bromo-1-naphthaldehyde 2.5 ± 0.3 2 ± 0.2* Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
 64 
 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
6-(Dimethylamino)-2-
naphthaldehydec 6.3 ± 1.8 20 ± 5* Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
5-Nitro-1-naphthaldehyde 11 ± 5 4.2 ± 0.6* Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Fluorene-2-carboxaldehyde 54 ± 6 46 ± 5* Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
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dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
p-(Dimethylamino)benzaldehyde 60 ± 20 16 ± 2* Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
4-Methoxy-1-naphthaldehyde 200 ± 20 34 ± 5* Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Indole-3-acetaldehydec 310 ± 20 86 ± 2* Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
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1996) 
Trans-cinnamaldehyde 400 ± 40 59 ± 5* Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
p-
(Dimethylamino)cinnamaldehyde 900 ± 200 62 ± 5* Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
7-(Dimethylamino)coumarin-4-
carboxaldehydec 1420 ± 230 60 ± 10* Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Phenylacetaldehyde 5500 ± 1200 380 ± 40* Human Liver cytosol purified enzyme 
(A. R. Klyosov, 
Possible role of 
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(ALDH1) liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Phenanthrene-9-carboxaldehyde 9400 ± 800 2700  ± 700 <4* Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Acetaldehyde 0.18 ± 0.10 - Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Propanal 4.5 ± 0.3 x 10-3 - Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
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aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Pentanal 0.16 ± 0.03 x 10-3 - Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Hexanal 0.041 ± 0.002 x 10-3 - Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Heptanal 0.018 ± 0.002 x 10-3 - Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
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metabolism 
1996) 
Octanal 0.012 ± 0.002 x 10-3 - Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Decanal 2.9 ± 0.4 x 10-6 - Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Retinal 0.99-1.3 x 10-3 - Human 
Liver cytosol 
purified enzyme 
(ALDH1) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Formaldehyde 0.32 ± 0.08 - Human Liver mitochondria (A. R. Klyosov, 
 70 
 
purified enzyme 
(ALDH2) 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Acetaldehyde 0.20 ± 0.02 x 10-3 - Human 
Liver mitochondria 
purified enzyme 
(ALDH2) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Propanal 95 ± 5 x 10-6 - Human 
Liver mitochondria 
purified enzyme 
(ALDH2) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Pentanal 34 ± 2 x 10-6 - Human 
Liver mitochondria 
purified enzyme 
(ALDH2) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
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mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Hexanal 30 ± 5 x 10-6 - Human 
Liver mitochondria 
purified enzyme 
(ALDH2) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Heptanal 27 ± 4 x 10-6 - Human 
Liver mitochondria 
purified enzyme 
(ALDH2) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Octanal 28 ± 4 x 10-6 - Human 
Liver mitochondria 
purified enzyme 
(ALDH2) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
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in acetaldehyde 
metabolism 
1996) 
Decanal 22 ± 3 x 10-6 - Human 
Liver mitochondria 
purified enzyme 
(ALDH2) 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Retinal <100 x 10-6 - - ALDH1A1 (Marchitti 2008) 
Acetaldehyde 0.9-5 x 10
-3 
0.8-1.4 - Mouse 
Mitochondrial 
fraction 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
1996) 
Acetaldehyde 10-50 x 10
-3 
0.1-0.6 - Mouse Cytosol 
(A. R. Klyosov, 
Possible role of 
liver cytosolic 
and 
mitochondrial 
aldehyde 
dehydrogenases 
in acetaldehyde 
metabolism 
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1996) 
 
*% Relative to acetaldehyde  
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1.3.4 Isoenzymes and Expression 
 
250 genes under the ALDH superfamily were identified in different species (V. P. 
Vasiliou 2000). Out of these genes, 16 genes were identified in human (V. P. Vasiliou 2000) and 
transcriped into around 20 families. Each family consists of enzymes having at least 40% of 
similarity in their sequence, symbolized by an Arabic number. If more than 60% of sequence 
similarity exists, these enzymes are categorized under the same subfamily indicated by a letter 
(Sophos 2003) (V. N. Vasiliou 2005). For example, ALDH1L2 has 72% homology with 
ALDH1L1 and ALDH3B2 has 83% similarity with ALDH3B1 (Marchitti 2008). In addition, 
ALDH1B shares 75% of homology with ALDH2 (Marchitti 2008). There is around 68% 
positional identity between ALDH1 and ALDH2 (Agarwal 1992). It is noteworthy that when 145 
ALDH proteins aliened, only Gly-245, Gly-299, Glu-399, and Phe-401 were the amino acids 
conserved among these proteins  (Manzer 2003). 
With respect to their subcellular expression, ALDH are expressed in all cell components 
(Marchitti 2008). However, the majority of the isoenzymes are located in the cytosol followed by 
mitochondria as shown in Table 1-9. For instance, ALDH2 is mainly present in mitochondria 
while ALDH1 and ALDH3 are present in the cytosol (C. D. Cheung 2003). 
In the body, ALDH are widely distributed in tissues (Marchitti 2008). While ALDH    
isoenzymes are abundant in the liver, as shown in Table 1-10, it is also expressed in different 
parts of the body. Even though the main isoenzymes, ALDH1-3, are expressed in liver, they are 
present in extrahepatic tissues (C. D. Cheung 2003). For example, ALDH1 and ALDH3 are 
expressed in cornea (Manzer 2003). Moreover, the expression of some ALDH enzymes increases 
in tumor tissues as a response for oxidative stress (Gaspar 2009).  
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Table  1-9. Subcellular locations of ALDH isoenzymes (Marchitti 2008) (V. P. Vasiliou 2000) 
  
Subcellular Location Isoenzyme 
Cytosol 
ALDH1A1, ALDH1A2, ALDH1A3, ALDH1L1, ALDH1L2, 
ALDH3A1, ALDH3B1, ALDH3B2, ALDH7A1, ALDH8A1, 
ALDH9A1 
Mitochondria ALDH1B1, ALDH2, ALDH4A1, ALDH5A1, ALDH6A1, ALDH7A1, ALDH18A1 
Nucleus ALDH3A1, ALDH7A1 
Microsomes, peroxisomes ALDH3A2 
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Table  1-10. Tissue expression of ALDH isoenzymes. 
Isoenzyme Expression Reference 
ALDH1A1 
Highest in liver but also present in eye lens, brain (dopaminergic neurons) 
kidney, lung, hematopoietic stem cells, red blood cells, genital tissues 
Androgen-inducible protein 
Highly conserved 
(V. P. Vasiliou 2000) 
(Marchitti 2008) 
ALDH1A2 Intestine, testis, lung, kidney, liver, brain, and retina. (Marchitti 2008) 
ALDH1A3 Salivary glands, stomach, breast, kidney, nasal mucosa, eye, olfactory bulbs, hair follicles, forebrain, and cerebral cortex. (Marchitti 2008) 
ALDH1A6 kidney, salivary glands, and stomach (V. P. Vasiliou 2000) 
ALDH1B1 Liver, kidney, muscle, heart, placenta, cornea, testis, and brain. (V. P. Vasiliou 2000) (Marchitti 2008) 
ALDH1L1 
Mainly in liver, pancreas, and kidney. Also in lung, prostate, brain, 
muscle, thymus, ovary, and testis.  Downregulated by xenobiotics as 
acetaminophen and methotrexate 
(Marchitti 2008) 
ALDH1L2 Spleen (Marchitti 2008) 
ALDH2 Liver, brain, heart, lung, leukocytes, and hair roots 
(V. P. Vasiliou 2000) 
(Yamamoto 1993) 
(Marchitti 2008) 
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ALDH3A1 
Cornea, stomach, lung, skin, esophagus 
Inducible by cortisone and xenobiotics (e.g. polycyclic aromatic 
hydrocarbons) and cancers. Can be downregulated by progesterone 
(V. P. Vasiliou 2000) 
(Marchitti 2008)  
(Liao 1991) 
ALDH3A2 Liver, kidney, stomach, intestine, muscle, skin, lung, pancreas, heart, brain, and placenta. 
(V. P. Vasiliou 2000) 
(Marchitti 2008)  
(Liao 1991) 
ALDH3B1 Mainly in liver and kidney and in lesser amounts in lung and brain. (Marchitti 2008) 
ALDH3B2 Salivary glands, lung, brain, liver, kidney, and prostate. (Marchitti 2008) 
ALDH4A1 Liver, muscle, and kidney. (Marchitti 2008) 
ALDH5A1 Mainly in brain but also present in liver, pituitary, muscle, heart, and ovary (V. P. Vasiliou 2000) (Marchitti 2008) 
ALDH6A1 Mainly in liver, kidney, heart, and to a less extent in  muscle and brain (V. P. Vasiliou 2000) (Marchitti 2008) 
ALDH7A1 Heart, liver, and kidney (Marchitti 2008) 
ALDH8A1 Liver, kidney mainly and moderately in brain, spinal cord (Marchitti 2008) 
ALDH9A1 Liver, kidney, muscle, and brain (V. P. Vasiliou 2000) (Marchitti 2008) 
ALDH18A1 Pancreas, ovary, testis, and kidney. (Marchitti 2008) 
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Despite the fact that a particular ALDH isoenzyme might be expressed in more than one 
tissue, its activity might be different from one tissue to another. An example of that is shown in 
Table 1-11 for ALDH2 enzyme.  
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Table  1-11. ALDH activity in human tissues relative to that in liver. (Yin 1994) 
 Liver Lung Esophagus Stomach Colon Rectum 
ALDH2 100 2.8 2.8 12 3.8 4.0 
 80 
 
1.3.5 Polymorphism and Pharmacogenetics   
 
Nine of 16 ALDH genes identified in humans are polymorphic and appear to play an 
important role in human development and neurological health (V. P. Vasiliou 2000). 
Consequently, this genetic mutation is associated with metabolic diseases having neurological 
manifestations, such as hyperprolinemia, where the increase in proline levels is associated with 
seizures and mental retardation, Sjogren-Larsson syndrome (SLS), and cancer (V. N. Vasiliou 
2005) (V. P. Vasiliou 2000). Moreover, a manipulation in the ALDH1 genes led to death of mice 
at their midgestational stage (V. P. Vasiliou 2000). In addition, ALDH deficiency is investigated 
as a contributing factor in Alzheimer disease (V. N. Vasiliou 2005). Table 1-12 summarizes 
diseases associated with ALDH polymorphism and deficiency. The importance of ALDH 
enzymes is evident by the diseases caused by mutations in its isoenzymes.   
A well-known pharmacogenetic issue that is associated with ALDH is alcoholism. While 
familial history is an important factor in alcoholism because of environmental and cultural 
issues, the inheritance of ALDH polymorphism is another factor in familial trends in alcoholism 
where ALDH polymorphism is thought to be protective against alcoholism (Agarwal 1992). In 
mice, acute alcohol intoxication affected the activity of ALDH2 but not ALDH1 (Tomita 1990). 
The loss of ALDH2 activity might be a consequence of a point mutation in the ALDH2 gene, 
which is common among Asian populations who are not alcoholics (48% vs 12%) (Thomasson 
1991) (Beedham 1997). This mutation causes sensitivity to alcohol consumption in 50% of 
Orientals and 40% of American Indians since they lack the activity of ALDH2 causing slower 
metabolism of acetaldehyde (Liao 1991) (Agarwal 1992) (Yamamoto 1993). Consequently, 
persons with ALDH2 deficiency suffer from aversive reactions including, facial flushing, nausea, 
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and palpitation as a result of catecholamine and kinins release (Thomasson 1991) (Beedham 
1997) (Hatake 1990) (Agarwal 1992). ALDH2 deficient population are characterized by the 
presence of ALDH2*1/ALDH2*2 and ALDH2*2/ ALDH2*2 alleles (Yamamoto 1993). The 
difference between ALDH2*1 and ALDH2*2 involves an alteration of a single base, where 
guanine is replaced by adenine (Yamamoto 1993). Consequently, this point mutation results in 
the expression of lysine in the 14 position from the C-terminus instead of glutamic acid (Agarwal 
1992). Moreover, alcohol flushing syndrome is associated with alcohol related cancer and 
hypertension (V. N. Vasiliou 2005) (V. P. Vasiliou 2000). Nevertheless, this polymorphism has 
an advantage through protecting against alcoholism (V. P. Vasiliou 2000). On the other hand, 
flushing in Caucasian population is due to several mutations leading to ALDH1 activity decrease 
(Agarwal 1992).  
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Table  1-12. Diseases associated with ALDH polymorphism and deficiency. 
ALDH 
Isoenzyme Disease Reference 
ALDH1A1 
Increased the likely risk of ethanol-induced cancers 
Decreased the likely risk of alcoholism 
Lower expression levels: Down’s syndrome. 
Testicular feminization 
Parkinson Disease 
Schizophrenia 
(V. P. Vasiliou 
2000)  
(Marchitti 2008) 
ALDH1A2 
Spina bifida 
Congenital  diaphragmatic hernia 
Alcohol-induced toxicity in liver and eye lens 
(Marchitti 2008) 
ALDH1A3 Congenital  diaphragmatic hernia Downregulated in breast cancer (Marchitti 2008) 
ALDH2 
Increased risk of ethanol-induced cancers (esophageal and 
upper aerodigestive tract cancers) 
Decreased risk of alcoholism 
Increased DNA damage in polyvinyl chloride workers 
who smoke. 
A decrease in nitroglycerin efficiency 
Myocardial infarction, and hypertension 
Late onset Alzheimer disease 
Parkinson disease 
(V. P. Vasiliou 
2000) 
 (Marchitti 2008) 
ALDH1L1 
Decrease reproductive efficiency 
Imbalances in tetrahydrofolate 
Increased risk of methanol toxicity 
Increased or decreased risk of postmenopausal breast 
cancer 
Downregulated in  pancreas, liver, prostate, ovarian, and 
lung cancers 
(Marchitti 2008) 
ALDH3A1 Susceptibility to cataract upon UV exposure (Marchitti 2008) 
ALDH3A2 Sjögren-Larsson syndrome Preterm birth 
(V. P. Vasiliou 
2000) 
 (Marchitti 2008) 
ALDH3B1 Mutation is associated with paranoid and schizophrenia (Marchitti 2008) 
ALDH4A1 Type II hyperprolinemia 
(V. P. Vasiliou 
2000)  
(Marchitti 2008) 
ALDH5A1 4-hydroxybutyric aciduria (V. P. Vasiliou 2000) 
ALDH6A1 Developmental delay (V. P. Vasiliou 2000) 
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1.3.6 Similarities between Species  
 
ALDH activity was observed in the liver of rat, rabbit, dog, monkey, cow, sheep, and pig 
(Deitrich 2007). In addition, ALDH was studied in the lung and kidneys of rat, rabbit, dog, and 
monkey (Deitrich 2007). Nevertheless, the expression, structure, presence of isoenzymes, 
catalytic activity, and inhibition sensitivity are factors that contributes to the differences 
observed between species with respect to ALDH activity. Hence, similarities between species 
ALDH1 enzyme was studied through its activity in metabolizing acetaldehyde and other 
compounds (A. R. Klyosov, Possible role of liver cytosolic and mitochondrial aldehyde 
dehydrogenases in acetaldehyde metabolism 1996). In addition, human, hamster, and rat liver 
homogenates were compared using agarose gel electrophoresis (A. R. Klyosov, Possible role of 
liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism 1996).  
Such studies demonstrated that there is a high similarity (91%) in ALDH1 between human and 
horse (Agarwal 1992).  
Although rodents are used for investigating ADH and ALDH activities assuming 
similarity in of these enzyme to the isoenzymes present in human (A. R. Klyosov, Possible role 
of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism 
1996), the cytosolic fraction for human liver was characterized by the presence of ALDH1 while 
the hamster and rat cytosolic fraction contained three isoenzymes of ALDH (A. R. Klyosov, 
Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde 
metabolism 1996). In addition, rodents’ cytosolic ALDH1 enzyme exhibits more basic character, 
lower molecular weight (120000-150000) than human ALDH1 (230000-240000) and are 
presumed to be dimeric in contrast to the tetrameric human ALDH1 enzyme (A. R. Klyosov, 
Possible role of liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde 
 84 
 
metabolism 1996). Furthermore, it was found that human cytosolic ALDH1 is different from 
rodents’ ALDH1 in its catalytic activity toward acetaldehyde (A. R. Klyosov, Possible role of 
liver cytosolic and mitochondrial aldehyde dehydrogenases in acetaldehyde metabolism 1996).  
With respect to isoenzyme expression, rabbits express ALDH1 in the cornea rather than 
ALDH3 that is expressed in the cornea of human, pigs, baboon, bovine, sheep, rat, and mice 
(Manzer 2003).  
1.3.7 ALDH in RBCs 
 
 
A tetramer ALDH enzyme has been characterized in human RBCs (Inoue 1979) (Rawles 
1987) (Ueshima 1993). Similarities between this enzyme and human cytosolic enzyme in the 
liver were reported including their sensitivity to acetaldehyde and disulfiram along with their 
optimum pH (Inoue 1979) (Rawles 1987). The physiological function for ALDH in RBCs is not 
known, however, it is thought to contribute to the metabolism of the acetaldehyde fraction that 
escapes liver metabolism (Rawles 1987). During a study conducted by Ueshima et. al., one 
subject out of 16 subjects had no expression of ALDH in his RBCs (Ueshima 1993). With the 
exception of that subject, ALDH activity was estimated as 25 nmol NADH/minute/g hemoglobin 
(Ueshima 1993). The same group conducted an in-vitro study, in which acetaldehyde was added 
at a concentration of 0.1 mM to 1 ml of heparinized blood and measured over 14 minutes by gas 
chromatography. Approximately 60-70% of the added acetaldehyde disappeared within the 14 
minutes, while only 20% disappeared in the person with ALDH deficiency (Ueshima 1993). At 
the physiological concentration of Mg+2, it inhibited ALDH probably by decreasing the rate of 
enzyme-NADH dissociation rate (Rawles 1987). Hence, while diluting the RBC matrix to 
conduct metabolic studies, the inhibitory effect of Mg+2 will be diluted. Hence, the activity of the 
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enzyme will be overestimated (up to 6-fold as implied by Rawles et al.) upon extrapolating the 
in-vitro activity to its corresponding in-vivo value.  
ALDH activity decreased upon storage of RBCs at 4, -20, -70 °C (Johnson 1992). 
Addition of sucrose at 40 g/l concentration increased ALDH stability upon storage at -20 °C 
(Johnson 1992). Lactate dehydrogenase might interfere in the results but can be inhibited by 
oxalate (Johnson 1992). It is noteworthy that ALDH activity was not observed in rat blood 
(Deitrich 2007).   
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1.4 Alcohol Dehydrogenase (ADH) 
 
ADH is a potential enzyme in the metabolism of 5-HMF. Below is a description of its 
structure, function, substrates, isoenzymes, expression, polymorphism, and pharmacogenetics.  
 
1.4.1 Structure 
 
ADH is an 80 kDa dimeric-enzyme that catalyzes an interconversion reaction between 
alcohol and aldehydes (Agarwal 1992) (C. D. Cheung 2003). Each subunit contains two zinc 
molecules and is consisted of around 374 amino acids (Yin 1994) (Agarwal 1992) (Liao 1991). 
There are seven structural genes encoding for the subunits of ADH, namely; α, β, γ, π, x, and µ 
(Liao 1991) (Agarwal 1992) (Ricciardi 1983) (Yin 1994). These subunits are the basis for the six 
identified mammalian classes, which are ADH1 through ADH6 (C. D. Cheung 2003). 
 
 
1.4.2 Function  
 
ADH catalyzes the interconversion of alcohols and their corresponding aldehydes, 
including primary, secondary, and tertiary alcohols that are primarily aliphatic in nature and to a 
lesser degree are cyclic (Agarwal 1992). ADH is involved in the metabolism of endogenous 
compounds, such as retinol, bile acid, and steroids (Agarwal 1992). Likewise, ADH catalyzes the 
bioconversion of xenobiotics, like food flavors and digoxin (Agarwal 1992). Ethanol is one of 
the most studied substrates, for which ADH is significantly responsible for converting it to 
acetaldehyde (Liao 1991) (Agarwal 1992) (Yin 1994). Besides its known function in the 
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oxidation of aliphatic and aromatic alcohol, it was reported to have aldehyde dismutase function 
transferring aldehydes into acids (C. D. Cheung 2003). 
 
 
1.4.3 Substrates 
 
The Km for ethanol was determined between 0.049-4.2 mM for class I ADH while it was 
30 mM for Class II, IV, V. Class III does not seem to be involved in ethanol metabolism (Yin 
1994).  
 
 
1.4.4 Isoenzymes and Expression 
 
ADH1-2 are predominantly expressed in liver while ADH3 is present in liver and 
extrahepatic tissues (C. D. Cheung 2003). With respect to extrahepatic tissues, ADH is expressed 
in stomach with 20% of ingested ethanol metabolized there (Liao 1991). The γ ADH is the 
predominant isoenzyme in the gastrointestinal tract with small amounts of β ADH present (Liao 
1991). In addition, ADH2 is also present in leukocytes (Yamamoto 1993). Table 1-13 
summarizes ADH activities in human tissue relative to liver. 
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Table  1-13. ADH activities in human tissue relative to liver (Yin 1994) 
 Liver Lung Esophagus Stomach Colon Rectum 
ADH1 100 2.1 26 8.2 7.2 10 
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1.4.5 Polymorphism and Pharmacogenetics  
 
There is 90% similarity in enzymes with the same class and 60% between the enzymes 
from different classes (Yin 1994). Genetic polymorphism that is associated with ADH occurs in 
β1, β2, β3 and γ1, γ2 genes of ethnic groups (Liao 1991) (Yamamoto 1993) (Yin 1994). 
Particularly, polymorphism in β and γ subunits of ADH2 and ADH3, respectively, are thought to 
be responsible for the genetic part that accounts for up to 50% of the three-fold difference in 
alcohol metabolism observed in different populations (Thomasson 1991). This polymorphism in 
ADH2 and ADH3 were more frequent in non-alcoholic Chinese when compared to alcoholics 
Chinese (Thomasson 1991). Non-alcoholic populations have ADH with higher capacity to 
metabolize ethanol since they have the ADH2*2 allele with β2 subunit, which has a higher 
enzymatic activity in comparison to the wild ADH2*1 allele with β1 subunit (Thomasson 1991) 
(Ricciardi 1983). However, it was shown later that a significant higher acetaldehyde 
concentration in the blood of individuals who are homozygous for ALDH2*2 in comparison to 
those who are homozygous for ADH2*2 (Yamamoto 1993) (Ricciardi 1983). The frequency of 
ADH 2*2 in Japanese and Chinese was found to be around 69%-85% while it was 20% in Swiss 
population (Yamamoto 1993) (Agarwal 1992) (Ricciardi 1983). Table 1-14 shows the frequency 
of ADH polymorphism in different population.  
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Table  1-14. ADH polymorphism in different population (Yin 1994) 
 ADH21 ADH22 ADH23 ADH31 ADH32 
Orientals 0.30 0.70 0 0.90 0.10 
Caucasian 0.90 0.10 0 0.60 0.40 
African-American 0.84 0 0.16 0.85 0.15 
American Indian 1.00 0 0 0.41 0.59 
Taiwanese Aborigines 0.09 0.91 0 0.99 0.01 
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1.4.6 Similarities between Species  
 
ADH1 is present in mouse, rat, guinea pig, and human liver and skin (C. D. Cheung 
2003). However, its expression level is dependent on the developmental stage, as shown in rat 
and mice (C. D. Cheung 2003). On the other hand, it was shown that ADH2 is not expressed in 
mouse, rat, guinea pig skin but expressed their livers and the liver and the skin of humans (C. D. 
Cheung 2003). The vmax determined for ADH in human skin was lower than that for rodents and 
guinea pig although their intrinsic clearance (vmax/Km) values were similar (C. D. Cheung 2003).  
In addition, Gupta reported different Km and vmax values ranging between 0.8-14 mM and 
0.05-2.8 mmol/min, respectively, for in-vivo ethanol metabolism, mediated by ADH, in rat, 
rabbit, dog, and human (Gupta 2006). Besides, Cheung and co-workers observed that the 
cytosolic ADH of rodents had a lower metabolic efficiency of ethanol metabolism than that of 
human (C. D. Cheung 2003). 
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1.5 Blood Composition  
 
 
Blood is a connective tissue that safeguards living cells in the body by delivering oxygen 
and nutrients as well as getting rid of toxins (Rhoades 1996). Blood is confined to the blood 
vessels and heart compartments (Rhoades 1996). Figure 1-21 shows the main components of 
sedimented blood layers. The average viscosity of an adult blood is 4.5-fold higher than water 
(Rhoades 1996).  
 
1.5.1 Plasma 
 
Plasma is a transparent fluid that carries blood platelets, cells, and proteins (Rhoades 
1996). Upon fractionation of blood, plasma is separated from the blood cells and platelets. When 
fractionated, plasma is mainly composed of water (93%) that contains proteins, organic, and 
inorganic substance (Rhoades 1996). Plasma proteins regulate the osmotic pressure of blood, 
which controls the exchange of substances between blood and interstitial fluid (Rhoades 1996). 
In addition, it acts as a reservoir for amino acids and as a buffering agent to keep the slightly 
alkaline environment of blood (Rhoades 1996). A well-known function of plasma proteins is the 
transport of endogenous substances, such as hormones and the otherwise insoluble fat (Rhoades 
1996). Moreover, exogenous material exemplified by drugs can bind to plasma proteins 
(Rhoades 1996).  
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1.5.2 Red Blood Cells 
 
Approximately 5000 million RBCs exist in each milliliter of the blood (Rhoades 1996). 
RBCs (erythrocytes) originates from the bone marrow through the erythropoiesis process 
(Rhoades 1996). In contrast to other cells in the body, mature RBCs do not contain a nucleus and 
are anchored by a cytoskeleton that is connected to the inner membrane of RBCs (Rhoades 
1996). They are characterized by their flexibility, which allow them to pass through blood 
vessels regaining their biconcave shape, after bending and twisting (Rhoades 1996). In addition, 
their distinct shape increases their main function efficiency, which involves gases exchange, 
because it maximizes the surface area to volume ratio (Rhoades 1996).  
Unfortunately, the flexibility and the doughnut shape of RBCs are impaired in genetic 
diseases like sickle cell anemia. Table 1-15 lists the differences between normal RBCs and 
sickled RBCs. 
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Table  1-15. Differences between normal and sickled RBCs. 
 Sickled RBCs relative to Normal RBCs Reference 
Reticulocytes Increased (Hebbel 1991) 
Abnormally dense RBCs 5-50% (Hebbel 1991) 
Water content Dehydrated (Hebbel 1991) 
Mean cell hemoglobin 
concentration (MCHC) Increased (Hebbel 1991) 
Irreversible sickled RBCs Present (Hebbel 1991) 
Monovalent cations Increased Na
+ 
Decreased K+ (Hebbel 1991) 
Ca+2 10 fold increase in total Ca+2 (Hebbel 1991) 
Lipid bilayer Phospholipid destabilization Adducts with  malondialdehyde (Hebbel 1991) 
Strength and flexibility Decreased (Hebbel 1991) 
Hemoglobin Decreased stability and solubility (Hebbel 1991) 
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1.5.3 White Blood Cells (WBCs) 
 
Approximately 7 to 10 million WBCs are present in each one milliliter of whole blood 
(Rhoades 1996). WBC types are distinguished by the shape of their nuclei and the presence or 
the absence of granulated vesicles (Rhoades 1996). WBCs need staining for differentaion 
purposes since they do not contain coloring molecules in contrast to RBCs (Rhoades 1996). 
Besides the blood stream, WBCs are found in the lymphatic system and connective tissues 
(Rhoades 1996). Their general function is defense against toxins and foreign substance entering 
the body (Rhoades 1996). As part of the immune system, they produce antibodies against and 
engulf invading bacteria (Rhoades 1996).  
 
1.5.4 Platelets 
  
Platelets (thrombocytes) are membrane bounded cell fragments that lack nuclei (Rhoades 
1996). There are approximately 150-350 million platelets in each milliliter of blood (Rhoades 
1996). Their main function is concerned with decreasing blood loss in injuries by playing a role 
in blood vessel contraction and blood coagulation at the site of injury (Rhoades 1996).  
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1.5.5 Blood Proteins  
 
Albumin and α-acid glycoprotein (AAG) are involved in drug binding. There are other 
proteins present in plasma at low concentration, such as lipoproteins, C-reactive proteins and are 
thought to have a minimal contribution to drug binding (Routledge 1986). The overall 
concentration of albumin and globulins in the blood are regulated to keep a constant total 
concentration with a variant albumin/globulin ratio depending on the health status of the patient.  
 
1.5.5.1 Albumin 
 
Albumin accounts for 60% of plasma proteins, thus represents the most abundant protein 
in plasma and it is a main contributor to the osmotic pressure of blood (Rhoades 1996). Hence, a 
decrease in its concentration, because of malnutrition or liver disease, results in a fluid shift from 
the blood compartment into interstitial fluid (Rhoades 1996). Albumin is a single chain peptide 
protein with a molecular weight of 66,478 Da (Sigma-Aldrich n.d.). Human serum albumin 
solubility is 50 g/l (Sigma-Aldrich n.d.). Although albumin concentration is relatively stable, 35-
50 g/l, it can decrease in disease states, such as renal and hepatic failures (Corti 1994). 
Nevertheless, changes in the concentration are less than two fold of the normal concentration. 
This concentration stability in addition to the fact that albumin has low affinity, high capacity of 
binding make drugs binding to albumin less susceptible to variations (Routledge 1986).  
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1.5.5.2 Hemoglobin  
 
Hemoglobin (Hb) is a tetramer protein that is soluble in water at a concentration of 20 g/l 
(Sigma-Aldrich n.d.). The molecular weight of hemoglobin is 64,677 Da (Sigma-Aldrich n.d.). 
The average concentration of hemoglobin in blood is 150 g/l (2.3 mM) (Dixon 1997), while the 
average normal mean corpscular hemoglobin concentration (MCHC), i.e. concentration of 
hemoglobin in erythrocytes, is 340 g/l (5.3 mM) (Clark 1989). Hemoglobin is major carrier of 
oxygen in the body and the absence of this function requires the heart to pump around 80 
l/minute since only a small percentage of oxygen is dissolved in blood (Sladen 1981). 
Hemoglobin is known for its cooperativety in binding to oxygen, as described by Hill, with 
conformational changes facilitating this binding (Riggs 1998). Upon oxygen binding to the heme 
groups in hemoglobin, it destabilizes salt bridges in the quaternary structure of hemoglobin 
leading to an increase in the affinity to oxygen that appears in the sigmoidal shape of oxygen 
saturation curve (Sladen 1981). This curve is characterized by the P50 value, which represent the 
oxygen pressure achieving 50% saturation of hemoglobin. The typical P50 value in healthy 
individuals is 26.5 mmHg (Sladen 1981). However, the P50 is affected by temperature and 
organic and inorganic ligands, such as proton ions (H+), carbon dioxide (CO2), and 2,3 
diphosphoglycerate (2,3-DPG). While the increase in CO2 and 2,3-DPG concentration is 
associated with an increase in the P50 (right-shift in the oxygen saturation curve), the increase in 
the pH affects the P50 inversely (left-shift in the oxygen saturation curve). The concentration of 
2,3-DPG is approximately 4 mM inside the RBCs and doubling its concentration has a major 
effect oxygen curve resulting a P50 of 37 mmHg (Sladen 1981). The decrease in hemoglobin 
affinity toward oxygen is a result of 2,3-DPG salt bridging interaction between the β–chains 
(Safo 2004).  
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1.5.5.3 AAG 
 
The molecular weight of AAG is 40,000 Da and it has an acidic pKa. The concentration 
of albumin is approximately 100 times more than AAG (Routledge 1986). Its physiological 
function of this acidic protein is not clear but it can contribute to immunological and repair 
processes (Routledge 1986). Hydrophobic rather than electrostatic interactions are mainly 
involved in drugs binding to AAG (Routledge 1986). AAG does not significantly contribute to 
the binding of acidic drugs, which are more attracted to human serum albumin. Propranolol and 
disopyramide are examples of drugs bound to AAG (Routledge 1986). AAG is present in both 
plasma and extra-vascular space (Routledge 1986). AAG concentration is affected by 
environmental conditions more than hereditary factors (Routledge 1986). Since the concentration 
of AAG differs according to the health status, drug binding to this protein is associated with 
variability (Routledge 1986). For example, the concentration of AAG increases in  infections, 
obese subjects, and in subjects on anticonvulsant therapy while it has lower levels in patients 
with nephrotic syndrome (Routledge 1986). Besides, AAG is characterized by a low capacity, 
high affinity binding interaction and subject to saturation (Routledge 1986).  
  
 99 
 
 
 
 
 
CHAPTER 2 
2  
HYPOTHESES, SPECIFIC AIMS, AND SIGNIFICANCE 
 
2.1 Hypotheses 
 
The main objective of this research is to help predict human in-vivo PK of 5-HMF using 
in-vitro-in-vivo extrapolation (IVIVE). The results will be useful in determining a non-toxic and 
biologically relevant dosage regimen to be used in phase I clinical trials. Therefore, the 
hypotheses guiding this research are as follows: 
• In hepatic cytosol:  
– 5-HMF is subject to ALDH- and ADH-mediated metabolism.  
– Significant species differences in 5-HMF disposition exist among mouse, rat, dog, 
and human.  
• In human blood:  
– 5-HMF is subject to ALDH-mediated metabolism.  
– 5-HMF demonstrates a time- and a concentration-dependent binding to Hb. 
– 5-HMF demonstrates a time- and a concentration-dependent binding to HSA. 
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2.2 Specific Aims 
 
In order to test the hypotheses specified in section 2.1, the following specific aims are 
proposed in this research project: 
1. To review the available literature on the physiochemical properties, PK, and 
PD of 5-HMF, as a potential antisickling agent.   
2. To optimize the experimental conditions needed to investigate 5-HMF 
metabolism and binding in blood and hepatic cytosol. 
3. To develop and validate an assay method for the quantitation of 5-HMF in neat 
solution, human plasma, and human RBCs.  
4. To identify the metabolic pathways of oxidative 5-HMF metabolism in human 
hepatic cytosol.   
5. To determine the in-vitro affinities and metabolic capacities of 5-HMF in 
mouse, rat, dog, and human hepatic cytosol.  
6. To perform IVIVE of hepatic metabolism for 5-HMF in mouse, rat, dog, and 
human hepatic cytosol and compare it with published data. 
7. To determine the in-vitro affinity and metabolic enzyme capacity of 5-HMF in 
human RBCs.  
8. To perform IVIVE for 5-HMF metabolism in human RBCs and compare it 
with published data. 
9. To investigate the time-dependent kinetics of 5-HMF binding to human 
hemoglobin and serum albumin.  
10. To determine the steady-state concentration-dependent parameters of 5-HMF 
binding to human hemoglobin and serum albumin.  
 101 
 
11. To develop a PK model that combines both hemoglobin binding and RBC 
metabolism of 5-HMF to explain its disposition in blood.  
 
 
2.3 Significance 
 
Sickle cell disease is classified as the most common inherited disease in the world 
(Howard 2009). The susceptibility of HbS to polymerize upon deoxygenation is severe enough to 
decrease the life expectancy of patients with this disease to 45-55 years (Howard 2009). 
Moreover, sickle cell disease is accompanied with a decrease in the quality of life of the patient 
and their families because of the recurring and unpredictable pain episodes and other chronic and 
acute complications related to obstruction of blood vessels by sickled RBCs (Howard 2009). 
Bone marrow transplantation represent a cure for this disease, however, it is hindered by the 
having a suitable donor and the eligibility of the patient for this procedure (Bolaños-Meade 
2009). The only treatment that specifically targets pathophysiology of sickle cell disease is 
hydroxyurea, through stimulating the production of HbF, which has higher oxygen affinity 
(Lanzkron 2008). Consequently, hydroxyurea decreases the fraction of hemoglobin that is 
susceptible to polymerization at certain oxygen pressure. Yet, hydroxyurea toxicities mire its 
use, especially in children (Lanzkron 2008). Therefore, there is an apparent need for having a 
curative and a relatively safe treatment for this disease. Besides, none of the current therapeutic 
approaches prevents the polymerization of HbS that precedes sickling of RBCs. In the process of 
searching for an agent targeting the pathophysiology of SCD, 5-HMF was found to reduce RBCs 
sickling in rodents though increasing the affinity of HbS to oxygen (Safo 2004). Consequently, 
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less HbS exists in the deoxygenated state at any specific oxygen pressure, therefore, 5-HMF 
decreases HbS polymerization. An attractive fact about 5-HMF, with regard to its safety, that 5-
HMF is found constitutively in food such as coffee, dried fruits, and traditional Chinese 
medicines (Lin 2008) (Janzowski 2000). In addition, 5-HMF is an adulteration product in honey, 
beer, fruit juice, and glucose infusion solutions (Godfrey 1999). 
 Despite the long history of 5-HMF research, the literature is scarce with respect to studies 
fully characterizing its human PK. 5-HMF was dosed to different animal species, rodents, dogs, 
rabbits, and chickens, with the oral route being the method of administration in most of the 
studies (Klimmek 1978) (Rasmussen 1982) (Godfrey 1999) (Czok, Tolerance of 5-
hydroxymethylfurfural (HMF). 2d communication: pharmacologic effects 1970) (Germond 
1987) (NTP 1994) (NTP 2008). In addition, 5-HMF was administered orally to humans in three 
clinical studies without elaborating its PK properties (Prior 2006) (Matzi 2007) (M. P. Murkovic 
2006). Differences in the estimated half-life and systemic clearance were found between and 
among species in the reported studies. Furthermore, 5-HMF oral bioavailability was not 
evaluated by a simultaneous administration of 5-HMF through systemic and oral routes.  
 In studies with the radiolabeled molecule, 5-HMF was shown to be extensively 
metabolized and the metabolites were mainly excreted in urine, however, the metabolic pathways 
were not identified (Godfrey 1999) (Germond 1987). Moreover, the metabolic affinity and 
capacity were not characterized along with any relevant differences and/or similarities among 
species. Furthermore, extra-hepatic metabolism was not investigated as a potential contributor 
for the overall clearance.  
 On the other hand, 5-HMF was reported to bind to hemoglobin by transient covalent 
binding to form a Schiff base (Safo 2004). However, the kinetics of this binding was not studied; 
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including the expected time to equilibrium and extent of binding. In addition, binding to the 
major serum protein, albumin, was not investigated to explore its interaction with hemoglobin 
binding.  
  Consequently, 5-HMF stability in human blood was investigated using a validated 
HPLC-UV assay in human plasma, where a decrease in 5-HMF concentration over time was 
observed. In addition, experiments were performed to evaluate the metabolic stability of 5-HMF 
in human hepatic cytosol. A concentration-dependent increase in nicotinamide adenine 
dinucleotide (NADH) formation was demonstrated, indicating the involvement of ALDH/ADH 
enzymes in the metabolism of 5-HMF. Hence, as a part of this research, the mechanistic basis 
behind 5-HMF metabolism in human hepatic cytosol was explored. In addition, this research 
intended to evaluate 5-HMF metabolic properties in hepatic cytosol of human, dog, rat, and 
mouse. These properties were compared among species to evaluate any similarities or variations. 
Furthermore, metabolism in human RBCs was studied as a potential source of extra-hepatic 
metabolism. More to the point, time- and concentration dependency studies were carried-out in 
human serum albumin and hemoglobin solutions. The overall objective of these in-vitro studies 
was to support first-time-in-human phase I studies with 5-HMF as a part of its development as 
antisickling agent.  
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CHAPTER 3 
3  
DEVELOPMENT AND VALIDATION OF HPLC ASSAY METHODS 
 
 
3.1 Introduction 
 
A number of analytical methods for the quantification of 5-HMF were described in the 
literature, as summarized in Table 3-1. The lowest reported concentration is listed in Table, 
except where indicated, since the LLOQ was not reported in most of these analytical methods. 
However, most of these were dedicated for the determination of 5-HMF in non-biological 
matrices. Other methods measured 5-HMF as a hydrolysis product of glycosylated RBCs and 
plasma proteins. Although few assay methods in biological matrices were reported, complex or 
tedious sample preparation was utilized in these. Hence, the need to a simple and a sensitive 
bioanalytical assay method was pointed-out to determine 5-HMF concentration in biological 
matrices involved in potential future clinical and animal studies. It is noteworthy that 5-HMF 
was investigated in a pilot study, which employed cancer patients with a dose of 3 g/l/day of 5-
HMF. The minimum concentration of 5-HMF in plasma in that study was anticipated to be 
around 2.4 µM (Michail 2007).  
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Table  3-1. 5-HMF literature-reported assays 
Author Matrix Method 
Lowest Reported 
Concentration 
(µM) 
(Coco 1996) Honey HPLC-UV/VIS 0.008 mg/kg (LOD) 
(Drifield 2005) Honey HPLC-UV 1.4 mg/kg (LOD) 
(E. B. Jellum 
1973) 
Intravenous nutrition 
and urine GC-MS NA 
(Standefer 1983) RBC (HbA1) 
Colorimetric 
spectrophotometry ~ ≥19.8 
(Menez 1984) RBC (HbA1) HPLC-UV 0.50 
(Sampietro 1987) Plasma (glycosylated protein)` HPLC-UV 0.50 
(Godfrey 1999) Tissues (including whole blood) and urine 
HPLC-UV and HMF-
derived radioactivity 
~ 0.16 in blood 
~ 0.013 µg/g brain 
 
(Abdulmalik 2005) Whole blood and plasma HPLC-UV ~ 23.8 
(Michail 2007) Plasma HPLC-UV 2.4 (LLOQ) 
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3.2 Methods 
 
3.2.1 Materials and Reagents 
 
1. Mobile Phase for 5-HMF Assay Method in Plasma and RBCs: 
- 93.5% Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory) 
- 6.2% Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ) 
- 1% Acetic acid, glacial, > 99% (Sigma, Milwaukee, WI) 
- 0.3 % Tetrahydrofuran, HPLC grade (Burdick and Jackson, Morristown, NJ) 
2. Mobile Phase for HMFA Assay Method in Human Hepatic Cytosol: 
- 83% Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory) 
- 17% Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ) 
- Tetrabutylammonium iodide, 99% (Sigma, St. Louis, MO)  
3. 5-Hydroxymethyl-2-furfural (5-HMF) Stock Solution: 
- 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO) 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory) 
4. 2-Furfuraldehyde (2F) Stock Solution: 
- 2-Furfural (Sigma, St. Louis, MO) 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory) 
5. Acetylfuran (AF) Stock Solution:  
- Acetylfuran (Sigma, St. Louis, MO) 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory) 
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6. 5-Methyl-2-furfuraldehyde (MF) Stock Solution: 
- 5-Methyl-2-furfural (Sigma, St. Louis, MO) 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory) 
7. 5-Hydroxymethyl-2-furoic Acid (HMFA) Stock Solution: 
- 5-Hydroxymethyl-2-furoic Acid (Toronto Research Chemicals, Inc., North York, 
On.Canada) 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory) 
8. Furan-2,5-dicarboxylic Acid (FDCA) Stock Solution: 
- Furan-2,5-dicarboxylic acid (Toronto Research Chemicals, Inc., North York, 
On.Canada) 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory) 
9. SPE Conditioning: 
- Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ) 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory) 
10. SPE Washing Solution: Phosphate-buffered Saline (PBS), pH 7.4: 
- Phosphate-buffered saline (PBS) tablets, pH 7.4 (Sigma, St. Louis, MO) 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory) 
11. SPE Eluting Solution: 50% Methanol: 
- Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ) 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory) 
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3.2.2 Equipment 
  
1. 25-µl, 50-µl, and 250-µl positive displacement pipettes and corresponding pipette tips 
(Microman, Rainin Instruments, Oakland, CA). 
2. 10-µl, 100-µl, and 1000-µl VWR pipettes and corresponding pipette tips (VWR, West 
Chester, PA). 
3. 0.5-5 ml Finnpipette (Thermo Scientific, Waltham, MA). 
4. Vortex (Vortex-Genie, VWR, West Chester, PA). 
5. Sonicator (American Brand Products C6450-11, VWR, West Chester, PA).  
6. pH meter (Corning, Glendale, AZ). 
7. Balance (Fisher Scientific A 250, Pittsburgh, PA). 
8. Oasis HLB cartridge, 1 cc/ 30 mg (Waters). 
9. Centrifuge 5804-R (Eppendorf, Hauppauge, NY). 
10. Glass vials with caps, 1 ml (Waters, Milford, MA). 
11. UV detector (Shimadzu, AV-10, Columbia, MA).  
12. C18 Zorbax Rx column, 4.6 X 150 mm (Agilent, Santa Clara, CA). 
13. C18 guard column, 12.5 mm x 4.6 mm (Agilent, Santa Clara, CA). 
14. 717 plus autosampler (Waters, Milford, MA). 
15. 600 Multisolvent controller (Waters, Milford, MA). 
16. Empower 2 software (Waters, Milford, MA). 
 
 
 
 109 
 
3.2.3 Preparation of Solutions 
 
– Mobile Phase for 5-HMF Assay Method in Plasma and RBCs (1 L): 
935 ml water, 62 ml methanol, 10 ml acetic acid glacial, and 3 ml     
tetrahydrofuran were mixed to prepare the mobile phase. 
 
– Mobile Phase for HMFA Assay Method in Human Hepatic Cytosol (1 L): 
2 g of tetrabutylamonium iodide were dissolved in 830 ml water mixed with     
170 ml methanol.  
  
– 5-Hydroxymethyl-2-furfural (5-HMF) Stock Solution, 39.6 mM 
20 mg of 5-hydroxymethyl-2-furfural (M.W.: 126.11 Da) in 4 ml of water.  
 
– 2-Furfuraldehyde (2F) Stock Solution, 12.1 mM. 
11.6 mg of 2-furfural (M.W.: 96.08 Da) was added to 10 ml of water. 
 
– Acetylfuran (AF) Stock Solution, 9.97 mM.  
             10.1 mg of acetylfuran (M.W.: 110.11 Da) was added to 10 ml of water. 
 
– 5-Methyl-2-furfuraldehyde (MF) Stock Solution, 10.1 mM. 
11.1 mg of 5-methyl-2-furfural (M.W.: 110.11 Da) was added to 10 ml water. 
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– 5-Hydroxymethyl-2-furoic Acid (HMFA) Stock Solution, 1.41 mM. 
2 mg of 5-hydroxymethyl-2-furoic acid (M.W.: 142.11 Da) was added to 10 ml 
water. 
 
– Furan-2,5-dicarboxylic acid (FDCA) Stock Solution, 12.8 mM. 
           10 mg of furan-2,5-dicarboxylic acid (M.W.: 156.09 Da) was added to 5 ml water. 
 
– SPE Washing Solution: Phosphate-buffered Saline (PBS), pH 7.4 
One tablet of phosphate-buffered saline was added to 200 ml of water. 
 
– SPE Eluting Solution: 50% Methanol. 
25 ml of methanol was mixed with 25 ml of water. 
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3.2.4 Procedures 
 
0.3 ml of plasma and 0.1 ml of thawed RBCs (after freezing at -80 °C) were diluted to 0.6 
ml and 1.2 ml, respectively. 0.6 ml of the diluted sample was loaded into preconditioned (with 
methanol and water) HLB (hydropilic-lipophilic balance) solid phase extraction cartridges. The 
undesired impurities were washed with PBS and the sample was finaly eluted with 0.5 ml of  
50% methanol in water. The extraction procedure is summarized in Table 3-2. Reference was 
made to Michail and co-workers, with minor amendments, for the sample prepartion by solid 
phase extraction (Michail 2007). However, the extract was injected directly into the HPLC-UV 
system with satisfactiory results without including the tedious and time-cosumimg dervitization 
step reported in that method.  
The mobile phase for the analysis of 5-HMF in plasma and RBCs was prepared in an 
identical way to that reported by Menez et al., where an isocratic mobile phase was prepared by 
mixing water, methanol, acetic acid, tetrahydrofuran, 93.5:6.2:1:0.3, respectively, were mixed 
and used in (Menez 1984). A UV scan was performed between 200 nm to 330 nm to check if the 
mobile phase contributes to the absorbance measured at 285 nm. Figure 3-1 demonstrates that 
the mobile phase absorbance is insignificant at that wavelength window. 
10 µl of the extracted samples were injected into Zorbax C18 analytical column (150 x 4.6 
mm) protected by a C18 guard column (12.5 mm x 4.6 mm) through an autosampler at 4 °C and 
the mobile phase flowed at 0.75 ml/minute rate. 5-HMF peak was detected using Shimadzu 10 
AV UV absorbance detector a at 285 nm.  
Another method was developed for the detection of the metabolite HMFA in the presence 
of the parent compound 5-HMF in human hepatic cytosol. 0.2 ml of hepatic cytosol reaction 
mixture was diluted with 1 ml ice-cold acetonitrile. Then, 0.15 ml of the mixture was diluted 
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further with 0.65 ml ice-cold water. 10 µl of the diluted samples was injected directly into 
HPLC. The mobile phase was a mixure of water and methanol, 87:13, respectively. In addition, 
0.2% w/v tetrabutylammonium iodide was added an ion-pairing agent. The flow ratewas 1 
ml/minute though Zorbax C18 analytical column (150 x 4.6 mm) protected by a C18 guard column 
(12.5 mm x 4.6 mm). HMFA peak was detected using Shimadzu 10 AV UV absorbance detector 
a at 260 nm.  
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Figure  3-1. UV spectrum for the mobile phase. 
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Table  3-2. Solid phase extraction procedure 
Step Solvent Volume (ml x times) Minimum centrifuge speed (rpm) – time (min)  
Conditioning 
Methanol  1 x 2 400-2 
Water  1 x 2 400-2 
Loading Plasma (diluted one fold) or RBCs suspension (diluted 6 folds) 0.6 x 1 400-7 
Washing Phosphate buffer saline pH 7.4 1 x 2 700-5 
Elution 50% methanol in water 0.5 x 1 400-5 
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3.3 Method Validation 
 
3.3.1 5-HMF in Human Plasma 
 
A summary of the 5-HMF assay method in human plasma is described in Table 3-3. In 
addition, representative chromatograms of 5-HMF in human plasma are shown in Figures 3-2, 3-
3, 3-4, 3-5, 3-6, and 3-7.  
To ensure the suitability and reliability of the developed method for the intended 
measurements, validation of this analytical method in human plasma was evaluated through the 
following: 
 
 
3.3.1.1 Recovery 
 
The response of extracted samples at low, medium, and high concentrations was 
compared to the response of unextracted known concentrations that represent 100% recovery. 
The efficiency of extraction was reproducible with a CV less than 4% and a recovery of more 
than 78%. Moreover, the recovery at the LLOQ was determined to be 84% with a CV not 
exceeding 1%, as summarized in Table 3-4.  
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Table  3-3. 5-HMF assay descriptive summary. 
Type of assay HPLC-UV 
Sample preparation Solid phase extraction of diluted plasma by Oasis HLB cartridges (Waters) 
Detector Shimadzu 10 AV Absorbance Detector 
LC pump Waters 600E Multisolvent Delivery System 
LC column  Zorbax Rx C18, 80 A
o, 150 mm x 4.6 mm, 5 μm  
(Agilent, Serial # USDU010028) 
Guard column C18, 12.5 mm x 4.6 mm (Agilent, Serial # USCI042710) 
Detection UV at 285 nm 
Autosampler temperature 4 °C 
Flow rate 0.75 ml/minute 
Regression algorithm Linear, weighted 1/X 
Sample volume and matrix 0.3 ml of plasma diluted with water to a total volume of 0.6 ml.  The 0.6 ml diluted sample is extracted to 0.5 ml sample using HLB cartridges 
Mobile phase Water-methanol-acetic acid-tetrahydrofuran (93.5:6.2:1:0.3) 
Injection volume 10 µL 
Chromatographic run time 10 minutes 
Calibration curve range 0.16 – 158.6 µM 
LLOQ 0.16 µM 
Quality control levels 0.48, 15.9, 126.9 µM 
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Figure  3-2. Representative chromatogram of 5-HMF standard in mobile phase. 
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Figure  3-3. Representative chromatogram of individual human plasma blank. 
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Figure  3-4. Representative chromatogram of LLOQ concentration. 
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Figure  3-5. Representative chromatogram of low QC concentration. 
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Figure  3-6. Representative chromatogram of mid QC concentration. 
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Figure  3-7. Representative chromatogram of high QC concentration. 
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Table  3-4. 5-HMF recovery in human plasma. 
Concentration (µM) R1 R2 R3 Mean CV 
0.16 85 84 85 84 0.9 
0.48 75 81 79 78 3.7 
15.9 105 108 109 107 1.9 
126.9 107 108 111 109 1.9 
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3.3.1.2 Accuracy 
 
Within-assay accuracy was determined for six replicate measurements at four different 
concentrations, in addition to the LLOQ. The mean deviation from the nominal value was used 
as a measure of accuracy in the analytical range (DFN). The DFN did not exceed 15% at any of 
these concentrations including the LLOQ, as shown in Table 3-5. 1/X weighted linear regression 
was used in the calibration curve.  
Inter-assay accuracy was determined at three levels with twelve replicates at each 
concentration, as summarized in Table 3-6. The accuracy was deemed acceptable as per the FDA 
guidance for industry “Bioanalytical Method Validation” criteria, with no more than 15% DFN 
for the selected concentrations and 20% as the DFN at the LLOQ.  
 
 
3.3.1.3 Precision 
 
 The analysis was applied repeatedly at three levels with twelve replicates at each 
concentration to evaluate the between-run repeatability, as summarized in Table 3-6. Within-run 
precision was determined for six replicates, shown in Table 3-5, at four concentrations in the 
analysis range. To measure the repeatability of the method with time, three different runs were 
analyzed. The FDA guidance for industry “Bioanalytical Method Validation” criteria was used 
as a reference, with no more than 15% coefficient of variation (CV) for the selected 
concentrations and ≤ 20% as a CV at the LLOQ.  
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Within the expected range of concentrations, the method produced satisfactory results 
without the use of an internal standard. In addition, sample preparative procedure did not 
diminish the recovery of 5-HMF. Consequently, an internal standard was deemed unnecessary.  
 
 
3.3.1.4 Selectivity 
 
As shown in Table 3-6, six sources of plasma were analyzed to test for interferences and 
to investigate the ability to differentiate and quantify 5-HMF in the presence of other endogenous 
components in the extracted plasma. The chromatograms for these are shown in Figures 3-8, 3-9, 
3-10, 3-11, 3-12, and 3-13. The ratio of the average area response of six replicates at the LLOQ 
concentration to that of six blank sources was 5.5.  
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Table  3-5. 5-HMF intra-run accuracy and precision in human plasma. 
Concentration 
(µM) R1 R2 R3 R4 R5 R6 Mean CV DFN% 
0 848 145 1028 705 1175 886.5 798 44.9  
0.16 4522 4131 4359 4357 4518 4405 4382 3.3 -11.8 
0.32 7080 7788 6609 7128 4936 6933 6746 14.3 7.5 
0.48 10006 10256 10084 9678 10358 9911 10049 2.4 4.3 
15.9 283536 281470 286576 282973 284034 286408 284166 0.7 14.6 
126.9 2716556 2454494 2391176 2404352 2387093 2415976 2461608 5.2 5.6 
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Table  3-6. 5-HMF inter-run accuracy and precision in human plasma. 
 0.16 µM 0.48 µM 15.9 µM 126.9µM 
First run R1 4348 10139 337282 3021407 
 R2 3964 10051 343673 3041115 
 R3 4410 9997 346116 3147102 
Second run R1 4522 10006 283536 2716556 
 R2 4131 10256 281470 2454494 
 R3 4359 10084 286576 2391176 
 R4 4357 9678 282973 2404352 
 R5 4518 10358 284034 2387093 
 R6 4405 9911 286408 2415976 
Third run R1 4825 12182 334845 2412090 
 R2 5907 13063 341995 2409259 
 R3 6510 13016 336680 2426958 
 
Mean 4688 10728 312132 2602298 
CV 16.0 11.7 9.4 11.4 
DFN% -18.6 -2.8 4.4 -0.1 
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Figure  3-8. Individual human plasma chromatogram (blank 1). 
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Figure  3-9. Individual human plasma chromatogram (blank 2). 
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Figure  3-10. Individual human plasma chromatogram (blank 3). 
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Figure  3-11. Individual human plasma chromatogram (blank 4). 
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Figure  3-12. Individual human plasma chromatogram (blank 5). 
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Figure  3-13. Individual human plasma chromatogram (blank 6). 
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In addition, three structurally related compounds, along with potential metabolites, 
namely, 5-hydroxymethylfuran-2-carboxylic acid (HMFA), and furan-2,5-dicarboxylic acid 
(FDCA), were studied to investigate the selectivity of this bioanalytical method. The three other 
compounds, named in Table 3-7, were reported to co-exist with 5-HMF in some infants dietary 
products as a result of excessive heat exposure of the protein and carbohydrates during the 
sterilization process of these products (Ferrer 2002). The absorbance of these compounds was 
scanned between 200 nm to 330 nm as demonstrated in Figure 3-14. As evident in Table 3-7, the 
calculated molar absorptivity and λmax indicates a potential interference of these compounds in 
case of their presence in the sample if they are co-eluted with 5-HMF. Consequently, the 
compounds were injected separately into the HPLC column and in a mixture along with 5-HMF 
under the same chromatographic conditions of this analytical method. The chromatogram for the 
mixture is shown in Figure 3-15 below.  
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Figure  3-14. Furan carboxylic acids and furfurals UV spectrum. 
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Table  3-7. Molar absorptivity of furan carboxylic acids and furfurals. 
 
λmax (nm) 
ε (AbsU/M/cm) 
 λmax 285 nm 
5-HMF 283.8 19913 19452 
5-Hydroxymethyl)furan-2-carboxylic acid (HMFA) 256.7 12854 817 
Furan-2,5-dicarboxylic acid (FDCA) 265.4 18692 3430 
Acetylfuran (AF) 274.4 11843 12224 
5-Methylfuran-2-carbaldehyde (MF) 292.3 15785 5473 
2-Furfural (2F) 276.9 12022 11748 
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Figure  3-15. Furan carboxylic acids and furfurals chromatogram. 
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The relationship between these compounds’ logP values, calculated via ChemSketch 
(ACD Labs), vs their retention factors (k’) was plotted in Figure 3-16. The k’ values were 
calculated according Equation 3-1 and are listed in Table 3-8. tR´ in Equation 3-1 was calculated 
according to Equation 3-2, where the mobile phase retention time (tM) was estimated to be 3.1 
minutes. A positive trend was observed with increasing the hydrophobicity of the compounds 
relative to their retention time (tR). However, the slope for the linear regression model was not 
significant (p-value > 0.05).  
 
k’=  tR´/tM… … … … … … … … … … … … … … … … … … … … … . . … … … … . … … … . … Equation 3 − 1 
 
tR´=  tR - tM… … … … … … … … … … … … … … … … … … … … … . . … … … … . … … … … Equation 3 − 2 
 
The insignificant model might be due to the small number of compounds incorporated in 
this relationship. In addition, considering the structure of 2-furfural, the calculated logP value 
seemed higher than what is expected. This calculated logP for 2-furfural is higher than that for 
acetylfuran although the latter has an additional methyl group. Therefore, the assigned logP 
value appears to be overestimated for 2-furfural. Moreover, FDCA was retained in the column to 
a greater extent than what is predicted using its logP value. The pH of the mobile phase is 3 and 
FDCA should be mainly unionized at that pH, which might increased its lipophilic 
characteristics. Unfortunately, we were not able to obtain a pka values for these compounds. 
Consequently, the compounds with acidic were excluded from the group and the relationship was 
re-plotted in Figure 3-17. An improvement in the association was observed, however, the slope 
remained insignificant.   
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Figure  3-16. Furan carboxylic acids and furfurals calculated logP vs k’. 
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Figure  3-17. Furfurals calculated logP vs k’. 
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Table  3-8. 5-HMF and its metabolites along with structurally related furfurals calculated logP and retention properties. 
Compound Name Structure Calculated logP Retention time (min) k' 
5-HMF 
O
O
HOH
 
-0.45 ± 0.27 6.6 1.1 
HMFA 
O
O
OH
OH
 
-0.55 ± 0.33 7.1 1.3 
FDCA 
O
O
OHO
OH
 
-0.02 ± 0.41 45.0 13.5 
AF 
O
O
CH3
 
0.52 ± 0.31 17.6 4.7 
2F 
O
O
H
 
0.73 ± 0.26 9.6 2.1 
MF 
 
O
O
H
CH3
 
1.19 ± 0.26 22.2 6.2 
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After the exclusion of acids from the correlation between the logP and the corresponding 
retention factor (k’) for the compounds, shown in Figure 3-17, the r value increased from 0.18 to 
0.79. Equation 3-3 describes the relationship between k’ and logP in this HPLC system.  
 
k’= 2.6*(logP) + 2.2… … … … … … … … … … … … … … … … … … … … … . . … … … … . Equation 3 − 3 
 
The use of logP value as a factor affecting the retention of the compounds is based on the 
partitioning properties of these compounds between the hydrophobic C18 stationary phase and the 
hydrophilic mobile phase. However, secondary hydrogen bonding interactions with the free 
silanol groups might have existed. A change in the column to one with better end capping quality 
to minimize the secondary interactions might result in an improved relationship between the logP 
and the retention properties.  
Both UV absorptivity and retention properties, summarized in Table 3-9, can potentially 
cause an interference in 5-HMF analysis if the compounds happened to coexist with 5-HMF in 
the sample. The interference of FDCA in this assay method is not expected due to the difference 
in the retention time between FDCA and 5-HMF. On the other hand, as shown in the 
chromatogram, HMFA and 5-HMF peaks overlap. In the presence of equimolar amounts of 
HMFA and 5-HMF, it will be difficult to recognize the presence of HMFA since 5-HMF 
absorption at 285 is 23.8 times higher than HMFA. Nevertheless, HMFA is not expected to 
survive the extraction method since the washing solution is PBS with a pH of 7.4, at which 
HMFA is expected to be fully ionized and washed away.   
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Table  3-9. HPLC-UV selectivity contributors of furfurals. 
 λmax (nm) Rt (min) 
5-HMF 283.8 6.6 
5-Hydroxymethylfuran-2-carboxylic acid (HMFA) 256.7 7.1 
Furan-2,5-dicarboxylic acid (FDCA) 265.4 45.0 
Acetylfuran (AF) 274.4 17.6 
2-Furfural (2F) 276.9 9.6 
5-Methylfuran-2-carbaldehyde (MF) 292.3 22.2 
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3.3.1.5 Calibration Curve 
 
The relationship between 5-HMF concentrations in plasma and the UV detector response 
was modeled by a linear regression algorithm in the range of 0.16 – 158.9 µM, as demonstrated 
in Figure 3-18. Three replicates were used to define the analytical relationship. As evident in 
Table 3-10, all the concentrations (excluding the blank) in the defined analytical range were 
within 92.6-104.4% of the nominal concentrations and did not exceed 7% in their coefficient of 
variation.  
The lowest value in the calibration curve, which is 0.16 µM, was deemed as the LLOQ. 
The response of the blank at the retention time of 5-HMF, was not more than the 20% of the 
LLOQ response at the specified retention time. The ratio of the average response of six replicates 
at the LLOQ to that of the six sources of blanks was 5.5. The average of the analytical results for 
a minimum of six replicates at the LLOQ had DFN value of 7.4 %. The CV at the LLOQ did not 
exceed 5.7% as a measure of precision.  
Due to the wide analytical range, a weighing factor of (1/X) was used in the established 
linear model. All the individual calibration curves had significant slopes and non-significant 
intercepts. The residual plot, shown in Figure 3-19, demonstrates over- and underestimation of 
the values predicted by the linear regression when compared with the observations. The residuals 
were distributed above and below the zero-line. Hence, the linear regression with a weighting 
factor of 1/X was deemed as a suitable model to describe and interpolate the response associated 
with 5-HMF analytical concentrations.   
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Figure  3-18. 5-HMF response-concentration curve in human plasma. 
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Table  3-10. 5-HMF standard curve. 
Concentration (µM) R1 R2 R3 Mean CV Average DFN% 
0.16 4348 3964 4410 4241 5.7 7.4 
0.32 7328 7737 6732 7266 7.0 1.0 
1.6 32592 32385 32873 32617 0.8 -1.7 
3.2 62716 63458 63556 63243 0.7 -3.7 
7.9 156979 153307 157812 156033 1.5 -4.4 
31.7 649542 650343 663931 654605 1.2 0.6 
79.3 1606296 1595854 1586900 1596350 0.6 -1.8 
158.9 3251346 3283051 3322955 3285784 1.1 1.1 
 
Slope 20364.9 20437.1 20611.2 20471.1 0.6 
 Intercept 782.0 594.3 568.3 697.5 18.0 
r2 0.9999 0.9997 0.9995 0.9997 0.02 
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Figure  3-19. Area residuals by the predicted area. 
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3.3.1.6 Dilution Integrity 
 
A solution was prepared at 7.9 mM of 5-HMF in the plasma matrix and then diluted with 
the blank plasma matrix to 158.9 µM. Triplicates were analyzed in three different runs. The 
results are shown in Table 3-11.  
 
3.3.1.7 Stock Solution Stability 
 
A solution of 15.8 µM of 5-HMF was analyzed using the HPLC method. Then, the 
solution was left at RT for about 5.5 hours. After that, triplicates of that solution were reanalyzed 
and compared to the measurement when freshly prepared. The 95% confidence intervals of the 
means, shown in Table 3-12, were compared and were considered equivalent. The working 
solution was deemed stable at RT for 5.5 hours.  
 
3.3.1.8 Post-Preparative Stability 
 
Triplicates of processed samples at low, mid, and high QC concentrations were kept in 
the autosampler for around 48 hours and then reanalyzed. Their results were compared to those 
freshly analyzed, as shown in Table 3-13. A null hypothesis (H0) of μ fresh ≥ μ48 hrs in autosampler  at 
each concentration was tested using a paired t-test. In each case the p-value was greater than 
0.05. Hence, the processed samples were considered stable for 48 hours residence-time in the 
autosampler.  
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Table  3-11. Accuracy and precision for diluted samples. 
First run 
R1 2898187 
R2 3114074 
R3 2992520 
Second run 
R1 3080501 
R2 2973592 
R3 3036628 
Third run 
R1 3160578 
R2 3099857 
R3 2962983 
 
Mean 3035436 
CV 2.6 
DFN% 7.1 
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Table  3-12. Working-solution stability at RT results. 
 Freshly  prepared After 5.5 hours at RT 
R1 256105 263072 
R2 260565 263659 
R3 264585 268184 
 
Mean 260418 264972 
CV 1.6 1.1 
95% Confidence interval 249881- 270956 258023- 271921 
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Table  3-13. Short-term stability results. 
 0.48 µM 15.8 µM 126.9 µM 
 Fresh 
After 
autosampler 
storage 
Fresh 
After 
autosampler 
storage 
Fresh 
After 
autosampler 
storage 
R1 10139 11264 337282 379305 3021407 3402782 
R2 10051 12425 343673 381153 3041115 3254875 
R3 9997 10993 346116 389284 3147102 3359762 
 
Mean 10062 11561 342357 383247 3069875 3339140 
CV 0.7 6.6 1.3 1.4 2.2 2.3 
Prob< t > 0.05 > 0.05 > 0.05 
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3.3.2 5-HMF in Rat, Mouse, and Dog Plasma 
 
The same HPLC-UV assay method validated in human plasma was investigated for the 
determination of 5-HMF in rat, mouse, and dog plasma. A descriptive summary of the method is 
shown in Table 3-14.  
To ensure the suitability and reliability of the developed method for the intended 
measurements, validation of this analytical method in rat, mouse, and dog plasma was evaluated 
through the following: 
 
 
3.3.2.1 Accuracy 
 
Within-assay accuracy was determined for six replicate measurements at three different 
concentrations, in addition to the LLOQ, were determined. The DFN value was used as a 
measure of accuracy in the analytical range. The absolute DFN value did not exceed 15% at any 
of these concentrations including the LLOQ, as shown in Tables 3-15, 3-16, and 3-17. 
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Table  3-14. 5-HMF assay descriptive summary in species plasma. 
Type of assay: HPLC-UV 
Sample preparation: Solid phase extraction of diluted Plasma by Oasis HLB cartridges (Waters) 
Detector: Shimadzu 10 AV Absorbance Detector 
LC pump: Waters 600E Multisolvent Delivery System 
LC column:  Zorbax Rx C18, 80 A
o, 150 mm x 4.6 mm, 5 μm 
(Agilent, Serial # USDU010028) 
Guard column: C18, 12.5 mm x 4.6 mm (Agilent, Serial # USCI042710) 
Detection: UV at 285 nm 
Autosampler temperature: 4 °C 
Flow rate: 0.75 ml/min 
Regression algorithm: Linear, weighted 1/X 
Sample volume and matrix: 0.3 ml of plasma suspension, extract to 0.5 ml sample 
Mobile phase Water-methanol-acetic acid-tetrahydrofuran (93.5:6.2:1:0.3) 
Injection volume: 10 µl 
Chromatographic run time: 10 minutes 
Calibration curve range: Mouse: 1.6 – 158.9 µM, Rat: 1.6 – 158.9 µM, Dog: 0.16 – 158.9 µM 
Lower limit of quantitation: Mouse: 1.6 µM, Rat: 1.6 µM, Dog: 0.16 µM 
Quality control levels: Mouse: 2.4, 15.8, 126.9 µM, Rat: 2.4, 15.8, 126.9 µM, Dog: 0.48, 15.8, 126.9 µM 
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Table  3-15. 5-HMF intra-run accuracy and precision in mouse plasma. 
Concentration 
(µM) R1 R2 R3 R4 R5 R6 Mean CV DFN% 
0 6603 2209 6982    5265 50.4  
1.6 21363 21757 21323 23279 18398 22461 21430 7.8 1.1 
2.4 34029 30138 27702 37173 34145 35892 33180 10.8 6.9 
15.8 174194 179427 174667 187060 183122 179418 179648 2.7 -9.4 
126.9 1550036 1669814 1502977 1542189 1654157 1635667 1592473 4.3 1.0 
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Table  3-16. 5-HMF intra-run accuracy and precision in rat plasma. 
Concentration 
(µM) R1 R2 R3 R4 R5 R6 Mean CV DFN% 
0 4470 4024 3558    4017 11.4  
1.6 24934 21537 20593 18901 19997 19795 20960 10.2 -3.8 
2.4 34530 35786 33950 35969 34698 35574 35085 2.3 7.7 
15.8 192685 199316 214060 212831 221287 199441 206947 3.4 -4.3 
126.9 1638235 1729048 1783345 1665379 1908818 1679190 1734003 5.8 0.4 
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Table  3-17. 5-HMF intra-run accuracy and precision in dog plasma. 
Concentration 
(µM) R1 R2 R3 R4 R5 R6 Mean CV DFN% 
0 772 805 416    664 32.5  
1.6 4516 4255 4531 3647 5158 3428 4256 14.9 -1.8 
2.4 8226 9775 9346 9709 8746 9588 9232 6.7 3.8 
15.8 217652 227034 229274 232000 247277 204856 226349 6.3 -1.6 
126.9 1732705 1730375 1995461 1795253 1870952 1851862 1829435 5.5 0.2 
 
 157 
 
3.3.2.2 Precision 
 
 Within-run precision was determined for six replicates, shown in Tables 3-15, 3-16, and 
3-17 at four concentrations in the analysis range including the LLOQ. The FDA guidance for 
industry “Bioanalytical Method Validation” criteria were considered for acceptance with no 
more than 15% coefficient of variation for the selected concentrations and 20% as CV at the 
LLOQ.  
 
 
3.3.2.3 Selectivity 
 
As shown in Tables 3-15, 3-16, and 3-17, pooled plasma blank from at least six different 
sources were analyzed to test for interferences and to investigate the ability to differentiate and 
quantify 5-HMF in the presence of other endogenous components in the extracted plasma.  
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3.3.3 5-HMF in Human RBCs 
 
An HPLC-UV assay was developed for the determination of 5-HMF in human RBCs. A 
descriptive summary of the method is shown in Table 3-18. In addition, representative 
chromatograms are shown in Figures 3-20, 3-21, 3-22, and 3-23.  
To ensure the suitability and reliability of the developed method for the intended 
measurements, validation of this analytical method in human RBCs was evaluated through the 
following: 
 
 
3.3.3.1 Recovery 
 
The response of the extracted samples at low, medium, and high concentrations was 
compared to the response of unextracted known concentrations that represent 100% recovery. 
The efficiency of the extraction was reproducible with a CV less than 4% at each concentration. 
The CV was 17% through the calibration range with a recovery mean of 75.7%. The variability 
might be due to the big range (approximately 500 fold range) that can cause a difference in the in 
the performance of the extraction cartridges. Moreover, the recovery at the LLOQ was 
determined to be 80% with a CV not exceeding 3%, as summarized in Table 3-19.  
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Table  3-18. 5-HMF assay descriptive summary in human RBCs. 
Type of assay: HPLC-UV 
Sample preparation: Solid phase extraction of diluted RBCs by Oasis HLB cartridges (Waters) 
Detector: Shimadzu 10 AV Absorbance Detector 
LC pump: Waters 600E Multisolvent Delivery System 
LC column:  Zorbax Rx C18, 80 Ao, 150 mm x 4.6 mm, 5 μm 
Guard column C18, 12.5 mm x 4.6 mm 
Detection: UV at 285 nm 
Autosampler temperature: 4 °C 
Flow rate: 0.75 ml/min 
Regression algorithm: Linear, weighted 1/X 
Sample volume and matrix: 0.1 ml of RBCs suspension, extracted to 0.5 ml sample 
Mobile phase Water-methanol-acetic acid-tetrahydrofuran (93.5:6.2:1:0.3) 
Injection volume: 10 µL 
Chromatographic run time: 10 minutes 
Calibration curve range: 4.3 – 2379 µM 
Lower limit of quantitation: 4.3 µM 
Quality control levels: 9.5, 47.6, 1903 µM 
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Figure  3-20. Representative chromatogram of individual human RBCs blank. 
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Figure  3-21. Representative chromatogram of the LLOQ concentration. 
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Figure  3-22. Representative chromatogram of low QC concentration. 
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Figure  3-23. Representative chromatogram of mid QC concentration. 
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Table  3-19. 5-HMF recovery in human RBCs. 
Concentration 
(µM) R1 R2 R3 Mean CV% 
4 81.2 77.4 81.5 80.0 2.9 
10 90.9 91.7 89.4 90.7 1.3 
48 69.7 74.0 73.6 72.4 3.2 
1903 59.7 59.7 60.1 59.8 0.4 
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3.3.3.2 Accuracy 
 
Within-assay accuracy was determined for six replicate measurements at three different 
concentrations and at the LLOQ. The DFN value was used as a measure of the accuracy in the 
analytical range. The absolute DFN value did not exceed 15% at any of these concentrations 
including the LLOQ, as shown in Table 3-20. 
 
 
3.3.3.3 Precision 
 
Within-run precision was determined for six replicates, shown in Table 3-20, at four 
concentrations in the analysis range including the LLOQ. The FDA guidance for industry 
“Bioanalytical Method Validation” criteria were considered for acceptance with no more than 
15% CV for the selected concentrations and 20%  or less as the CV at the LLOQ.  
 
3.3.3.4 Selectivity 
 
As shown in Table 3-20, six different sources of RBCs were analyzed to test for 
interferences and to investigate the ability to differentiate and quantify 5-HMF in the presence of 
other endogenous components in the extracted RBCs. The ratio of the average area response of 
six replicates at the LLOQ concentration to that of six blank sources was 5.1.  
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Table  3-20. 5-HMF intra-run accuracy and precision in human RBCs. 
Concentration 
(µM) R1 R2 R3 R4 R5 R6 Mean CV DFN% 
0 2934 2514 2552 2594 3001 3897 2915 17.9  
4 15287 14555 15341 14730 14394 14350 14776 3.0 -3.2 
10 42751 43151 42055 43816 43857 42589 43037 1.7 -12.6 
48 211185 224117 222822 221966 220153 225901 221024 2.4 -7.8 
1903 7598597 7603656 7649638 8279831 8025133 7950308 7851194 3.6 6.0 
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3.3.3.5 Calibration curve 
 
The relationship between 5-HMF concentration in RBCs and the UV detector response 
was modeled by a linear regression algorithm in the range of 4-2379 µM, as demonstrated in 
Figure 3-24. Three replicates were used to define the analytical relationship. As evident in Table 
3-21, the concentrations in the defined analytical range were within 88.2-114.6% of the nominal 
concentrations and did not exceed 3% in their coefficient of variation. These results meet the 
acceptance criteria of having at least four of six concentrations within the accuracy and precision 
limits including the lowest and highest concentration.  
The lowest value in the calibration curve, which is 4 µM, was deemed as the LLOQ. The 
response of the blank at the retention time of 5-HMF, was not more than the 20% of the LLOQ 
response at the specified retention time. The ratio of the average response of six replicates at the 
LLOQ to that of the six sources of thee blanks was 5.1. The average of the analytical results for a 
minimum of six replicates at the LLOQ had DFN value of 13.6%. The CV at the LLOQ did not 
exceed 3% as a measure of precision. The intercept of the equation was not statistically 
significant. 
Due to the wide analytical range, a weighing factor of (1/X) was used in the established 
linear model. The calibration curve had a significant slope and a non-significant intercept.  
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Figure  3-24. 5-HMF response-concentration curve. 
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Table  3-21. 5-HMF standard curve. 
Concentration 
(µM) R1 R2 R3 Mean CV 
Average 
DFN% 
4 15287 14555 15341 15061 2.9 13.6 
5 20287 20134 20635 20352 1.3 14.6 
24 90157 88275 91153 89862 1.6 -11.8 
95 367338 366141 376163 369881 1.5 -11.1 
238 995900 1013878 999394 1003057 1.0 -3.3 
952 3995286 3827174 4055532 3959331 3.0 -5.0 
2379 10763231 10884655 10384749 10677545 2.4 2.6 
 
 Value p-value 
Intercept -4479.3 0.52 
Slope 4372.9 <0.0001 
r2 0.998  
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3.3.4 5-HMF in Rat, Mouse, and Dog RBCs 
 
An HPLC-UV assay was developed for the determination of HMF in rat, mouse, and dog 
RBCs. A descriptive summary of the method is shown in Table 3-22.  
To ensure the suitability and reliability of the developed method for the intended 
measurements, validation of this analytical method in rat, mouse, and dog RBCs was evaluated 
through the following: 
 
 
3.3.4.1 Accuracy 
 
Within-assay accuracy was determined for six replicate measurements at three different 
concentrations and at the LLOQ. The DFN value was used as a measure of accuracy in the 
analytical range, as shown in Tables 3-23, 3-24, and 3-25. 
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Table  3-22. 5-HMF assay descriptive summary in species RBCs. 
Type of assay: HPLC-UV 
Sample preparation: Solid phase extraction of diluted RBCs by Oasis HLB cartridges (Waters) 
Detector: Shimadzu 10 AV Absorbance Detector 
LC pump: Waters 600E Multisolvent Delivery System 
LC column:  Zorbax Rx C18, 80 A
o, 150 mm x 4.6 mm, 5 μm 
(Agilent, Serial # USDU010028) 
Guard column C18, 12.5 mm x 4.6 mm (Agilent, Serial # USCI042710) 
Detection: UV at 285 nm 
Autosampler temperature: 4 °C 
Flow rate: 0.75 ml/min 
Regression algorithm: Linear, weighted 1/X 
Sample volume and matrix: 0.1 ml of RBCs suspension, extracted to 0.5 ml sample 
Mobile phase Water-methanol-acetic acid-tetrahydrofuran (93.5:6.2:1:0.3) 
Injection volume: 10 µL 
Chromatographic run time: 10 minutes 
Calibration curve range: Mouse: 8.6 – 4757.8 µM, Rat: 8.6 – 4757.8 µM, Dog: 8.6 – 4757.8 µM 
Lower limit of quantitation: Mouse: 8.6 µM, Rat: 8.6 µM, Dog: 8.6 µM 
Quality control levels: Mouse: 19.0, 95.2, 3806.2 µM, Rat: 19.0, 95.2, 3806.2 µM, Dog: 19.0, 95.2, 3806.2 µM 
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Table  3-23. 5-HMF intra-run accuracy and precision in mouse RBCs. 
Concentration 
(µM) R1 R2 R3 R4 R5 R6 Mean CV DFN% 
0 1851 2029 1379    1753 19.2  
8.6 4055 3427 3637 4058 3072 4878 3854 16.3 -492.4 
19 9084 8992 8641 11221 8397 9679 9336 10.9 -46.2 
95 135741 126266 127200 132624 125519 123645 128499 3.6 -14.1 
3806 6437939 6537972 6681089 6647384 6923159 6542404 6628325 2.5 0.3 
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Table  3-24. 5-HMF intra-run accuracy and precision in rat RBCs. 
Concentration 
(µM) R1 R2 R3 R4 R5 R6 Mean CV DFN% 
0 2686 1215 1174    1692 50.9  
8.6 26021 23840 26034 24697 24542 24981 25019 3.5 11.6 
19 33723 35661 33846 31389 26440 - 32212 11.1 -24.8 
95 208477 215522 202883 209306 210404 195089 206947 3.4 8.1 
3806 7442537 7419570 7552769 7304463 7151040 7679852 7425039 2.5 -0.1 
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Table  3-25. 5-HMF intra-run accuracy and precision in dog RBCs. 
Concentration 
(µM) R1 R2 R3 R4 R5 R6 Mean CV DFN% 
0 0 1060 822    627 88.7  
8.6 24142 21922 22295 23465 22352 23009 22864 3.7 -3.5 
19 44696 45340 43986 42051 46204 46407 44781 3.6 3.0 
95 206939 188630 179375 188713 191056 178310 128499 3.6 2.1 
3806 7445653 6887127 6821685 6933841 6663242 7780804 6628325 2.5 -0.1 
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3.3.4.2 Precision 
 
 Within-run precision was determined for at least five replicates, shown in Tables 3-23, 3-
24, and 3-25 at four concentration levels in the analytical range including the LLOQ. The FDA 
guidance for industry “Bioanalytical Method Validation” criteria were considered for acceptance 
with no more than 15% coefficient of variation for the selected concentrations and 20% or less as 
the CV at the LLOQ. 
 
 
3.3.4.3 Selectivity 
 
As shown in Tables 3-23, 3-24, and 3-25, pooled RBCs from at least six different sources 
were analyzed to test for interferences and to investigate the ability to differentiate and quantify 
5-HMF in the presence of other endogenous components in the extracted RBCs.  
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3.3.5 Other Matrices 
 
The development of this analytical method involved 5-HMF analysis in neat solution, as 
shown in to Table 3-26. In addition, the same method was used in the measurement of 5-HMF in 
the ultrafiltrate of human serum albumin and hemoglobin PBS solutions. For each study, a 
calibration curve in PBS was analyzed in conjunction with the samples. Samples and calibration 
curve standards were injected directly into HPLC. Table 3-27 is showing some of the PBS 
calibration curves.  
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Table  3-26. 5-HMF standards in neat solution. 
Concentration (µM) R1 R2 R3 Mean CV 
0.08 20280 21533 21900 21238 4 
0.40 111678 112737 113100 112505 0.7 
0.79 218133 218354 218880 218456 0.2 
11.9 3330060 3322928 3319840 3324276 0.2 
47.6 13349916 13302739 13323871 13325509 0.2 
79.3 21462393 21492723 21453369 21469495 0.1 
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Table  3-27. 5-HMF standards in PBS. 
Concentration (µM) R1 R2 R3 R4 Mean CV 
0.2 6312 6764 6904 5165 6286 13 
0.8 21454 20635 22599 19085 20943 7 
4.0 97756 90331 99556 91037 94670 5 
7.9 216324 185712 175796 172020 187463 11 
39.6 1142549 958669 837630 866326 951294 14 
79.3 2175225 1753218 1687014 1727478 1835734 12 
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3.3.6 HMFA in Human Hepatic Cytosol 
 
In order to supplement 5-HMF metabolic stability studies in hepatic cytosol, a method 
was developed to qualitatively detect HMFA in human hepatic cytosol incubated with 5-HMF. 5-
HMF and HMFA peaks overlapped, as shown previously in Figure 3-15, using the above 
described method. Consequently, a new mobile phase was prepared of water and methanol, in 
which tetrabutylammonium was dissolved. A summary of the method is described in Table 3-28 
and a chromatogram showing the peaks of both 5-HMF and HMFA standards in Tris buffer, is 
shown in Figure 3-25. Response-concentration curves for 5-HMF and HMFA in buffer are 
shown in Figures 3-26 and 3-27, respectively. In addition, the chromatograms of a blank cytosol 
and two concentrations of HMFA added to the cytosol are shown in Figures 3-28, 3-29, and 3-
30. As demonstrated in Figure 3-28, a peak in the blank cytosol is present in the retention 
window of 5-HMF, and in particular HMFA. However, for a qualitative purpose, the method was 
deemed satisfactory. A standard curve of HMFA was investigated in the cytosol and is shown in 
Figure 3-31.   
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Table  3-28. 5-HMF assay descriptive summary in human hepatic cytosol 
Type of assay: HPLC-UV 
Sample preparation: Dilution of with ice-cold acetonitrile and water.  
Detector: Shimadzu 10 AV Absorbance Detector 
LC pump: Waters 600E Multisolvent Delivery System 
LC column:  Zorbax Rx C18, 80 A
o, 150 mm x 4.6 mm, 5 μm 
(Agilent, Serial # USDU010028) 
Guard column C18, 12.5 mm x 4.6 mm (Agilent, Serial # USCI042710) 
Detection: UV at 260 nm 
Autosampler temperature: 4 °C 
Flow rate: 1 ml/minute 
Sample volume and matrix: 100 µl diluted to 800 µl (650 µl water and 50 µl acetonitrile) 
Mobile phase Water-methanol (83:17), 0.2% w/v tetrabutylammonium iodide 
Injection volume: 10 µL 
Chromatographic run time: 10 minutes 
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Figure  3-25. 5-HMF (0.79 mM) and HMFA (0.90 mM) chromatogram. 
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Figure  3-26. HMFA response-concentration curve. 
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Figure  3-27. 5-HMF response-concentration curve. 
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Figure  3-28. Cytosol blank chromatogram. 
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Figure  3-29. HMFA standard in hepatic cytosol (0.9 mM) 
 
 
HMFA 
 186 
 
 
 
Figure  3-30. HMFA standard in hepatic cytosol (6.0 mM). 
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Figure  3-31. HMFA calibration curve in human cytosol. 
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CHAPTER 4 
4  
5-HMF IN-VITRO METABOLISM IN HEPATIC CYTOSOL OF DIFFERENT SPECIES 
 
 
4.1 Introduction 
 
Different in-vitro methodologies are used to predict human clearance. An example of that 
is recombinant enzymes; however, the artificial nature of this matrix represents a drawback of 
the recombinant system (Hallifax 2009). Hepatocytes are considered more physiological and 
give an idea about the cumulative metabolic rate for a drug if detoxified by different enzymes. 
However, identifying the exact metabolic pathway is challenging with the use of hepatocytes 
(Gupta 2006).   
In general, metabolic stability studies follow the scheme introduced in Figure 4-1. These 
studies investigate the disappearance of the parent drug or the formation of the metabolite 
(Houston 2008). Initially, they result in pseudo-zero order kinetics that is estimated over a period 
of time (Houston 2008). Non-linear regression modeling is used to estimate the in-vitro 
metabolic parameters from the concentration-dependent initial metabolic rate profile. Then the 
metabolic parameters are used in the in-vitro intrinsic clearance calculation. Physiological 
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scaling variables are used to predict the in-vivo intrinsic clearance value from the in-vitro 
intrinsic clearance. This is further extrapolated to organ clearance using different models such as 
the well-stirred model to incorporate the hepatic blood flow limitation. The use of well-stirred 
model for projecting the hepatic clearance was justified by its mathematical simplicity and 
applicability for drugs with low intrinsic clearance (Houston 2008). This model assumes a 
uniform distribution of the relevant enzymes in the liver tissues and that merely the unbound 
drug fraction is subject to metabolism, which is made available to enzymes by hepatic perfusion 
(Houston 2008).  
5-HMF structure and the known metabolites indicate its in-vivo oxidation rather than 
reduction, which might, otherwise, utilized the aldo/keto reductase enzymes (Marchitti 2008). 
Alternatively, aldehyde group oxidation can be carried-out by different enzymes, such as 
xanthine oxidase, aldehyde oxidase, and aldehyde dehydrogenase (ALDH) (Marchitti 2008). 
Nevertheless, xanthine oxidase, as its names indicates, is involved in the oxidation of purines 
(Beedham 1997). Thus, its role in 5-HMF metabolism is assumed to be minimal. On the other 
hand, aldehyde oxidase is implicated in the oxidation of N-containing heterocyclic compounds, 
such as antiviral drugs (Beedham 1997). Nevertheless, aldehyde oxidase metabolizes other 
aromatic aldehydes such as vanillin (Sahi 2008). The other moiety of 5-HMF that is susceptible 
to metabolism is the alcohol group, which is most likely metabolized by alcohol dehydrogenase 
(ADH) after excluding the other oxidizing enzymes and considering its structural similarity with 
ethanol. Table 4-1 lists these oxidizing enzymes and their respective cofactors. 
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Figure  4-1. In-vitro-in-vivo extrapolation steps. Adapted from (Hallifax 2009) 
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Table  4-1. Oxidative enzymes (Beedham 1997) 
Enzyme Oxidative Reaction Cofactor 
ALDH Aldehyde oxidation NAD(P)+ 
ADH Alcohol oxidation NAD+ 
Aldehyde oxidase Aldehyde oxidation, C-oxidation of N-heterocycles O2 
Monoamine oxidase Oxidative deamination O2 
Flavine monooxygenase N-oxidation NADPH, O2 
Xanthine oxidase C-oxidation of purines NAD+, O2 
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Hepatic cytosol was selected for the purpose of predicting the intrinsic clearance of 5-
HMF in humans and other species for the following reasons: 
- The liver was reported to have high 5-HMF- related radioactivity in mice and rats 
after oral administration of 5-HMF (Godfrey 1999).   
- It is a rich resource of ALDH and ADH enzymes (Gupta 2006). 
- Human and other species cytosol is commercially available (Brandon 2003).   
- It is an ethically acceptable medium for investigating enzyme kinetics (Brandon 
2003). 
- Studies with hepatic cytosol from different species were carried-out in the PK/PD 
laboratory at VCU and the following were demonstrated (Gupta 2006):  
- Successful prediction of in-vivo clearance of other substrates, such as 
ethanol and propylene glycol. 
- Demonstration of inter-species differences in hepatic cytosol metabolism.   
- The metabolism by both ALDH and ADH enzymes can be measured simultaneously 
by a simple spectrophotometric method. NADH is measured as a common product for 
both enzymes at 340 nm.  
The specificity of NADH production is assumed since none of the other oxidizing 
enzymes, if present in this system, has the potential to oxidize 5-HMF and produce NADH 
simultaneously.  
Since NADH is a common product for both of ALDH and ADH enzymes, selective 
inhibitors were used to determine the individual contribution of each enzyme. 4-methylpyrazole 
and disulfiram were selected as the selective inhibitors for ADH and ALDH, respectively.  4-
methylpyrazole, known as fomepizole, is used clinically as an antidote to treat alcohol and 
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ethylene glycol intoxication (Druteika 2002) (Bestic 2009). 4-methylpyrazole was shown to be a 
competitive reversible inhibitor for ADH enzyme (Bestic 2009) (C. D. Cheung 2003) (Plapp 
1984). In comparison with ethanol, its affinity for ADH was reported to be approximately 8000 
fold greater than that of ethanol (Bestic 2009). Its mechanism of action was found to involve the 
formation of a ternary complex involving NAD+, ADH Zinc element, and 4-methylpyrazole 
preventing the substrate from the interaction with the enzyme (Bestic 2009). In a study 
conducted by Cheung, 38% of the control ADH activity remained in rat liver cytosol after using 
1 M of 4-methylpyrazole  as the highest inhibitory concentration (C. D. Cheung 2003).  
On the other hand, disulfiram (tetraethylthiuram disulfide, Antabuse) is also used 
clinically for the treatment of alcoholism by inducing obnoxious effects of drinking, termed as 
“aversion therapy” (Kitson 1975) (Shena 2001). Although it is well agreed that these effects are 
due to the accumulation of acetaldehyde as a consequence of ALDH inhibition after the 
administration of disulfiram (Keung 1993), its mode of inhibition is controversial. The 
interaction with ALDH was stated to be a rapid, strong, non-competitive, and reversible 
inhibition (A. R. Klyosov, Possible Role of Liver Cytosolic and Mitochondrial Aldehyde 
Dehydrogenases in Acetaldehyde Metabolism 1996). Cheung et. al. used disulfiram as an 
inhibitor of ALDH enzyme stating that it is a competitive, reversible inhibitor (C. H. Cheung 
2003). On the other hand, when tested with cytoplasmic ALDH of sheep liver, disulfiram caused 
an initial inhibition, after which an increase in the inhibition was observed over time, indicating 
an irreversible mode of inhibition (Kitson 1975). Cytosolic ALDH is believed to be “disulfiram 
sensitive” with a Ki of 13, 15, and 200 nM in hamster, rat, and human, respectively (A. R. 
Klyosov, Possible Role of Liver Cytosolic and Mitochondrial Aldehyde Dehydrogenases in 
Acetaldehyde Metabolism 1996).  
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In addition to human, the metabolic studies were conducted in mouse, rat, and dog 
hepatic cytosol to explore potential differences in 5-HMF metabolism and consequently 
disposition among these species. Gupta reported different Km and vmax values ranging between 
0.8-14 mM and 0.05-2.8 mmol/min, respectively, for in-vivo ethanol metabolism, mediated by 
ADH, in rat, rabbit, dog, and human (Gupta 2006). Cheung and co-workers also observed that 
the cytosolic ADH of rodents had a lower metabolic efficiency of ethanol than that of human (C. 
D. Cheung 2003). Moreover, interspecies differences in ALDH enzyme were also reported. 
Klyosov and co-workers found that human cytosolic ALDH is more acidic than that of rat and 
hamster (A. R. Klyosov, Possible Role of Liver Cytosolic and Mitochondrial Aldehyde 
Dehydrogenases in Acetaldehyde Metabolism 1996). In addition, human ALDH appears to be 
tetrameric with a molecular weight exceeding 1.5 fold of that in rodents, which is probably 
dimeric (A. R. Klyosov, Possible Role of Liver Cytosolic and Mitochondrial Aldehyde 
Dehydrogenases in Acetaldehyde Metabolism 1996). All of these findings emphasize the 
complementary role of in-vitro approaches in explaining the results of in-vivo animal studies in 
the preclinical phase. Hence, the objective of the proposed in-vitro studies is to mechanistically 
investigate 5-HMF disappearance in human hepatic cytosol and to identify and compare the 
metabolism of 5-HMF in human, dog, rat, and mouse hepatic cytosol. 
 
 
  
 
 
.  
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4.2 Methods 
 
4.2.1 Materials and Reagents 
 
1. BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
2. 4-Dimethylaminonaphthaldehyde, (DN) Solution:  
- 4-Dimethylaminonaphthaldehyde 97% (Aldrich, Milwaukee, WI) 
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
3. Ethanol Solution:  
- Ethanol 200 proof, 99.5% (Aldrich, Milwaukee, WI). 
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
4. Acetaldehyde Solution: 
- Acetaldehyde, ACS 99% (Sigma-Aldrich, Milwaukee, WI).  
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
5. 5-Hydroxymethyl-2-furfural (5-HMF) Solution: 
- 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO). 
-  BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
6. 4-Methylpyrazole (4-MP) Solution: 
- 4-MP, 99% (Sigma-Aldrich, Milwaukee, WI).  
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
7. Tetraethylthiuram Disulfide (Disulfiram) Solution: 
- Disulfiram, purum 97% (Sigma-Aldrich, Milwaukee, WI).  
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
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8. Liver Cytosol: 10 mg protein/ml (XenoTech, Lenexa, KS):  
- human: mixed gender, pool of 50 (Hispanic (8), Caucasian (41), Asian (1), 50 ± 14 
years old). 
- dog: pooled Beagle males.  
- rat: pooled Fischer 344 males. 
- mouse: pooled B6C3F1 males.  
9. Cytosol Diluent: 
- Bovine serum albumin (BSA) (Sigma, St. Louis, MO). 
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
10. Cofactor Solution,  β-Nicotinamide Adenine Dinucleotide (NAD+) Solution: 
- NAD+ from yeast (Sigma, St. Louis, MO). 
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
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4.2.2 Equipment 
 
1. 25-µl, 50-µl, and 250-µl positive displacement pipettes and corresponding pipette tips 
(Microman, Rainin Instruments, Oakland, CA). 
2. 10-µl, 100-µl, and 1000-µl VWR pipettes and corresponding pipette tips (VWR, West 
Chester, PA). 
3. 0.5-5 ml Finnpipette (Thermo Scientific, Waltham, MA). 
4. Vortex (Vortex-Genie, VWR, West Chester, PA). 
5. Sonicator (American Brand Products C6450-11, VWR, West Chester, PA).  
6. pH meter (Corning, Glendale, AZ). 
7. Balance (Fisher Scientific A 250, Pittsburgh, PA). 
8. Synergy™ 2 multi-mode microplate reader (BioTek, Winooski, VT). 
9. Falcon assay plate, 96 reaction wells (VWR, West Chester, PA). 
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4.2.3 Preparation of Solutions 
 
- Cofactor solution, β-nicotinamide adenine dinucleotide (β-NAD+) solution 
22.3 g of NAD+ (M.W.: 663.43 Da) was dissolved in 3 ml of Tris buffer to prepare 1.4 
mM solution.  
 
- Cytosol diluent 
BSA (M.W.: 66 kDa) was dissolved in Tris buffer to prepare 0.1% w/v. Solutions were 
kept cold during the experiment. 
 
- Cytosol solution  
Concentrated cytosol protein solution (10 mg/ml) was mixed with the cytosolic diluents 
to prepare a 4 mg/ml solution. For DN concentration-dependency experiments, a 2 mg/ml 
solution was prepared. Fresh solutions were prepared and kept cold during the 
experiment.  
 
- Substrates solution 
Solution at different concentrations of 5-HMF were prepared in Tris buffer. The 
measurement of NADH at low substrate concentration was limited by the assay 
sensitivity in some cases. In addition, the measurement of NADH at a high substrate 
concentration was limited by the solubility of 5-HMF and its high baseline absorbance. 
Since the Km for other substrates: ethanol (M.W. 46.07 Da), acetaldehyde (M.W. 44.05 
Da), and DN (M.W. 199.25 Da) were reported in the literature, their solutions were 
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perpared considering a range of ten-times lower and ten-times higher concentration 
relative to their reported Km values, as summarized in Table 4-2.  
 
- Inhibitor solutions 
Solution of inhibitors, 4-methylpyrazole (M.W. 82.10 Da) and disulfiram (M.W. 296.54 
Da) were prepared to achieve a maximum inhibition of the relevant enzymes taking into 
consideration their reported Ki values, as shown in Table 4-3.  
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Table  4-2. Selective Substrates. 
Substrate Ethanol DN Acetaldehyde 
Structure 
 
 
 
Reported Km 
0.7 mM (Gupta 
2006) 
1.9 nM (A. R. Klyosov 
1996) 
180 µM (A. 
Klyosov 1996) 
Concentration 
Range Up to 24 mM Up to 66 nM 
Up to 333 µM in 
the presence of 
244 µM 4-MP 
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Table  4-3. Selective inhibitors. 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 4-Methylpyrazole Disulfiram 
Structure 
  
Reprted Ki (µM) 0.1-5 (Bestic 2009) 0.2   (A. R. Klyosov 1996) 
Concentration range (µM) 0.03-281 0.03-33.8 
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4.2.4 Procedures 
 
Cytosolic protein, NAD+ cofactor, and substrates at different concentrations in Tris buffer 
(pH 7.5) were mixed at a final volume of 0.2 ml. The reaction was initiated by the addition of 
cytosolic protein solution after allowing the mixture to equilibrate for approximately 5 min. 
Then, the increase in the absorbance at 340 nm at 37 °C was monitored over time. The change in 
the absorbance was converted to NADH concentration using Beer’s law, that relates the change 
in the absorbance to the concentration of absorbing species, as described by Equation 4-1. 
 
∆A =  ε × b × ∆c … … … … … … … … … … … … … … … … … … … … … . . … … … … . Equation 4 − 1  
 
Where  
∆A: measured absorbance change 
ε: the extenction coefficient of NADH at 340 nm  
b: pathlenght of the cell 
∆c: the concentration change of the absorbing species (NADH) 
The change in the concentration of NADH over time represents the velocity at which the 
enzyme is forming NADH and simulatenously oxidizing 5-HMF, assuming 1:1 reaction. For 
each concentration, the reaction time and the points used for charcterization of the intitial 
velocity were selected where a linear increase in the absorbance over time existed, demonstrating 
a pseudo-zero order reaction. At each concentration, a minumum of duplicate reactions were 
included in the data analysis. 
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4.2.5 Optimization Experiments 
 
The incubation conditions for the reaction were optimized through preliminary 
experiments. The concentration of the cofactor and the cytosol were selected after several 
experiments, so that the initial reaction rate could be observed at a zero-rate order increase in the 
absorbance, reflecting the NADH formation.  
 
 
4.2.6 Concentration-Dependency Studies 
 
These initial velocities were plotted against their corresponding substrate concentrations 
and were evaluated using Michaelis Menten kinetics. Michaelis Menten kinetics is characterized 
by a maximum velocity and an affinity constant, as shown in Equation 4-2. 
 
vi = vmax × CKm +  C +  v0 … … … … … … … … … … … … … … … … … … … … … … … … … … . Equation 4 − 2 
 
Where  
vi: the observed velocity 
v0: the baseline velocity observed in the absence of the substrate  
C: the substrate concentration 
vmax: the maximum velocity 
Km: the affinity constant  
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The data were fitted to Equation 4-2 using nonlinear regression (SigmaPlot® 10.0, Systat) 
to obtain the model parameter estimates. The goodness of fit was evaluated through the 
coefficient of determination (r2) values.   
                    In addition, linearization graphing methods, namely: a Lineweaver-Burk (double-
reciprocal) plot, a Eadie-Hofstee plot, and a Hanes-Woolf (half-reciprocal) plot, were used to 
inspect 5-HMF metabolic reaction in different species hepatic cytosol. The methods are 
described in Table 4-4.                  
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Table  4-4. Linearization graphing methods to assess Michaelis Menten kinetics. 
Lineweaver-Burk 
(double-reciprocal) Eadie-Hofstee 
Hanes-Woolf (half-
reciprocal) 
   
1/v against 1/[S]0 giving 
intercepts at 1/vmax and -
1/Km 
v against v/[S]0 giving 
intercepts at vmax and vmax/Km 
[S]0/v against [S]0 giving 
intercepts at Km/vmax and Km 
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4.2.7 Inhibition Studies 
 
 Taking into consideration their reported Ki values, different concentrations of inhibitors 
of 4-methylpyrazole and disulfiram were used. All reaction components except 5-HMF were 
incubated for approximately 15 minutes and 25 minutes with 4-methylpyrazole and disulfiram, 
respectively, after which 5-HMF (26 mM) was added. Reactions were run in triplicate and 
monitored at 340 nm. In addition, 26 mM of 5-HMF was incubated with 273 µM 4-
methylpyrazole and 17.4 µM disulfiram, simultaneously, using the same incubation conditions 
described previously. 
 The same approach was used for investigation of the inhibitory effect on ethanol and 
acetaldehyde at 1.8 mM and 5.3 mM, respectively. 257 µM of 4-methylpyrazole was used in the 
acetaldehyde experiment.  
 The data were modeled using Equation 4-3 by non-linear regression (SigmaPlot® 10.0, 
Systat) to estimate the maximum inhibition, as shown in Equation 4-3. IC50 is the concentration 
at which half of the maximum inhibition is achieved.  
 
  % inhibition = Maximum Inhibition × Inhibitor Concentration IC50 +  Inhibitor Concentration … … … … … Equation 4 − 3  
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4.2.8 In-Vitro-In-Vivo Extrapolation 
 
The in-vitro intrinsic clearance (CLintin-vitro) was calculated according to Equation 4-5: 
 
CLint𝑖𝑛−𝑣𝑖𝑡𝑟𝑜 = VmaxKm … … … … … … … … … … … … … … … … … … … … … … … … … Equation 4 − 5  
 
Where CLintin-vitro is a measure of the innate ability of each milligram of cytosolic protein to clear 
a substrate (at concentrations below Km). This in-vitro measure was extrapolated to the in-vivo 
intrinsic clearance (CLint) using the cytosolic protein content per gram liver and the total liver 
weight. The values of these are listed in Table 4-5 as reported in the literature. CLint refers to the 
innate ability of the whole liver cytosol to clear the substrate without flow restrictions.  
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Table  4-5. Physiological reference values for mouse, rat, dog, and human (Bogaards 2001) (Gupta 2006). 
 
Cytosolic Protein 
Concentration 
(mg/g liver) 
Liver Weight 
(g) 
Hepatic Blood 
Flow 
(ml/min) 
Hepatic Blood 
Flow 
(ml/min/kg) 
Body Weight 
(kg) 
Total Body 
Water 
(l) 
Mouse 83 2.2 9.7 280.2 0.03 0.02 
Rat 108 12.5 22.4 89.7 0.25 0.15 
Dog 67 320 309 30.9 10 6 
Human 45 1799 1502 21.5 70 42 
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In order to scale-up the estimated intrinsic clearance to total body clearance and estimate 
the hepatic extraction ratio, the following assumptions were made: 
– 5-HMF is subject to oxidative metabolism in hepatic cytosol, only; no other significant 
hepatic metabolism, or biliary excretion.  
– 5-HMF has negligible renal excretion. 
This assumption of negligible biliary and renal excretion was based on the extensive 
metabolism reported in different studies with a minimum amount of unchanged 5-HMF excreted 
in feces or urine, as discussed in Chapter 1. In addition, the hydrophilic 5-HMF structure with a 
small molecular weight implies that 5-HMF is not a substrate for biliary excretion. 
CYP-450 is the other potential class of enzymes that might be involved in 5-HMF 
metabolism. However, CYP-450 enzyme substrates have affinity in the single micromolar range. 
If this is the case with 5-HMF, the enzymes will be saturated at the proposed therapeutic 
concentration of 5-HMF (1-2 mM) and their contribution will be minimal to the over metabolism 
of 5-HMF.   
– 5-HMF has no extrahepatic metabolism.  
Extraheptic metabolism was not indicated by the reported studies. In addition, most of the drugs 
in the market do not undergo hepatic extraction.  
– Fraction unbound of 5-HMF in plasma (fu)= 1.  
The hydrophilic 5-HMF structure supports the assumption of insignificant unbound fraction. 
Moreover, it was reported that binding to hemoglobin was not affected in the presence or 
absence of plasma protein (Abdulmalik 2005). 
The hepatic extraction ratio (ERhep) was estimated using the well-stirred model as shown 
in Equation 4-5 involving the hepatic blood flow (Qhep): 
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 ERhep =  fu  × CLintQhep + fu  × CLint … … … … … … … … … … … … … … … … … … … … . … … … . . Equation  4 − 5 
 
In addition, in-vivo intrinsic clearance was used in the calculation of hepatic clearance (CLhep) as 
per Equation 4-6: 
 CLhep =  ERhep ×  Qhep … … … … … … … … … … … … … … … . . … … … … . . … … … . Equation 4 −  6  
 
To estimate the oral bioavailability (Foral) and the elimination half-life (t1/2), the following 
were assumed:  
– No limitations in gastrointestinal solubility, stability, or permeability. 
As discussed in Chapter 1, the solubility of 5-HMF is 48 g/l at 25 °C over a pH range of 1 
to 10 (ACS 2009), which means that up to 12 g of 5-HMF can be dissolved in 250 ml of aqueous 
media, which is representative to what 5-HMF might be exposed in the gastrointestinal tract. 
Probably the highest strength dose will be less than 12 g. Thus, 5-HMF is not expected a 
limitation in its solubility. 
The calculated logD value of 5-HMF equals -0.45 (ACS 2009) over a pH range of 1-10 
and its small molecular weight (MW: 126 D) makes it a candidate for passive diffusion in the 
gastrointestinal tract (Hurst 2007). Germond and co-workers reported that 95-100% of the 
radioactivity was recovered in urine within 24 hours of oral and intravenous [14C]-5-HMF 
administration to rats (Germond 1987). The doses ranged between 0.8-330 mg/kg administered 
for two rats at each dose level (Germond 1987). This indicates that ≥90% is orally absorbed in 
rats. Assuming a similar absorption behavior in human, 5-HMF will have a good permeability in 
human gastrointestinal tract.  
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– Distribution along total body water compartment (as ethanol), i.e., Vd=0.6 l/kg in all 
species. 
This assumption was based on the small, neutral, and hydrophilic structure of 5-HMF, as 
discussed above, and its similarity to ethanol structure. 
 
ERhep was used in the calculation of oral bioavailability (Foral) as per Equation 4-7. 
 Foral = 1 − ERhep … … … … … … … … … … … … … … … . . … … … … . … … . … … … . . Equation 4 − 7  
 
The elimination half-life (t1/2) was calculated according to Equation 4-8: 
 
t1/2 = 0.693 × VdssCLhep … … … … … … … … … … … … … … … … … … … … … … … . … … Equation 4 − 8  
 
The predicted 5-HMF elimination half-life was then compared to the half-life reported in 
or extrapolated from in-vivo studies. The in-vitro-in-vivo prediction accuracy was evaluated 
through calculating the ratio of the predicted value to the observed value.  
In addition, 5-HMF AUC∞ was estimated after oral dosing using Equation 4-9 that 
involves the oral bioavailability and hepatic clearance assuming the equivalency of the latter to 
the total clearance.   
AUC∞ = Foral  × DoseCLtot … … … … … … … … … … … … … … … … … … … … … … … . … Equation 4 − 9  
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The above equation was used in predicting the AUC after 100 mg/kg oral dose 
administered in mice. Then, this value was compared to the estimated value from in-vivo study 
reported by Abdulmalik and co-workers. Moreover, the predictions were performed for the AUC 
after oral administration of 5-HMF for the First-Time in Man (FTIM) Study in a dose-escalating 
study with proposed doses (100-10,000 mg). 
 
4.2.9 Detection of HMFA in Human Hepatic Cytosol 
 
Cytosolic protein, NAD+ cofactor, and 5-HMF at 0.8 and 3.2 mM in Tris buffer (pH 7.5) 
were mixed at a final volume of 0.2 ml. The reaction was incubated at 36.5±1 °C between 20-80 
minutes. The reaction was stopped by the addition of 0.1 ml ice-cold acetonitrile. Then, 0.15 ml 
of the mixture was further diluted with 0.65 ml ice-cold water and was subject to HPLC analysis, 
as described in Chapter 3.  
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4.3 Results 
 
Upon incubation of the selective substrates of ALDH and ADH enzymes, ethanol, DN, 
and acetaldehyde with human hepatic cytosol, an increase in the absorbance at 340 nm was 
observed. This increase was expected due to the production of NADH in conjunction with 
NADH-dependent oxidation of these substrates by ADH and ALDH enzymes. Initial velocities 
(vi) were estimated from the slope of the linear portion representing the pseudo-zero order 
increase in the absorbance for each concentration within a ten-minute frame during 
spectrophotometric monitoring. These initial velocities, when plotted against concentration 
resulted in a hyperbolic relationship that was modeled by the Michaelis Menten kinetics by non-
linear regression, as shown in Figures 4-2, 4-3, and 4-4 for ethanol, DN, acetaldehyde. 
An increase in the absorption was observed when 5-HMF was incubated with human 
hepatic cytosol and it was modeled by non-linear regression, as shown Figure 4-5. The maximum 
metabolic capacity and enzyme affinity are summarized in Table 4-6 along with the in-vitro 
intrinsic clearance. The in-vitro intrinsic clearance is expressed in µl/min/mg cytosolic protein.  
The metabolic activity of ethanol in human hepatic cytosol was inhibited to a higher 
extent by 4-methylpyrazole than by disulfiram, as demonstrated in Figures 4-6 and 4-7. On the 
other hand, Figure 4-8 shows that acetaldehyde metabolism was inhibited to a great extent by 
disulfiram. 5-HMF metabolism was inhibited by both 4-methylpyrazole and disulfiram, 
However, the inhibition was larger with disulfiram as shown in Figures 4-9 and 4-10. The 
increase in the absorbance diminished in the presence of the two inhibitors. The results of the 
inhibition studies are listed in Tables 4-7, 4-8, and 4-9.     
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Figure  4-2. Concentration-dependent human hepatic cytosol metabolism of ethanol.  
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Figure  4-3. Concentration-dependent human hepatic cytosol metabolism of DN.   
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Figure  4-4. Concentration-dependent human hepatic cytosol metabolism of acetaldehyde. 
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Figure  4-5. Concentration-dependent human hepatic cytosol metabolism of 5-HMF. 
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Table  4-6. Final Michaelis Menten metabolic parameter estimates (SE) for various substrates in 
human hepatic cytosol. 
Substrate Ethanol DN Acetaldehyde 5-HMF 
v0 
(nmol/min/mg) 0.13 (0.03) - 1.8 (0.4) 1.78 (0.15) 
vmax 
(nmol/min/mg) 0.70 (0.03) 3.6 (0.3) 2.8 (0.6) 33.2 (8.0) 
Km (µM) 1.27 (0.23).103 3.5 (1.4).10-3 149 (123) 218 (74).103 
CLintin-vitro  
(µl/min/mg) 0.55 1.0 X 10
6 18.8 0.15 
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Figure  4-6. Inhibition of NADH-mediated human hepatic cytosol metabolism of ethanol by 4-
methylpyrazole. 
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Figure  4-7. Inhibition of NADH-mediated human hepatic cytosol metabolism of ethanol by 
disulfiram. 
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Table  4-7. Inhibition metabolism of NADH-mediated human hepatic cytosol of ethanol by 4-
methylpyrazole and disulfiram (SE). 
 4-Methylpyrazole Disulfiram 
Maximum inhibition (%) 84.9 (6.9) 40.7 (2.3) 
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Figure  4-8. Inhibition of NADH-mediated human hepatic cytosol metabolism of acetaldehyde 
by disulfiram. 
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Table  4-8. Inhibition of NADH-mediated human hepatic cytosol metabolism of acetaldehyde by 
disulfiram (SE). 
 Disulfiram 
Maximum inhibition (%) 92.4 (7.8) 
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Figure  4-9. Inhibition of NADH-mediated human hepatic cytosol metabolism of 5-HMF by 4-
methylpyrazole.  
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Figure  4-10. Inhibition of NADH-mediated human hepatic cytosol metabolism of 5-HMF by 
disulfiram. 
.  
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Table  4-9. Inhibition of NADH-mediated human hepatic cytosol of 5-HMF metabolism by 4-
methylpyrazole and disulfiram (SE). 
 4-Methylpyrazole Disulfiram 
Maximum inhibition (%) 33.6 (5.1) 59.9 (7.8) 
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            The increase in the absorption was also observed when 5-HMF was incubated in mouse, 
rat, and dog hepatic cytosol: The resulting Michaelis Menten curves for 5-HMF in different 
species hepatic cytosol are shown in Figures 4-11, 4-12, 4-13, and the parameters are 
summarized in Table 4-10. The estimated v0 in the metabolism of 5-HMF in the mouse and 
human hepatic cytosol might indicate the involvement of high affinity/low capacity enzymes in 
the metabolism of 5-HMF. In addition, the corresponding linearization graphs are shown in 
Figures 4-14, 4-15, 4-16, 4-17, and 4-18 for 5-HMF metabolism in mouse, rat, dog, and human 
hepatic cytosol along with ethanol in human hepatic cytosol.  
The final IVIVE results are summarized in Table 4-11, including CLintin-vivo, CLmet, ERhep, 
Foral, and t1/2. In addition, a half-life comparison between that predicted by IVIVE and that 
obtained from in-vivo studies along with the projected AUC(s) after oral administration of 5-
HMF for the First-Time in Man (FTIM) Study are shown in Tables 4-12 and 4-13. 
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Figure  4-11. Concentration-dependent metabolism of 5-HMF in mouse hepatic cytosol.   
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Figure  4-12. Concentration-dependent metabolism of 5-HMF in rat hepatic cytosol.   
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Figure  4-13. Concentration-dependent metabolism of 5-HMF in dog hepatic cytosol.  
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Table  4-10. Final Michaelis Menten metabolic parameter estimates (SE) for 5-HMF in hepatic 
cytosol from various animal species. 
 
 
 
Mouse Rat Dog Human 
v0 (nmol/min/mg) 0.78 (0.24)  1.78 (0.15) 
vmax 
(nmol/min/mg) 16.2 (1.0) 27.7 (6.8) 14.9 (2.3) 33.2 (8.0) 
Km (mM) 37.1 (6.3) 76.6 (32.4) 18.3 (8.0) 218 (74) 
CLintin-vitro 
(µl/min/mg) 0.44 0.36 0.81 0.15 
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Figure  4-14. Linearization graphs for concentration-dependent metabolism of 5-HMF in mouse 
hepatic cytosol. 
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Figure  4-15. Linearization graphs for concentration-dependent metabolism of 5-HMF in rat 
hepatic cytosol.  
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Figure  4-16. Linearization graphs for concentration-dependent metabolism of 5-HMF in dog 
hepatic cytosol. 
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Figure  4-17. Linearization graphs for Concentration-dependent metabolism of 5-HMF in human 
hepatic cytosol. 
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Figure  4-18. Linearization graphs for concentration-dependent metabolism of ethanol in human 
hepatic cytosol. 
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Table  4-11. IVIVE for 5-HMF in mouse, rat, dog, and human using physiological variables listed in Table 4-5. 
 CLint (ml/min) 
CLint 
(ml/min/kg) 
CLhep 
(ml/min) 
CLhep 
(ml/min/kg) 
ERhep 
(%) 
Foral 
(%) 
t1/2 
(hour) 
Mouse 0.08 2.3 0.08 2.3 0.8 99 3.1 
Rat 0.49 2.0 0.48 1.9 2.1 98 3.6 
Dog 17.4 1.7 16.5 1.7 5.0 95 4.2 
Human 12.3 0.18 12.2 0.17 0.8 99 39.7 
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Table  4-12. Comparison of IVIVE predictions for 5-HMF with the reported values. 
 
IVIVE Predictions Literature 
t1/2  
(hr) 
AUC 
(mg/ml*min) 
t1/2  
(hr) 
AUC 
(mg/ml*min) Dose Species Reference 
Mouse 3.1 44 1.5 26 100 mg/kg orally 
Transgenic 
mice 
(Abdulmalik 
2005) 
Dog 4.2 
 
2.1 
 
397 mg/kg  
infused 
over an 
hour 
Male 
beagles 
(Klimmek 
1978) 
Human 39.7 
1.2 (for 
HMFA 
metabolite) 
7.5 mg/kg  
of 5-HMF 
in dried 
plum juice 
65-70 yrs 
old 
women 
(Prior 2006) 
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Table  4-13. Predicted AUC∞ after oral administration of 5-HMF FTIM study. 
Dose (mg) Projected AUC∞ (mg/ml.min) 
100 8 
300 24 
1000 81 
3000 244 
6000 487 
10000 812 
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HMFA was detected in human cytosol after incubation of 5-HMF at different 
concentrations for different periods. Unfortunately, the peak of HMFA overlapped with a peak 
present in the blank, as discussed in Chapter 3. Nevertheless, it is demonstrated in Figures 4-19, 
4-20, 4-21, 4-22, and 4-23 that the peak height increased with the increase in the concentration of 
5-HMF and with the increase in the incubation period indicating the formation of HMFA in 
human hepatic cytosol after the addition of NAD+.    
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Figure  4-19. HPLC chromatogram for blank human hepatic cytosol, no 5-HMF added. 
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Figure  4-20. HPLC chromatogram for 0.8 mM of 5-HMF incubated in human hepatic cytosol for 20 minutes. 
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Figure  4-21. HPLC chromatogram for 0.8 mM 5-HMF incubated in human hepatic cytosol for 40 minutes. 
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Figure  4-22. HPLC chromatogram for 3.2 mM 5-HMF incubated in human hepatic cytosol for 20 minutes. 
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Figure  4-23. HPLC chromatogram for 3.2 mM 5-HMF incubated in human hepatic cytosol for 80 minutes. 
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4.4 Discussion and Conclusions 
 
The NAD+-dependent oxidation of all ADH/ALDH model-substrates (ethanol, 
acetaldehyde, and DN) in human hepatic cytosol were adequately characterized by Michaelis 
Menten kinetics as indicated by the goodness of fit of the non-linear regression. This validated 
the hepatic cytosolic system and confirmed the presence of active ADH and ALDH enzymes. 
The estimated Km values for all these substrates was similar to these reported previously in the 
literature, as listed in Table 4.2. Similarly, the NAD+-dependent oxidation of 5-HMF in human 
hepatic cytosol was described by Michaelis Menten kinetics, indicating 5-HMF metabolism by 
ALDH and ADH enzymes. This was further supported by the observed formation of the 
metabolite, HMFA, in human hepatic cytosol.  
Overall, low-affinity (Km: 218 mM)/high capacity (vmax: 33.2 nmol/min/mg) metabolism  
was observed for 5-HMF relative to ethanol (1.3 mM/0.7 nmoles/min/mg) and DN and 
acetaldehyde (3.5 nM/3.6 nmol/min/mg and 149 μM/2.8 nmol/min/mg). However, the Km 
estimation for 5-HMF is limited by the fact that 5-HMF concentrations greater than Km could not 
be achieved experimentally since the UV absorption saturated the instrument and 5-HMF 
solubility was exceeded.  
The observed increase in the absorbance is a result of NADH production. Since this a 
common product for ALDH and ADH, the following reactions might be involved: 
ALDH  + O
H
O
OH
 
 O
OH
O
OH
 
+NADH 
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The effect of the selective ALDH and ADH inhibitors was demonstrated by the inhibition 
of ethanol and acetaldehyde metabolism by 4-methylpyrazole and disulfiram, respectively, 
ethanol metabolism by ADH was inhibited mainly by 4-methylpyrazole, while acetaldehyde 
metabolism by ALDH was inhibited to a large extent by disulfiram.  
Relative to the control, the activity of 5-HMF in the presence of disulfiram declined to 
40% of the control activity, indicating a significant role of ALDH enzyme in its metabolism. On 
the other hand, 5-HMF metabolism was inhibited to a lesser extent (33%) by 4-methylpyrazole. 
This suggests that ALDH-mediated oxidation of 5-HMF to HMFA (a human metabolite 
identified in-vivo) is the major route of hepatic metabolism.  
In concordance with the conclusion of ADH and ALDH-mediated oxidation of 5-HMF, 
Modig and co-workers investigated 5-HMF in isolated yeast ADH and ALDH enzymes (Modig 
2002). This study involved 5-HMF concentrations up to 32 mM, which is lower than that used in 
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this research, and studied NAD+ conversion into NADH. However, the investigators were 
interested in 5-HMF interaction with another ALDH and ADH substrate rather than the 
characterization of the metabolic parameters for 5-HMF (Modig 2002).  
When linearization-graphing methodologies were used to fit ethanol metabolism in 
human hepatic cytosol and 5-HMF metabolism in different species hepatic cytosol, the best 
linear fits were achieved for ethanol metabolism in human hepatic cytosol and 5-HMF 
metabolism in mouse hepatic cytosol. The involvement of multiple enzymes in the metabolism 
of 5-HMF might cause the observed deviation from linearity. In our case, it is assumed that the 
enzyme involved are both ADH and ALDH. Furthermore, the non-linearity might be due to the 
inherent errors in these methods as mentioned below:  
– The errors associated with small concentration are exaggerated in the Lineweaver-
Burk (double-reciprocal) due to the use of concentration reciprocal on the x-axis. 
In addition to the aggregation of the points at the left side of the plot with high 
concentrations.  
– The x-axis in the Eadie-Hofstee is not independent since it contains the dependent 
variable (velocity).  
Furthermore, 5-HMF oxidative metabolism in the hepatic cytosol of mouse, rat, dog, and 
human was described well by Michaelis Menten kinetics, with the most precise vmax and Km 
estimates observed in the mouse. While vmax values/enzyme capacity in the four animal species 
were relatively similar (per mg protein of hepatic cytosol), the enzyme affinity was more 
variable - with the highest affinity observed in the dog and the lowest in humans. This suggests 
involvement of ALDH and/or ADH in 5-HMF metabolism in all animal species, however, with 
quantitative differences in their intrinsic clearance. The highest intrinsic clearance (per kg body 
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weight) was predicted for the mouse (2.3 ml/min/kg), while the lowest intrinsic clearance was 
predicted for humans (0.18 ml/min/kg). The use of Equation 4-5 to estimate the intrinsic 
clearance entails the assumption of therapeutic concentrations lower than the Km value and 
similarity between the substrate concentration at the enzyme site and the unbound plasma 
concentration (Houston 2008).   
Despite the quantitative differences in the intrinsic clearance, in all animal species 
studied, 5-HMF is predicted to be subject to low hepatic extraction and thus to show high oral 
bioavailability in-vivo. The actual in-vivo oral bioavailability is unknown since no IV reference 
dose was administered concurrently with an oral dose.  
In-vivo systemic exposure predictions (AUC and t1/2) using the respective IVIVE 
parameter estimates in the mouse were within two-fold of those reported for in-vivo exposures 
after oral administration of 100 mg/kg of 5-HMF. In dogs, the IVIVE-predicted t1/2 is 
approximately two-fold longer than that reported in-vivo after I.V. infusion of 5-HMF (397 
mg/kg for 1 hr). In both cases, the IVIVE predictions may have underestimated CLmet for 5-
HMF, possibly due to other (minor) routes of metabolism, e.g., hepatic mitochondrial oxidation. 
Nevertheless, the IVIVE exposure predictions were reasonable for dogs and mice. 
On the other hand, the IVIVE-predicted t1/2 for humans is more than 30-fold longer than 
the reported plasma t1/2 of the (presumed) primary metabolite, HMFA after oral administration of 
approximately 7.5 mg/kg of 5-HMF. This major discrepancy most likely implies a significant 
involvement of other hepatic fractions and/or extrahepatic metabolism of 5-HMF in humans, 
most likely oxidative, ALDH-mediated metabolism in RBCs (see Chapter 5).  
As observed from the IVIVE, all the prediction were underestimated to some extent in 
comparison to in-vivo data. Under-prediction is a common issue that is encountered when 
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dealing with different in-vitro systems. Considering the average inaccuracy, it was reported that 
IVIVE for human microsomes and hypatocytes were 9-fold and 5-fold lower than their 
corresponding in-vivo values and were associated with low precision of 30 -150 fold (Houston 
2008) (Hallifax 2009). On the other hand, our observation of higher bias in human vs. other 
species IVIVE is a common annotation in the literature. The IVIVE was reported to mispredict 
rat in-vivo data by 1.4- and 2.2-fold using microsomes and hepatocytes, respectively (Houston 
2008). When the repeatability of in-vitro estimates was investigated in hepatocytes, 28% 
variation was found using midazolam as a substrate (Hallifax 2009). Unfortunately, a definite 
mechanistic understanding of this misprediction is not always available (Hallifax 2009).  
 In-vivo predictions from in-vitro systems suffers from inaccuracy if the in-vivo data was 
collected from a population with different genetic characteristic in comparison to those used in 
the generation of the in-vitro data (Hallifax 2009). Both of ALDH and ADH enzymes, involved 
in this research, were reported to have extensive polymorphism among ethnic groups (Goedde 
1983). The hepatic cytosol is pooled from different donors, which introduces variability in age, 
gender, disease, medications, smoking, drinking, and cause of death. In contrast, these variability 
factors are well-controlled in the in-vivo studies (Hallifax 2009). In addition, errors from 
experimental procedures and extrapolation using the physiological values, which are subject to 
inter-individual variability, contribute to random error associated with IVIVE leading to the 
uncertainty in the hepatic clearance prediction (Hallifax 2009). For instance, the human cytosolic 
protein recovery per gram liver was reported with a significant variation, 45 -134 mg/g liver vs. 
78-105 mg/g liver in rats.  
In the experiments conducted in this research project, the total added concentration of 5-
HMF was used and the unbound fraction in the in-vitro system was assumed to be one. This may 
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contribute to under-prediction if the drug was non-specifically bound in the hepatic cytosol in-
vitro and was less bound in the physiological system. In addition, diffusion into the subcellular 
fraction, increasing or decreasing the concentration available to enzymes, is not accounted for 
with the use of hepatic cytosol.  
Moreover, the activity of the enzymes might have decreased because of the procedures 
associated with liver resection and cellular fractionation (Hallifax 2009). The speed, at which 
subcellular fractions are obtained from different species, can be different leading to a variation in 
the accuracy of IVIVE among species (Hallifax 2009). Furthermore, endogenous activators or 
inhibitors might exist in the physiological setting but not in in-vitro system (Hallifax 2009). In 
addition, errors are introduced at the metabolic pharmacokinetics model level due to the inability 
to reach saturation due to high background absorbance and substrate solubility (Hallifax 2009).  
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CHAPTER 5 
5  
5-HMF METABOLISM IN HUMAN RBCS 
 
 
5.1 Introduction  
 
ALDH was first extracted from human erythrocytes by Inoue and co-workers in 1979 as a 
tetrameric protein  (Inoue 1979). Unfortunately, the literature is sparse with studies investigating 
this ALDH enzyme in RBCs. This might be a result of the low number of drugs with an aldehyde 
moiety that are administered to humans therapeutically. As discussed in Chapter 1, the ALDH 
isoenzyme present in RBCs has similar properties as the ALDH isoenzyme in hepatic cytosol 
(Goedde 1983) (Inoue 1979). It was shown by Goedde et al. that the ALDH isoenzyme in RBCs 
corresponds to ALDH1 enzyme present in the liver. This fact together with the discrepancy in 
the IVIVE prediction with the observed t1/2 (Chapter 4), suggest that 5-HMF may be metabolized 
in human RBCs. Consequently, 5-HMF metabolism was investigated in human RBCs.  
The same methodology used in studying 5-HMF metabolic stability in the hepatic cytosol 
was used to study the metabolism of 5-HMF in human RBCs. NADH production was 
spectrophotometrically monitored to investigate 5-HMF oxidation.  
 254 
 
5.2 Methods 
 
5.2.1 Materials and Reagents 
 
1. BD Gentest™ TRIS Buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
2. 5-Hydroxymethyl-2-furfural (5-HMF) Solution: 
- 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO). 
-  BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
3. Ethanol Solution:  
- Ethanol  99.5%, 200 proof  (Aldrich, Milwaukee, WI) 
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
4. 4-Methylpyrazole (4-MP) Solution: 
- 4-MP, 99% (Sigma-Aldrich, Milwaukee, WI).  
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
5. Tetraethylthiuram Disulfide (disulfiram) Solution: 
- Disulfiram, purum 97% (Sigma-Aldrich, Milwaukee, WI).  
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
6. Human Blood:  
- Human: mixed gender, pool of three black females, two black males, and one white 
male (35.3 ± 13.5 years).  
- Water (BD Bioscience, San Jose, CA). 
7. Cofactor Solution,  β-Nicotinamide Adenine Dinucleotide (NAD+) Solution: 
- NAD+ from yeast (Sigma, St. Louis, MO). 
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
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5.2.2 Equipment 
 
1. 25-µl, 50-µl, and 250-µl positive displacement pipettes and corresponding pipette tips 
(Microman, Rainin Instruments, Oakland, CA). 
2. 10-µl, 100-µl, and 1000-µl VWR pipettes and corresponding pipette tips (VWR, West 
Chester, PA). 
3. 0.5-5 ml Finnpipette (Thermo Scientific, Waltham, MA). 
4. Vortex (Vortex-Genie, VWR, West Chester, PA). 
5. Sonicator (American Brand Products C6450-11, VWR, West Chester, PA).  
6. pH meter (Corning, Glendale, AZ). 
7. Balance (Fisher Scientific A 250, Pittsburgh, PA). 
8. Synergy™ 2 multi-mode microplate reader (BioTek, Winooski, VT). 
9. Falcon assay plate, 96 reaction wells (VWR, West Chester, PA). 
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5.2.3 Preparation of Solutions 
 
- Cofactor solution, β-nicotinamide adenine dinucleotide (β-NAD+) solution 
22.3 g of NAD+ (M.W.: 663.43 Da) was dissolved in 3 ml of Tris buffer to prepare 1.4 
mM solution.  
 
- Diluted human RBCs  
RBCs were obtained after centrifugation of whole blood. The RBCs were lysed and 
diluted 625-fold with water on two stages.  
 
- Substrates solution 
Solutions of different concentrations (12-142 mM) of 5-HMF (M.W. 126.11 Da) were 
prepared in Tris buffer. The estimation of NADH at low substrate was limited by the 
assay sensitivity in some cases. In addition, the estimation of NADH at high substrate 
was limited by the high baseline absorbance of 5-HMF and its solubility.  
 
- Inhibitors solution 
Solutions of inhibitors, 0.03-281 µM 4-methylpyrazole (M.W. 82.10 Da) and 0.03-33.8 
µM disulfiram (M.W. 296.54 Da) were prepared to achieve maximum inhibition of the 
relevant enzymes taking into consideration their reported Ki, as stated in Chapter 4.  
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5.2.4 Procedures 
 
Diluted RBCs, NAD+ cofactor, and 5-HMF at different concentrations were mixed at a 
final volume of 0.2 ml. The reaction was initiated by the addition of diluted RBC solutions after 
allowing the mixture to equilibrate for approximately 5 minutes. The increase in the absorbance 
at 340 nm at 37 °C was monitored over time. The change in the absorbance was converted to an 
NADH concentration using Beer’s law, as discussed in the method section of Chapter 4.  
 
5.2.5 Concentration Dependency Studies 
 
When the initial velocities were plotted against their corresponding concentrations, they 
did not reach saturation. Consequently, the initial velocities were related to their corresponding 
concentrations by the intrinsic clearance, which was represented by the slope.  
 vi = CLint𝑖𝑛−𝑣𝑖𝑡𝑟𝑜 × C +  v0 … … … … … … … … … … … … … … … … … … … … … … … . Equation 5 − 1 
 
Where  
vi: the observed velocity 
v0: the baseline velocity observed in the absence of the substrate  
C: the substrate concentration    
CLintin-vitro: in-vitro intrinsic clearance                    
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5.2.6 Inhibition Studies 
 
 Taking into consideration their reported Ki value, different concentrations of disulfiram 
and 4-methylpyrazole were used. All reaction components except for 5-HMF were incubated for 
approximately 15 minutes and 25 minutes with 4-methylpyrazole and disulfiram, respectively, 
after which 5-HMF, 26 mM, was added. At each concentration, a minimum of duplicate 
reactions were considered in the data analysis. 
  The data were modeled using non-linear regression as discussed in the methods section 
of Chapter 4.  
   
 
5.2.7 In-Vitro-In-Vivo Extrapolation  
 
CLintin-vitro in Equation 5-2 is a measure of the innate ability of each milliliter of RBCs to 
clear a substrate. This in-vitro measure was extrapolated to in-vivo clearance (CLRBCs) using the 
RBCs fraction of blood (0.4) and the total blood volume (5000 ml) according to Equation 5-2. 
Consequently, CLRBCs refers to the innate ability of whole RBCs volume to clear 5-HMF.  
 CLRBCs = CLint𝑖𝑛−𝑣𝑖𝑡𝑟𝑜 × 0.4 ×  5000 … … … … … … … … … … … … … … … … … … … . Equation 5 − 2 
 
However, in order to scale-up the estimated clearance in RBCs together with the hepatic 
clearance to a total body clearance, the following were assumed: 
– 5-HMF is subject to oxidative metabolism in hepatic cytosol and RBCs, only; no other 
significant hepatic metabolism, or biliary excretion. 
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– 5-HMF has negligible renal excretion.  
– Fraction unbound of 5-HMF in plasma (fu)= 1.  
 
The bases for these assumptions are stated in Chapter 4. Consequently, Equation 5-3 was 
used to estimate the total clearance.  
 CLtot = CLhep +  CLRBC … … … … … … … … … … … … … … … … … … … … … … … … Equation 5 − 3 
 
IVIVE exposure predictions were calculated as described in the methods section of 
Chapter 4.  
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5.3 Results 
 
An increase in the absorption was not observed when ethanol was incubated in the RBC 
system. This is expected since ADH expression in human RBCs was not reported. On the other 
hand, upon the incubation of 5-HMF with diluted RBCs, an increase in absorbance at 340 nm 
was observed, indicating the production of NADH in conjunction with 5-HMF oxidation. Initial 
velocities (vi) were estimated from the slopes of the linear portion, representing the pseudo-zero 
order increase in the absorbance for each concentration within a ten-minute frame of 
spectrophotometric monitoring. When these initial velocities were plotted against their 
corresponding concentrations, they resulted in a linear relationship that was modeled by linear 
regression, as shown in Figure 5-1. The in-vitro intrinsic clearance, expressed in ml/min/ml 
RBCs, is shown in Table 5-1. The estimated metabolic activity of 5-HMF was partially inhibited 
by disulfiram as demonstrated in Figure 5-2. The parameters of the non-linear regression 
inhibition model are shown in Table 5-2.  
The IVIVE results are summarized in Table 5-3, including CLRBCs, CLtot, and t1/2. The 
predicted half-life by the IVIVE (41 minutes) was 0.6 of that obtained from in-vivo studies (69 
minutes) after oral administration of 5-HMF  (Prior 2006). In addition, Table 5-4 summarizes the 
modified predictions of AUC∞ after oral administration of 5-HMF FTIM study. 
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Figure  5-1. Concentration-dependent human RBC metabolism of 5-HMF. 
  
r2: 0.99 
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Table  5-1. Final metabolic parameter estimates (SE) for 5-HMF in human RBC. 
v0 (µmol/min/ml RBCs)  1.4 (1.8) 
CLintin-vitro (ml/min/ml RBCs)  0.35 (0.02) 
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Figure  5-2. Inhibition of NADH-mediated human RBC metabolism of 5-HMF by disulfiram. 
.   
  
r2: 0.97 
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Table  5-2. Inhibition of NADH-mediated human RBC of 5-HMF metabolism by disulfiram 
(SE). 
Maximum inhibition (%) 52.6 (3.62) 
IC50 (µM) 0.0053 (0.0027) 
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Table  5-3. Modified IVIVE predictions for 5-HMF in humans. 
CLhep (ml/min) 12 
CLRBCs (ml/min)  690 
CLtot (ml/min) 702 
t1/2 (min) 41.5 
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Table  5-4. Modified predictions of AUC∞ for oral administration of 5-HMF FTIM study. 
Dose (mg) Projected AUC∞ (mg/ml.min) 
100 0.14 
300 0.41 
1000 1.4 
3000 4.2 
6000 8.3 
10000 14 
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5.4 Discussion and Conclusions 
 
Significant NAD+-dependent oxidation of 5-HMF was observed in RBCs. Overall, low-
affinity metabolism was observed for 5-HMF, where Km estimation for 5-HMF was not possible 
due to the fact that 5-HMF concentrations greater than Km could not be achieved experimentally 
due to saturation in the instrument response and limitations in 5-HMF solubility. 
The failure to observe NAD+-dependent oxidation of ethanol and 5-HMF inhibition by 4-
methylpyrazole indicated the absence of ADH enzyme in RBCs. On the other hand, 5-HMF 
metabolism and inhibition by disulfiram was in concordance with the presence of ALDH in 
RBCs, as reported in the literature suggesting ALDH-mediated oxidation of 5-HMF in RBCs. 
The use of the slope to estimate the intrinsic clearance entailed the assumption of therapeutic 
concentrations lower than the Km value and similarity between the substrate concentration at the 
enzyme site and the unbound plasma concentration  (Houston 2008).   
The IVIVE-predicted t1/2 for humans is similar to the reported plasma t1/2 of the 
(presumed) primary metabolite, HMFA after oral administration of approximately 7.5 mg/kg of 
5-HMF. This resolves the discrepancy noted in Chapter 4 that suggested the involvement of 
extrahepatic metabolism of 5-HMF in humans and led the study of RBC metabolism.  
As discussed in Chapter 4, in-vivo predictions from in-vitro systems suffers from 
inaccuracy if different genetic characteristic were associated with the in-vivo data population in 
comparison to those used in the generation of the in-vitro data (Hallifax 2009). Ueshima et al. 
studied ALDH activity in the blood of an individual with normal ALDH1 homozygote after the 
addition of 1 mM of acetaldehyde for 14 minutes and found that approximately 80% of the added 
acetaldehyde disappeared, while approximately 30% of the acetaldehyde disappeared in the 
blood taken from an individual with ALDH1 deficiency (Ueshima 1993). Moreover, errors from 
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experimental procedures and extrapolation using blood volume and hematocrit value, which are 
subject to inter-individual variability, contribute to IVIVE inaccuracy in this research project. 
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CHAPTER 6 
6  
5-HMF IN-VITRO PROTEIN BINDING 
 
 
6.1 Introduction  
 
As stated in Section 1.2.2 in Chapter 1, the pharmacological activity of 5-HMF has been 
shown to be a consequence of the increased oxygen affinity to hemoglobin upon the formation of 
a Schiff adduct between the aldehyde group of 5-HMF and α-valine (Safo 2004). This valine 
amino acid is located in the hemoglobin water cavity, as shown in Figure 6-1.  
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Figure  6-1. 5-HMF binding to a hemoglobin molecule. (Abdulmalik 2005) 
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Likewise, Schiff base formation has been reported between hemoglobin and other 
endogenous moieties. An example of a clinically relevant Schiff base adduct with hemoglobin is 
HbAIc. The normal blood glucose concentration, 3.6-7.0 mM, is associated with 5.0-8.5% 
glycosylated hemoglobin in healthy non-fasting humans (John 1988). Glucose interacts with 
hemoglobin, forming a Schiff base that undergoes further rearrangement to form a stable 
ketoamine linkage at the amino terminus of the β chain (Higgins 1981) (Bunn 1981). This 
interaction results in a slow formation of HbAIc throughout the life cycle of RBCs (Higgins 
1981). Moreover, albumin also undergoes non-enzymatic glycosylation (Day 1979). The 
principal site for this glycosylation is the lysine amino acid at the 525 position (Garlick 1983).  
In 1977, Zaugg et al. investigated Schiff base adducts between aldehydes and hemoglobin 
at the amino terminals as a potential approach to decrease HbS polymerization (Zaugg 1977). In 
that study, 31 compounds with carbonyl groups were incubated with a 20% RBC suspension, 
whole blood, and 6% of cell free hemoglobin (Zaugg 1977).  The compounds included twenty 
five aromatic aldehydes, most of which were benzaldehyde derivatives, such as salicylaldehyde, 
vanillin, and carboxybenzaldehydes (Zaugg 1977). In addition, four aliphatic aldehydes were 
studied, namely, glyceraldehydes, cyclohexanecarbxaldehyde, glucose, and valeraldehyde 
(Zaugg 1977). Although Schiff base is reversible, it is considered as a relatively stable adduct 
since it could be characterized by isoelectric focusing (Zaugg 1977). A hemoglobin molecule 
with a Schiff base is slightly more anionic than the unmodified hemoglobin. These studies 
showed that aromatic aldehydes have higher affinity towards hemoglobin (typical association 
constant (KA) value of 220 M-1) than aliphatic aldehydes (typical KA value of 70 M-1) (Zaugg 
1977). These observed association constants are higher than those obtained for small amine 
molecules, possibly due to water exclusion by the microenvironment that hemoglobin tetramer 
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provides favoring the formation of adduct (Zaugg 1977). In general, ketones and aliphatic 
aldehydes (including glucose) binding to hemoglobin did not affect oxygen affinity (Zaugg 
1977).  
It is noteworthy, that 5 mM of o-vanillin demonstrated 75% left shift of the control P50 
value in 20% suspension of normal erythrocytes.  This result was followed-up by Abraham and 
coworkers, where they incubated different concentrations (2.5, 5, and 10 mM) of vanillin in 
whole blood with homozygote sickle hemoglobin (Abraham 1991). With all of the above 
concentrations more than 85% of HbS molecules were modified to adducts with vanillin in less 
than an hour without affecting the hydration of RBCs (Abraham 1991). Nevertheless, vanillin 
was found to possess low oral bioavailability, which hindered its development (C. L. Zhang 
2004).  
This chapter presents the results of in-vitro binding studies of 5-HMF to human HbA and 
HSA. Time–dependency studies were designed to characterize the protein interaction and to 
estimate the appropriate rate constants, while concentration-dependency studies were performed 
to estimate the binding affinity and capacity of these proteins.  
Various methods can be used to perform the physical separation of bound and unbound 
concentration of drugs to protein. Equilibrium dialysis is a commonly used method that employs 
semipermeable membrane, with a suitable molecular cutoff, to separate two chambers (Cheng 
2004). The plasma spiked with the drug is added to one of the chambers while the other chamber 
contains a buffer. Despite its widespread use, equilibrium dialysis takes is time-consuming, 
which might be problematic to unstable drugs (Pacifici 1992). In addition, non-specific binding 
of the drug to the apparatus and volume shift between the compartments are disadvantages of 
equilibrium dialysis (Pacifici 1992).  
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HPLC using immobilized HSA is a recently developed method that can be used to 
determine protein binding (Cheng 2004). However, this method is hindered by the availability of 
the column and the drug since a large amount of drug is needed for the analysis (Cheng 2004).  
Ultrafiltration uses a semipermeable membrane and forces the plasma or buffer with the 
unbound (ultrafiltrate) into a separate compartment using centrifugation that causes a pressure 
gradient (Bowers 1984). As with other protein binding determination methodologies, it suffers 
from non-specific binding to the instrument and membrane. In addition, centrifugation is usually 
performed at room temperature, which might disturb the equilibrium that might have been 
initiated at 37 °C (Pacifici 1992).  
As a simple and rapid technique in protein binding determination, ultrafiltration was used 
in this study. Non-specific binding was determined in the absence of proteins to overcome this 
disadvantage. The molecular weight of HSA and Hb were considered in selecting the cutoff of 
the semipermeable membrane to avoid protein leakage. The temperature of the centrifuge was set 
to 37 °C.   
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6.2 Methods 
 
6.2.1 Materials and Reagents 
 
1.   Phosphate-Buffered Saline (PBS), pH 7.4: 
- Phosphate-buffered saline  tablets, pH 7.4 (Sigma, St. Louis, MO). 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory). 
2. Human Hemoglobin Solution: 
- Human hemoglobin lyophilized powder (Sigma, St. Louis, MO). 
- Phosphate-buffered saline, pH 7.4. 
3. Human Serum Albumin Solution (Sigma, St. Louis, MO): 
- Human hemoglobin, fatty acid free, lyophilized powder (Sigma, St. Louis, MO). 
- Phosphate-buffered saline, pH 7.4. 
4. 5-Hydroxymethyl-2-furfural (5-HMF) Solution: 
- 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO). 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory). 
5. Mobile Phase for 5-HMF Assay Method: 
- 93.5% Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory). 
- 6.2% Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ). 
- 1% Acetic acid glacial, > 99% (Sigma, Milwaukee, WI). 
- 0.3 % Tetrahydrofuran HPLC grade (Burdick and Jackson, Morristown, NJ). 
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6. SPE Conditioning: 
- Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ). 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory). 
7. SPE Washing Solution: Phosphate-buffered Saline (PBS), pH 7.4: 
- Phosphate-buffered saline  tablets, pH 7.4 (Sigma, St. Louis, MO). 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory). 
8. SPE Eluting Solution: 50% Methanol: 
- Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ). 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory). 
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6.2.2 Equipment 
 
1. 25-µl, 50-µl, and 250-µl positive displacement pipettes and corresponding pipette tips 
(Microman, Rainin Instruments, Oakland, CA). 
2. 10-µl, 100-µl, and 1000-µl VWR pipettes and corresponding pipette tips (VWR, West 
Chester, PA). 
3. 0.5-5 ml Finnpipette (Thermo Scientific, Waltham, MA). 
4. Vortex (Vortex-Genie, VWR, West Chester, PA). 
5. Sonicator (American Brand Products C6450-11, VWR, West Chester, PA).  
6. pH meter (Corning, Glendale, AZ). 
7. Balance (Fisher Scientific A 250, Pittsburgh, PA). 
8. Centrifuge 5804-R (Eppendorf, Hauppauge, NY). 
9. Amicon® Ultra-4 centrifugal filter units with Ultracel-10 and Ultracel-50 membranes 
(Millipore, Billerica, MA). 
10. Glass vials with caps, 1 ml (Waters, Milford, MA). 
11. UV detector (Shimadzu, AV-10, Columbia, MA).  
12. C18 Zorbax Rx column, 4.6 X 150 mm (Agilent, Santa Clara, CA). 
13. C18 guard column, 12.5 mm x 4.6 mm (Agilent, Santa Clara, CA). 
14. 717 plus autosampler (Waters, Milford, MA). 
15. 600 Multisolvent controller (Waters, Milford, MA). 
16. Empower 2 software (Waters, Milford, MA) 
17. Forma Scientific incubator.   
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6.2.3 Preparation of Solutions 
 
– Mobile Phase for 5-HMF Assay Method (1 L) 
935 ml water, 62 ml methanol, 10 ml acetic acid glacial, and 3 ml     
tetrahydrofuran were mixed to prepare the mobile phase. 
 
– 5-Hydroxymethyl-2-furfural Solution (5-HMF) 
5-hydroxymethyl-2-furfural (M.W.: 126.11 Da) was dissolved in PBS.  
 
– Phosphate-buffered Saline (PBS), pH 7.4 
One tablet of phosphate-buffered saline was added to 200 ml of water. 
 
– SPE Eluting Solution: 50% Methanol 
25 ml of methanol was mixed with 25 ml of water. 
 
– Human Hemoglobin Solution 
Human hemoglobin powder (M.W.: 64,677 Da) was dissolved in PBS. 
 
– Human Serum Albumin Solution 
Human serum albumin powder (M.W.: 66,478 Da), was dissolved in PBS. 
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6.2.4 Procedures 
 
 
5-HMF was added to human serum albumin or hemoglobin solutions in PBS at different 
concentrations. The solution was incubated at 36.5 ± 1 °C. Two milliliter samples were 
transferred to Amicon® Ultra-4 and centrifuged (5,000 rpm) for 20 minutes at 36.5 ± 1 °C. 50 
kDa and 10 kDa were chosen as the molecular cut-off values for the membranes used in the 
ultrafiltration of human serum albumin and hemoglobin solutions, respectively. The ultrafiltrate 
was transferred to HPLC for analysis to quantitate the unbound 5-HMF concentrations (UC). The 
difference between the initial concentration and the measured 5-HMF concentration was 
assumed to represent the total 5-HMF binding to both the protein and the ultrafiltration system 
(TB). Non-specific binding was determined, in unicate, after ultrafiltration of 5-HMF solutions 
in the absence of proteins (NSB).  
The chemical stability of 5-HMF was investigated at 36.5 ± 1 °C for 30 hours; where 
samples of 5-HMF solution at 16 µM in PBS were analyzed by HPLC in unicate. In all of the 
experiments, calibration curves of 5-HMF in PBS (0.2 – 80 µM) were established in PBS in 
parallel with the analysis of the samples in various experiments in order to estimate the unbound 
concentration of 5-HMF.   
  
6.2.4.1 Time-Dependency Studies 
 
5-HMF was pre-incubated in the suspension of RBCs containing HbS in the experiments 
reported by Abdulmalik. This was justified by the notion that Hb adduct needed some time to 
form (Abdulmalik, 2005). This rationale triggered this research to investigate time-dependency 
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in 5-HMF binding to hemoglobin. Therefore, studies were conducted with 5-HMF in 
concentrations ranging from 8 µM to 0.3 mM, incubated in Hb (217 μM) or HSA (63 and 202 
μM) solutions in PBS at 37°C. Serial samples (unicate, mostly) for up to 30 hours were taken 
and ultra-filtered using the Amicon® Ultra-4 centrifugal filter unit with Ultracel-10 and Ultracel-
50 membranes for Hb and HSA, respectively, by centrifugation for 20 minutes at 5,000 rpm at 
37 °C.   
 
6.2.4.2 Concentration-Dependency Studies 
 
Studies were conducted with various concentrations of 5-HMF ranging from 5 µM to 5 
mM and incubated in Hb (217 μM) or HSA (63 and 202 μM) solutions at 37 °C. Duplicate 
samples at 24 hours (Hb solution) and 6 hours (HSA solution) were taken and ultrafiltered. 
Unbound 5-HMF concentrations were measured by HPLC. Specific binding was estimated after 
the correction for non-specific binding using the equations discussed in the Data Analysis 
section.  
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6.2.5 Data Analysis 
 
The general scheme for the binding reaction, which leads to the formation of 5-HMF 
Schiff base adduct with the amino group of a protein (human hemoglobin or serum albumin), is 
described by Figure 6-2. In this scheme, k1 is the Schiff base formation rate constant, following 
second-order kinetics, while k-1 is the adduct degradation constant that follows first-order 
kinetics (Ge 1997). Any rearrangement of the aldimine bond in 5-HMF adduct to a stable 
covalent bond (as it is the case for glucose) was assumed to be negligible. 
The rate of change in the concentration of the adduct [Adduct] at any time in the binding 
reaction is estimated according to Equation 6-1: 
 d[Adduct] dt = k1 × [5HMF](t) × [Protein ](t)−  k−1 × [Adduct](t) … … … … . . Equation 6 − 1 
 
where [5HMF](t): the concentration of free 5-HMF at time (t)  [Protein](t): the concentration of free protein at time (t) [Adduct](t): the concentration of the adduct between 5-HMF and the protein at time (t)   
 
In these studies, free (i.e. unbound) 5-HMF at a certain time point (ti), namely [5HMF](ti), was measured using the validated HPLC method. On the other hand, Equations 6-2 
and 6-3 were used to estimate the adduct formed, [Adduct](ti), and the concentration of free 
protein, [Protein](ti), at the relevant time point, ti:  
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[Adduct](ti) = [5HMF](t0) − [5HMF](ti) … … … … … … … … … … … … … … … … Equation 6 − 2  [Protein](ti) = [Protein](t0) − �[5HMF](t0) − [5HMF](ti)�… … … … … … … Equation 6 − 3 
 
where [5HMF](t0) and [Protein](t0) are the initial concentrations of 5-HMF and the protein, 
respectively. At equilibrium, the rate of change is zero, as described by Equations 6-4 and 6-5: 
 k1 × [5HMF]eq  × [Protein]eq =  k−1 × [Adduct]eq … … … … … … … … … … … … Equation 6 − 4 
 
KA = k1k−1 =  [Adduct]eq[5HMF]eq  × [Protein]eq … … … … … … … … … … … … … … … … … . . Equation 6 − 5 
 
where KA is association equilibrium constant, while [5HMF]eq, [Protein]eq, and [Adduct]eq are 
the concentrations of free 5-HMF, free protein, and protein adduct, respectively, at equilibrium. 
 
As a measure of affinity, the dissociation constant, KD, can be estimated, as an inverse of 
KA as described by Equation 6-6: 
 
KD = 1KA … … … … … … … … … … … … … … … … … … … … … … … … … … … … … … … Equation 6 − 6 
 
After performing the non-linear regression of the time dependency studies, the final 
estimates for the forward and backward rate constants (k1 and k-1) were used to estimate an 
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apparent first-order equilibration rate constant, keq (assuming that 5-HMF concentrations are 
lower than the protein concentration, i.e., [5-HMF]<<[Protein]) as described in Equation 6-7.  
 keq = k−1 + (k1 × [Protein]t0) … … … … … … … … … … … … … … … … … … . … Equation 6 − 7 
  
keq (apparent first-order rate constant) was estimated for 7.9 and 19.8 μM 5-HMF 
incubated with Hb and HSA, respectively, using the rate constant estimates. keq was compared to 
the actual rate constant, kobs, obtained from the slope when the natural logarithmic value for 
difference between the adduct concentration at steady-state (Css) and the concentration of the 
adduct at different time points (Ct), i.e. (ln (Css-Ct)), was plotted against time.  
In addition, the final estimates of the rate constants were compared to those reported for 
glucose and the equilibration rate for 5-HMF-Hb adduct was extrapolated to physiological blood 
concentrations of Hb (2.3 mM) and the expected clinically relevant concentrations of 5-HMF (1-
2 mM). In addition, the overall results of this study were put in context with the previously 
reported data (Abdulmalik 2005).  
In the data analysis performed, specific binding (SB) was estimated from the nominal 
concentration (NC) and nonspecific binding (NSB), as follows: 
Total Concentration Bound (TB) = NC – Ultrafiltrate (=Unbound) Concentration (UC) 
Specific Binding (SB) = TB - NSB 
Fraction Specifically Bound (fSB) = SB/(NC – NSB) 
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Figure  6-2. Schiff base interaction between 5-HMF and protein.
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6.2.6 Modeling 
 
For all models, goodness of fit was assessed by r2. Parameter estimates are reported along 
with their standard errors. 
 
6.2.6.1 Time-Dependency Studies 
   
6.2.6.1.1 INITIAL ESTIMATES 
 
To obtain initial estimates for the rate constants, shown in Figure 6-3, Equation 6-1 was 
combined with Equation 6-5. The reaction was rewritten as shown in Equations 6-9 and 6-10 
using KA and k-1 to express k1.  
 d[Adduct] dt = k−1 × KA  × [5HMF](t) × [Protein](t)−  k−1 × [Adduct](t) … Equation 6 − 8 d[Adduct] dt = k−1 × (KA × [5HMF](t) × [Protein](t) −  [Adduct](t)) … … … Equation 6 − 9 
 
The above differential equation was approximated by Equations 6-10 and 6-11: 
 
∆[Adduct]
∆t = k−1 × (KA ×  [5HMF](t) × [Protein](t)−  [Adduct](t)) … … … Equation 6 − 10 
 B = k−1 × A … … … … … … … … … … … … … … … … … … … … … … … … … … … … . . Equation 6 − 11 
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Where B represents the left side of the equation and A is the right side of the equation divided by 
k-1.  
An initial estimates of KA was obtained according to Equation 6-5 by measuring the 
steady state concentration of 5-HMF and estimating the steady-state concentration of the adduct 
and the protein in accordance with Equations 6-2 and 6-3. Consequently, k1 was estimated using 
Equation 6-5.   
 
6.2.6.1.2 FINAL ESTIMATES 
 
Equation 6-1 describes the rate of adduct formation using forward and backward reaction 
rate constants. However, the adduct was not directly measured experimentally, alternatively, 
unbound 5-HMF was measured. Therefore, nonlinear regression, (Scientist®, version 2.1, 
Micromath), was fitted to the data across initial 5-HMF concentrations, and the initial model 
estimates (k1 and k-1) were optimized using non-linear regression using Equation 6-12. 
 d[5HMF] dt = k−1 × [Adduct](t)− k1 × [5HMF](t) × [Hb](t) … … … … … … … . Equation 6 − 12 
 
The above equation assumes that all of the lost 5-HMF is involved in the adduct formation after 
the correcting for the NSB. The final model parameter estimates were compared to those 
reported for the Schiff adduct of glucose and Hb. The built Scientist model is shown in Appendix 
C.  
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6.2.6.2 Concentration-Dependency Studies 
 
After correction for nonspecific binding, specific binding was used to estimate steady-
state binding affinity (KD) and the maximum binding capacity or that which can be attained at a 
very high concentration of 5-HMF (binding capacity, Bmax) by nonlinear regression (SigmaPlot® 
10.0, Systat), using the hyperbolic relationship described by Equation 6-13.  Bmax was expressed 
as a molar ratio of 5-HMF bound to the total protein. 
 
CB =   Bmax × CuKD  + Cu … … … … … … … … … … … … … … … … … … … … … … … … … … . . Equation 6− 13 
 
Where saturable binding was not observed, linear regression was employed using Equation 14. 
 CB =  SB × Cu  + Y0 … … … … … … … … … … … … … … … … … … … … … … . . … … Equation 6 − 14 
 
where CB is 5-HMF concentration bound to the protein, SB is the specific binding coefficient, Y0 
is the y-axis intercept, and Cu is the concentration of unbound 5-HMF.   
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6.3 Results 
 
6.3.1 Non-Specific Binding Studies 
 
In the hemoglobin study, non-specific binding to Amicon® Ultra-4 centrifugal filter units 
with Ultracel-10 membrane was fitted to a quadratic equation, as shown in Figure 6-3. This 
model was used to estimate the specific binding to hemoglobin at different concentrations. On 
the other hand, non-specific binding to Amicon® Ultra-4 centrifugal filter units with Ultracel-50 
membrane was fitted to a linear equation, as shown in Figure 6-4. This model was used to 
estimate the specific binding to albumin at different concentrations. The goodness of fit of these 
models was assessed through the coefficient of determination r2 as shown the corresponding 
figures.  
 
 
6.3.2 Time-Dependency Studies 
 
The concentration of 5-HMF was constant when incubated in PBS in the absence of 
protein for 30 hours, as shown in Figure 6-5, indicating that it was chemically stable under the 
experimental conditions. However, 5-HMF concentration decreased in the ultrafiltate when 
incubated in the protein (Hb or HSA) solutions as demonstrated in Figures 6-6, 6-7, 6-8, 6-9, 6-
10, 6-11, 6-12. The extent of decrease was higher in the presence of hemoglobin in comparison 
to serum albumin, as demonstrated in Figures 6-6 and 6-10. Since only a small fraction of 5-
HMF was bound to albumin, the y-axis scale in Figures 6-9, 6-10, and 6-11 was changed to make 
the decrease in the free concentration of 5-HMF more visible.   
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Figure  6-3. Non-specific binding of 5-HMF in Amicon® Ultra-4 centrifugal filter units with 
Ultracel-10 membrane.  
  
r2=0.99 
 289 
 
 
 
 
Figure  6-4. Non-specific binding of 5-HMF in Amicon® Ultra-4 centrifugal filter units with 
Ultracel-50 membrane. 
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Figure  6-5. 5-HMF (16 µM) stability in PBS. 
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Figure  6-6. Time-dependency of 5-HMF (7.9 µM) binding to hemoglobin (217 µM). 
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Figure  6-7. Time-dependency of 5-HMF (63 µM) binding to hemoglobin (217 µM). 
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Figure  6-8. Time-dependency of 5-HMF (397 µM) binding to hemoglobin (217 µM). 
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Figure  6-9. Time-dependency of 5-HMF (37 µM) binding to HSA (202 µM). 
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Figure  6-10. Time-dependency of 5-HMF (7.9 µM) binding to HSA (63 µM). 
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Figure  6-21. Time-dependency of 5-HMF (20 µM) binding to HSA (63 µM). 
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Figure  6-12. Time-dependency of 5-HMF (150 µM) binding to HSA (63 µM). 
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It appears from Figure 6-6 that equilibrium between 5-HMF and hemoglobin was 
achieved in this experiment. According to Equation 6-5, the average of last two points were used 
in estimating the equilibrium constant (KA) for the purpose of obtaining the initial estimates as 
follows: 
= 2.86 (0.08)3.60 (0.08) × 214 (0.08) × 106 
                                                 = 3711 ± 128 M-1 
 
After that, the data from the experiment shown in Figure 6-7 were  used for the purpose 
of obtaining an initial estimate of the backward constant (k-1) as per Equation 6-11.  
Consequently, the slope,  0.099 ± 0.025 hr-1,  in Figure 6-13 represents k-1 for 5-HMF binding to 
hemoglobin. This approach in estimating k-1 and k1 was previously reported by (Ge 1997). The 
values of A and B are shown in Table 6-1. The initial estimate for k1 was calculated using 
Equation 6-5: 
= 3711 (128) X 0.099 (0.025) 
= 367 ± 93.6 M-1hr-1 
 
The same approach was used in obtaining initial estimates for the rate constants of 5-
HMF binding to human serum albumin. The equilibrium between 5-HMF and albumin was 
achieved in the experiment shown in Figure 6-10. Consequently, the initial estimate of KA for 5-
HMF binding to human serum albumin was:  
= 0.09 (0.03)6.87 (0.03) × 62.9 (0.03) × 106 
 
= 208 ± 69 M-1 
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Plotting Equation 6-11, as shown in Figure 6-14, k-1 was obtained from the slope and 
estimated to be 0.61 ± 0.12 hr-1. The values of A and B are shown in Table 6-2. Using Equation 
6-5, k1 was estimated  
= 208 (69) X 0.61 (0.12) 
= 127 ± 49 M-1hr-1 
 
The initial estimates of the rate constants for both human hemoglobin and serum albumin 
binding were optimized through non-linear regression across various concentrations. The final 
parameter estimates of Equation 6-12 are shown in Table 6-3. 
The final estimates of 5-HMF binding to hemoglobin were used to fit the experimental 
data at three different 5-HMF initial concentrations. The fitted lines vs. the observed data are 
shown in Figures 6-15, 6-16, 6-17. 
When the natural logarithmic value for the adduct concentration yet to be formed , i.e. ln 
(Css-Ct),  was plotted against the incubation time for 5-HMF with human hemoglobin and serum 
albumin, as shown in Figures 6-18 and 6-19, respectively, the observed  rate constants (kobs) 
were 0.194 ± 0.09 hr-1 and  0.66 ± 12 hr-1, while the  t1/2  (=0.693/ kobs) was equal to 3.58 hours 
and 1.1 hours for hemoglobin and albumin, respectively. kobs is equivalent to the  product of the 
forward and backward rate constants according to Equation 6-7. Consequently, the final estimate 
of the rate constants (k1 and k-1) were used to calculate keq for hemoglobin and albumin. As 
shown in Table 6-4, the estimated keq were similar to their corresponding kobs values.  
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Table  6-1. Estimation of A and B for Hb-5-HMF adduct using Equation 6-11. 
Time 
(hr) 
Free 5-HMF, 
[5-HMF](t) 
(μM) 
Adduct 
Formed 
[Adduct](t) 
(μM) 
Free Hb, 
[Hb](t) 
(μM) 
“A” 
(KA*[Hb](t)       
*[5-HMF](t)) -
[Adduct](t) 
“B” 
∆[5-HMF](t)/ 
∆t 
(μM/hr) 
0 60.43 0 217.2  
0.4 58.75 1.68 215.5 47.1 4.59 
1.2 55.53 4.90 210.6 43.7 3.86 
3.0 49.03 11.4 199.2 37.0 3.75 
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Figure  6-13. Initial estimate of k-1 for 5-HMF binding to hemoglobin using Equation 6-11. 
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Table  6-2. Estimation of A and B for HSA-5-HMF adduct using Equation 6-11. 
Time 
(hr) 
Free 5-HMF, 
[5-HMF](t) 
(μM) 
Adduct 
Formed 
[Adduct](t) 
(μM) 
Free HSA, 
[HSA](t) 
(μM) 
“A” 
(KA*[HSA](t)       
*[5-HMF](t)) -
[Adduct](t) 
“B” 
∆[5-HMF](t)/ 
∆t 
(μM/hr) 
0.2 19.7 0 63.0  
1.1 19.1 0.6 62.4 0.26 0.60 
2.8 18.9 0.8 61.6 -0.31 0.17 
5.2 18.7 1.0 60.5 -0.61 0.08 
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Figure  6-14. Initial estimate of k-1 for 5-HMF binding to albumin using Equation 6-11. 
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Table  6-3. Final model parameter estimates for 5-HMF with HSA and Hb. 
 k1 (M-1hr-1) k-1 (hr-1) KA  (M-1) KD (mM) 
Human Serum Albumin 523 ± 274 0.769 ± 0.502 680 ± 569 1.5 ± 1.2 
Human Hemoglobin 414 ± 35 0.107 ± 0.026 3879 ± 998 0.26 ± 0.07 
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Figure  6-15. Observed vs. fitted concentration of 5-HMF (7.9 µM). 
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Figure  6-16. Observed vs. fitted concentration of 5-HMF (63 µM). 
 
  
0.00000
0.00002
0.00004
0.00006
0.00008
0 2 4 6
5-
H
M
F 
Co
nc
en
tr
at
io
n 
(M
)
Time (hrs)
Observed Fitted
 307 
 
 
Figure  6-17. Observed vs. fitted concentration of 5-HMF (397 µM). 
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Figure  6-18. Apparent first-order decline in (Css-Ct) to estimate kobs for 5-HMF (7.9 μM) 
binding to hemoglobin (217 μM). 
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Figure  6-19. Apparent first-order decline in (Css-Ct) to estimate kobs for 5-HMF (19.8 μM) 
binding to human serum albumin (63 μM). 
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Table  6-4. Apparent first-order decline rate constant (SD) estimated from the data vs. that 
obtained from the model. 
 Data kobs  (hr-1) Model keq  (hr-1) 
Human Serum Albumin 0.66 (0.12) 0.80 (0.67) 
Human Hemoglobin 0.19 (0.09) 0.20 (0.05) 
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6.3.3 Concentration-Dependency Studies 
 
After correction for non-specific binding using the equations discussed in Section 6.2.5,   
specific binding to human hemoglobin and albumin was estimated, as summarized in Tables 6-5 
and 6-7. Specific binding to hemoglobin and albumin was plotted against the unbound 
concentration, as shown in Figures 6-20 and 6-21. The data points represent the average of the 
duplicate samples and the error bars represent their associated standard deviation (hard to 
visualize due to their small value). The parameter estimates of 5-HMF- hemoglobin and 5-HMF-
albumin binding models, are summarized in Tables 6-6 and 6-8 along with the standard error of 
these estimates.  
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Table  6-5. 5-HMF bound to hemoglobin at different initial 5-HMF concentrations ([Hb]= 217 µM, n=2 per concentration, mean 
(SD)). 
Nominal  
5-HMF 
Concentration 
(µM) 
Ultrafiltrate (UC) 
Concentration (µM) 
NSB  
(µM) 
Specific Binding 
(µM) 
Fraction 
Specifically 
Bound% 
Bound  
5-HMFmol/ 
Hbmol 
4.76 3.12 0.758 0.882 22.1 0.004 
14.3 8.72 (0.037) 1.85 3.70 (0.04) 29.8 0.017 (0.0002) 
42.8 11.7 (0.279) 8.80 22.3 (0.28) 65.6 0.103 (0.001) 
119 62.9 (0.983) 10.5 45.5 (0.98) 42.0 0.209 (0.005) 
357 224 (2.60) 29.1 104 (2.6) 31.8 0.480 (0.012) 
714 487 (1.34) 64.3 163 (1.3) 25.1 0.751 (0.006) 
5952 4170 1455 328 7.29 1.51 
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Figure  6-20. 5-HMF specific binding to human hemoglobin. 
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Table  6-6. Final parameter estimates of 5-HMF binding to hemoglobin (217 µM). 
Parameter 
Value (SE) 
Concentration (µM) Molar Ratio 
Bmax 370 (6.93) 1.7 (0.03) 
KD  (µM) 577 (32.0) 577 (32.0) 
r2 0.993 0.993 
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Table  6-7. Concentration-dependency of 5-HMF binding to human serum albumin. ([HSA]= 202 µM, n=2 per concentration, mean 
(SD)). 
Nominal 
5-HMF 
Concentration 
(µM) 
Ultrafiltrate (UC) 
Concentration 
(µM) 
NSB 
(µM) 
Specific Binding 
(µM) 
Fraction 
Specifically 
Bound% 
Bound  
5-HMFmol/ 
HSAmol 
12 8.8 (0.2) 1 2.9 (0.07) 32 0.014 (0.0003) 
37 33 (1) 2 1.7 (0.05) 5.0 0.008 (0.0003) 
74 66 (1) 4 3.7 (0.07) 5.6 0.018 (0.0003) 
222 177 (6) 12 33 (1.1) 19 0.17 (0.005) 
667 521 (52) 36 110 (11) 21 0.55 (0.05) 
2000 1588 (189) 107 306 (36) 19 1.5 (1.8) 
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Figure  6-21. 5-HMF specific binding to human serum albumin. 
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Table  6-8. Final parameter estimates of 5-HMF binding to human serum albumin (202 µM). 
 
 
  
Parameter 
Value (SE) 
Concentration (µM) Molar Ratio 
SB 0.197 (0.005) 0.001 (0.00002) 
Y0  (µM) -1.82 (3.37) -0.009 (0.016) 
r2 0.998 0.998 
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6.4 Discussion and Conclusions 
 
Under the experimental conditions of the binding experiments, 5-HMF was chemically 
stable at 37 °C for at least 30 hours – allowing the assessment of time-dependent binding. On the 
other hand, binding of 5-HMF to both proteins, namely Hb and HSA, showed the expected time 
dependency, reflecting the “transiently covalent” nature of this Schiff base binding reaction. The 
time-dependency studies showed that the binding of 5-HMF to its target site of action, Hb, was 
characterized by a time-dependent binding reaction with a high affinity and selectivity to Hb 
relative to HSA. Hb had over 5-fold higher equilibrium association constant for 5-HMF than that 
with human serum albumin, as shown in Table 6-3, indicating that 5-HMF is a high affinity 
substrate for Hb.  
Upon the comparison of the estimated rate constants with those estimated for glucose 
binding to hemoglobin (Higgins 1981), as shown in Table 6-9, 5-HMF has a faster rate constant 
of adduct formation (k1= 0.9 M-1hr-1 for glucose vs. 414 M-1hr-1 for 5-HMF ). In contrast, 5-HMF 
has a slower rate constant of the adduct degradation (k-1= 0.33 hr-1 for glucose vs. 0.11 hr-1 for 5-
HMF) and this coincides with the duration of action shown in Figure 1-8, Chapter 1. In addition, 
the affinity constant (KD) for 5-HMF binding to Hb is 10-fold higher than that observed for a 
typical aromatic aldehyde (Zaugg 1977), listed in Table 6-9, which is consistent with the fact that 
5-HMF has a better in-vitro pharmacological activity when compared to other structurally-
related aromatic aldehydes (Safo 2004). Besides, because 5-HMF has a faster rate constant of 
Hb-adduct formation than glucose, while it has a slower rate constant of Hb-adduct degradation, 
5-HMF has more than a 1,000-fold larger association constant, i.e., much higher affinity for Hb 
than glucose. Again, this is consistent with the observation that aromatic aldehydes (similar to 5-
HMF) have higher affinity than aliphatic aldehydes (glucose) (Zaugg 1977).  
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At a relatively low concentrations of human serum albumin, 63 µM, only a small fraction 
of 5-HMF was bound to serum albumin (approximately 20% of total binding). On the other 
hand, non-specific binding was quite high (approx. 80% of total binding), which may have 
prevented better characterization of HSA binding to 5-HMF. However, at a higher human serum 
albumin concentration, 202 µM, binding to human serum albumin showed a non-saturable 
pattern. Abdulmalik et al, implied that 5-HMF does not have significant binding to plasma 
proteins (Abdulmalik 2005). This might be due to the fact that serum albumin has a lower 
physiological blood concentration compared to hemoglobin (0.6 vs. 2.3-5.3 mM), which makes 
hemoglobin have higher capacity of binding than that of serum albumin in addition to its higher 
affinity. 
 Both time-dependency and (steady-state) concentration-dependency studies resulted in 
similar affinity (KD) estimates for Hb (0.26 mM vs. 0.59 mM). In addition, the Bmax value for Hb 
is consistent with approximately two moles of 5-HMF bound per mole of hemoglobin. This 
observation was expected, since each Hb molecule has two 5-HMF binding sites, one at each α-
chain of the hemoglobin molecule, i.e., α-valine (Safo 2004). 
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Table  6-9. Hemoglobin binding rate constants (SD) to different substrates. 
Substrate k1 (M-1hr-1) k-1 (hr-1) KD (mM) Reference  
Aliphatic aldehydes 
(Typical) 
 
14 (Zaugg 1977) 
Aromatic aldehydes 
(Typical) 5 (Zaugg 1977) 
Glucose 0.9 (0.2) 0.33 (0.04) 367 (91) (Higgins 1981) 
5-HMF 414 (35) 0.11 (0.03) 0.26 (0.07) 
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As shown in Table 6-4, the predicted first rate-order equilibrium constants for 5-HMF 
binding with Hb and HSA, (keq) were 102% and 121% of the observed constants (kobs), 
respectively, obtained from the decline in the concentration of the adduct to be formed (Css-Ct).  
A good estimate of keq, is expected if the initial Hb concentration is much higher than 5-HMF 
concentration; thus, the free Hb concentration remains relatively constant during the 
binding/unbinding reaction. 
At the physiological Hb concentration in whole blood, the presumed effective 
concentrations of 5-HMF (i.e., 1-2 mM, exceeding KD, i.e., beginning to saturate Hb binding 
sites) are expected to show fast association with, but slow dissociation from Hb, resulting in 
prolonged persistence of the Hb adduct (t1/2eq of 0.7 hrs). Thus, this unique drug-receptor 
interaction may lead to a prolonged in-vivo PD effect. 
Overall, these in-vitro findings are consistent with the results from an in-vivo PK study in 
transgenic mice, which received single, oral 5-HMF doses of 50 to 200 mg/kg (Abdulmalik 
2005). There was an initial lag-time observed between in-vivo plasma concentrations of 5-HMF 
and the “modified” Hb (adduct) concentrations, semi-quantitatively determined by Hb gel 
electrophoresis – consistent with the time-dependent binding of 5-HMF to hemoglobin, as shown 
in Figure 1-10, Chapter 1.Moreover, the results of an accompanying in-vitro study, assessing 
hypoxia-induced RBC sickling after 1 hour pre-incubation and immediate addition of 5-HMF (5 
mM) demonstrated that pre-incubation enhanced the antisickling effects of 5-HMF relative to 
direct addition, as shown in Figure 1-8, Chapter 1 - consistent with time depending binding and 
an equilibration half-life of 0.7 hours, as reported above.  
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CHAPTER 7 
7  
IN-VITRO DISPOSITION IN HUMAN BLOOD 
 
 
7.1 Introduction  
 
As discussed in Chapters 5 and 6, 5-HMF is subject to human hemoglobin and serum 
albumin binding, as well as being metabolized in human RBCs. Consequently, studies were 
carried-out to investigate 5-HMF concentration changes in the presence of blood proteins and 
enzymes at their physiological concentration. The studies were performed in RBC hemolysate 
suspension and in whole blood. Models were built combining both binding and metabolism 
processes to examine their ability in predicting the free concentration of 5-HMF and the fraction 
bound to hemoglobin, its site of action. In addition, studies were designed to verify whether the 
validated HPLC method in Chapter 3 is measuring the total concentration of 5-HMF (bound and 
unbound fractions) or only the free (unbound) fraction. Moreover, this project aimed to explore 
the sensitivity of 5-HMF metabolism to inhibitors in order to estimate the contribution of RBC 
metabolism to the observed 5-HMF disappearance rate in human blood.  
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7.2 Methods 
 
7.2.1 Materials and Reagents 
 
1. Milli-Q® Water (Virginia Commonwealth University, PK/PD Laboratory). 
2. 4-Methylpyrazole (4-MP) Solution: 
- 4-MP, 99% (Sigma-Aldrich, Milwaukee, WI).  
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory). 
3. Tetraethylthiuram Disulfide (Disulfiram) Solution: 
- Disulfiram, purum 97% (Sigma-Aldrich, Milwaukee, WI).  
- BD Gentest™ TRIS buffer 0.5 M, pH 7.5 (BD Bioscience, San Jose, CA). 
4. Human Blood: 
From a single female caucasian individual. 
5. Phosphate-Buffered Saline (PBS), pH 7.4: 
- Phosphate-buffered saline (PBS) tablets, pH 7.4 (Sigma, St. Louis, MO). 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory). 
6. Phosphate-Buffered Saline (PBS), pH 7.4: 
-Sodium phosphate dibasic (Sigma, St. Louis, MO). 
-Potassium phosphate (Sigma, St. Louis, MO). 
-Sodium chloride (Sigma, St. Louis, MO). 
-Potassium chloride (Sigma, St. Louis, MO).  
-Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory). 
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7. 5-Hydroxymethyl-2-furfural (5-HMF) Solution: 
- 5-Hydroxymethyl-2-furfural (Sigma, St. Louis, MO). 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory). 
8. Mobile Phase for 5-HMF Assay Method in Plasma and RBCs: 
- 93.5% Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory). 
- 6.2% Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ). 
- 1% Acetic acid glacial, > 99% (Sigma, Milwaukee, WI). 
- 0.3 % Tetrahydrofuran HPLC grade (Burdick and Jackson, Morristown, NJ). 
9. SPE Conditioning: 
- Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ). 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory). 
10. SPE Washing Solution: Phosphate-buffered Saline (PBS), pH 7.4: 
- Phosphate-buffered saline (PBS) tablets, pH 7.4 (Sigma, St. Louis, MO). 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory). 
11. SPE Eluting Solution: 50% Methanol: 
- Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ). 
- Milli-Q® water (Virginia Commonwealth University, PK/PD Laboratory). 
 
 
 
  
 325 
 
7.2.2 Equipment 
 
1. 25-µl, 50-µl, and 250-µl positive displacement pipettes and corresponding pipette tips 
(Microman, Rainin Instruments, Oakland, CA). 
2. 10-µl, 100-µl, and 1000-µl VWR pipettes and corresponding pipette tips (VWR, West 
Chester, PA). 
3. 0.5-5 ml Finnpipette (Thermo Scientific, Waltham, MA). 
4. Vortex (Vortex-Genie, VWR, West Chester, PA). 
5. Eppendorf vials (VWR, West Chester, PA).  
6. Sonicator (American Brand Products C6450-11, VWR, West Chester, PA).  
7. pH meter (Corning, Glendale, AZ). 
8. Balance (Fisher Scientific A 250, Pittsburgh, PA). 
9. Centrifuge 5804-R (Eppendorf, Hauppauge, NY). 
10. Amicon® Ultra-4 centrifugal filter units with Ultracel-10 membrane (Millipore, Billerica, 
MA). 
11. Oasis HLB cartridge, 1 cc/ 30 mg (Waters). 
12. Glass vials with caps, 1 ml (Waters, Milford, MA). 
13. UV detector (Shimadzu, AV-10, Columbia, MA).  
14. C18 Zorbax Rx column, 4.6 X 150 mm (Agilent, Santa Clara, CA). 
15. C18 guard column, 12.5 mm x 4.6 mm (Agilent, Santa Clara, CA). 
16. 717 plus autosampler (Waters, Milford, MA). 
17. 600 Multisolvent controller (Waters, Milford, MA). 
18. Empower 2 software (Waters, Milford, MA). 
19. Forma Scientific incubator.    
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7.2.3 Solution Preparation 
 
– Mobile Phase for 5-HMF Assay Method in Plasma and RBCs (1 L) 
935 ml water, 62 ml methanol, 10 ml acetic acid glacial, and 3 ml     
tetrahydrofuran were mixed to prepare the mobile phase. 
 
– 5-Hydroxymethyl-2-furfural Solution (5-HMF) Stock Solution (381 mM) 
48 mg of 5-hydroxymethyl-2-furfural, M.W.: 126.11 Da, was dissolved in 1 ml of 
PBS.  
 
– Phosphate-buffered Saline (PBS), pH 7.4 
One tablet of phosphate-buffered saline was added to 200 ml of water. 
 
– SPE Eluting Solution: 50% Methanol 
25 ml of methanol was mixed with 25 ml of water. 
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7.2.4 Procedures 
 
Human blood was collected from a healthy female volunteer using heparinized vacutainer. 
 
7.2.4.1 Total vs Free 5-HMF Concentration in Hemolyzed RBCs.  
 
After centrifuging the whole blood, plasma layer was removed and RBCs were washed 
with PBS. RBCs were re-suspended in Milli-Q® water (0.4 RBCs: 0.6 water) and hemolyzed by 
centrifugation. Concentrated PBS mixture was added to the hemolyzed RBCs together with 5-
HMF to achieve a concentration of 2 mM of 5-HMF.  The suspension was then incubated at 
36.5±1 °C for approximately 3 hours. Two sets, each with duplicate samples, taken at different 
time points, were analyzed by the validated HPLC method after extracting the samples using 
either solid phase extraction as described in Chapter 3 or by ultrafiltration using Amicon® Ultra. 
 
7.2.4.2 5-HMF Metabolism in Hemolyzed RBCs.  
 
Hemolyzed RBCs were processed using the same approach stated above. However, water 
was replaced by 4-methylpyrazole and disulfiram solution in Milli-Q® water (0.4 RBCs: 0.6 
inhibitors solution). The final concentrations of 4-methylpyrazole and disulfiram were 375 µM 
and 40.5 µM, respectively. After incubation for 30 minutes, 5-HMF was added to the mixture to 
achieve a concentration of 2 mM and the suspension was incubated at 36.5±1 °C for 
approximately 3 hours.  Duplicate samples, taken at different time points, were analyzed by the 
validated HPLC method using solid phase extraction as described in Chapter 3.  
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7.2.4.3 5-HMF in Whole Blood 
 
5-HMF was incubated in whole blood and RBC suspension at concentrations of 2 mM 
and 0.3 mM at 36.5 ± 1 °C over 2 hours. Duplicate samples, taken at different time points, were 
analyzed by the validated HPLC method after separating plasma and RBCs using centrifugation 
for 12 minutes at 3500 rpm, 3 °C.  
 
 
7.2.5 Data Analysis and Modeling Assumptions 
 
The first-order rate constants (k) for the disappearance of 5-HMF in different studies 
were obtained as the negative value of the slope when the natural logarithmic values of 5-HMF 
concentrations were plotted vs time. Consequently, the half-life (t1/2) was estimated using 
Equation 7-1: 
 
t1/2 = 0.693k … … … … … … … … … … … … … … … … … … … … … … … … … … … … … Equation 7 − 1  
These rate constants and half-lives were compared to: 
1. Verify the fraction of 5-HMF measured by the validated HPLC method, where the 
samples were extracted using solid phase extraction. Only the unbound fraction of    
5-HMF was assumed to survive sample extraction using ultrafiltation.  
2. Investigate the sensitivity of 5-HMF metabolism in RBCs to inhibition by disulfiram 
and 4-methylpyrazole. 
3. Explore any difference in 5-HMF decline-rate between plasma and RBCs.  
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In the non-linear regression carried-out for 5-HMF disappearance in human blood, the 
concentration of hemoglobin was fixed, considering that the average hematocrit in females is 
42% and is associated with an Hb concentration of 14 g/dl (Dixon 1997) (Rhoades 1996). In this 
study, the hematocrit was adjusted to 40% and the Hb concentration was assumed to be 13.3 
g/dl. Having a molecular weight of 64,677 g/mol, the concentration of Hb in this study was 
equivalent to 2.06 mM.   
The intrinsic clearance was estimated in Chapter 5 as 0.35 ml/min/ml RBCs, which is 
equivalent to 21 ml/hr/ml RBCs. In this part of the research project, studies were carried-out in 
whole blood or in RBCs suspension. Hence, the RBCs intrinsic clearance was diluted with PBS 
or with plasma. With the RBCs accounting for approximately 40% in these matrices, the 
metabolic activity of the enzymes was decreased by a factor of 2.5.  Accounting for this dilution 
factor, the intrinsic clearance was scaled by the volume of RBCs in the body resulting in a 
metabolic rate constant of 8.3 hr-1, which was used as an initial model parameter. The data of the 
ultrafiltrate of the RBCs hemolysate was selected for modeling purposes since it is believed to 
reflect the free fraction of 5-HMF. 
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7.2.6 Modeling  
 
In blood, 5-HMF is subject to simultaneous hemoglobin binding and enzyme metabolism 
in RBCs, as shown in Figure 7-1. Considering these processes, Equation 7-2 was used to 
simulate the change of free 5-HMF in RBCs over time as follows: 
 d[5 − HMF]dt = 
 
−kmet  [5HMF](t) + k−1 × [Adduct](t) − k1 × [5HMF](t) × [Hb](t) … … … Equation 7 − 2 
 
 
where [5HMF](t): the concentration of free 5-HMF at time (t)  [Protein](t): the concentration of free protein at time (t) [Adduct](t): the concentration of the adduct between 5-HMF and the protein at time (t)  kmet: the metabolic rate constant 
 
Moreover, 5-HMF might be prone to binding to RBCs membrane. Hence, a factor was 
added to account for this binding in the initial concentration of 5-HMF available for hemoglobin 
binding and metabolism in RBCs. This value was estimated using the difference between the 
nominal and the observed initial 5-HMF concentration. The simulation was performed assuming 
four scenarios: 
Scenario (1): 5-HMF binding to hemoglobin is the sole contributor to 5-HMF 
disappearance over time.  
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Scenario (2): Concurrent metabolism and binding of 5-HMF contribute to 5-HMF 
disappearance over time.  
Scenario (3):  In the third scenario, the metabolic rate constant was re-estimated since it is 
assumed to involve higher inter-individual variability than hemoglobin 
binding.  
Scenario (4):  In whole blood: in addition to hemoglobin binding and RBC metabolism, 
5-HMF can bind to serum albumin. Consequently, a second term in the 
initial conditions of the model was added to account for human serum 
albumin binding. 
The parameters used in the simulation are summarized in Table 7-1. The model 
parameters were used in the simulations of 5-HMF free concentration in RBC hemolysate 
suspension and whole blood using non-linear regression of Equation 7-2. Scientist non-linear 
regression models are shown in Appendix C.  
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Figure  7-1. Concurrent 5-HMF binding and metabolism in blood.  
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Table  7-1. Model parameters. 
Parameter Scenario (1) Scenario (2) Scenario (3) Scenario (4) 
HB0 (M) 0.00206  0.00206 0.00206 0.00206  
HMF0 (M) 0.002  0.002 0.002 0.002, 0.0003 
k1 (M-1hr-1) 414  414 414 414 
k-1 (hr-1) 0.107 0.107 0.107 0.107 
kmet (hr-1) 0  8.3  0.174 0.174 
khsa  0 0 0 0.2 
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7.3 Results 
 
The concentrations of 5-HMF over time in the RBC hemolysates, which were analyzed 
using solid phase extraction and by ultrafiltration, are shown in Figure 7-2. In addition, the 
concentrations of 5-HMF in the presence of inhibitors, are shown in Figure 7-3. The 
concentration of 5-HMF in the samples prepared by ultrafiltraton and that prepared by solid 
phase extraction were found to be similar. The same was observed when 5-HMF concentration 
was compared in the presence of inhibitors and in their absence. In addition, the concentration of 
5-HMF over time when incubated in whole blood is shown in Figures 7-4 and 7-5. For all of 
these studies, the first-order disappearance rate constant and the half-life are summarized in 
Table 6-2. 
  The simulation for hemoglobin binding using the physiological concentration of 
hemoglobin is shown in Figure 7-7. When the metabolism process was added to the process, the 
fitted line underestimated the observed concentrations as shown in Figure 7-8. Upon optimizing 
the metabolic rate constant, the kmet was estimated as 0.174 ± 0.047 hr-1 and the fit is shown in 
Figure 7-9.  
 When the optimized metabolic and binding parameters were used in the simulation of 5-
HMF in whole blood, it fitted better to the data of higher 5-HMF concentration, 2 mM, than that 
of the lower concentration, 0.3 mM, as demonstrated in Figures 7-10 and 7-11.  
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Figure  7-2. Decline in 5-HMF concentration (2 mM) in RBC hemolysate measured after SPE or ultrafiltration. 
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Figure  7-3. Decline in 5-HMF concentration (2 mM) in RBC hemolysate in the presence or absence of inhibitors. 
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Figure  7-4. Decline in 5-HMF concentration (2 mM) in whole blood.  
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Figure  7-5. Decline in 5-HMF concentration (0.3 mM) in whole blood.  
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Figure  7-6. Decline in 5-HMF concentration (2 mM) in RBCs of whole blood and RBCs hemolysate suspension.  
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Table  7-2. Disappearance rate constants (SD) and t1/2 of 5-HMF in various matrices. 
Matrix Sample Preparation Presence of Inhibitors 
k (hr-1) 
 t1/2 (hour) r
2 
Hemolysate 
Suspension (2 mM) 
Ultrafiltration  
Absent 
0.67 (0.02) 1.0 0.99 
SPE 
0.76 (0.04) 0.9 0.99 
Present 0.72 (0.03) 1.0 0.99 
RBCs of Whole 
Blood (2 mM) 
Absent 
0.58 (0.17) 1.2 0.80 
RBCs of Whole 
Blood (0.3 mM) 2.8 (0.17) 0.3 0.99 
Plasma (2 mM) 1.0 (0.10) 0.7 0.97 
Plasma (0.3 mM) 2.9 (0.38) 0.2 0.95 
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Figure  7-7. Simulated 5-HMF free concentration in RBCs hemolysate using Scenario (1) with no metabolism included. 
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Figure  7-8. Simulated 5-HMF free concentration in RBCs hemolysate using Scenario (2) including kmet= 8.3 hr-1. 
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Figure  7-9. Simulated 5-HMF free concentration in RBCs hemolysate using Scenario (3) including kmet= 0.174 hr-1.
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Figure  7-10. Simulated 5-HMF free concentration (2 mM) in RBCs of whole blood using Scenario (4) including HSA binding.  
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Figure  7-11. Simulated 5-HMF free concentration (0.3 mM) in RBCs of whole blood using Scenario (4) including HSA binding. 
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7.4 Discussion and Conclusions 
 
Due to the small difference in the concentration between 5-HMF in the ultrafiltrate and 5-
HMF exposed to solid phase extraction, it seems that the extraction method developed in Chapter 
3 is unable to dissociate the bound 5-HMF from proteins and that HPLC determination reflects 
mainly the free, i.e. the unbound, fraction of 5-HMF. This is further supported by the similar rate 
constants for 5-HMF decline, shown in Table 7-2. In addition, there was no significant difference 
in 5-HMF concentrations (or the determined decline rate constants) measured in the presence of 
inhibitory concentrations of the inhibitors, as discussed in Chapter 4, and 5-HMF concentrations 
measured in their absence. This indicates the absence of significant metabolic activities that are 
sensitive to these inhibitors. The metabolic enzymes might have their activity decreased or 
diminished during the experiment.  
The rate constant for 5-HMF decline in the plasma was higher than that for 5-HMF 
decline in the RBCs. This might be attributed to a higher rate of distribution of 5-HMF from the 
plasma into the RBCs compartment in comparison to the redistribution rate. Higher capacity of 
RBCs for 5-HMF versus that of the plasma may justify this difference in the distribution and 
redistribution rates.  
However, the higher rate constant for 5-HMF decline with lower initial 5-HMF 
concentration was not expected. At the concentration of hemoglobin employed in these studies, 
saturation of its binding sites is not anticipated at 2 mM. On the other hand, binding of 5-HMF to 
blood components (other than hemoglobin) is assumed to be instantaneous, hence, it contributes 
only to the initial decline of 5-HMF but not to the decline of 5-HMF over time. This might not be 
true with low concentrations of 5-HMF that can show some time-dependency in its 5-HMF 
 347 
 
binding and increase the overall observed rate of 5-HMF decline over time.  This coincides with 
what is demonstrated in Figure 7-12, where the model initially underpredicts the free 5-HMF 
concentration and overpredict it later in the experiment for the 0.3 mM 5-HMF concentration.  
The simulations showed that 5-HMF binding to hemoglobin alone overestimated the free 
concentration of 5-HMF in RBCs hemolysate suspension. This might be attributed to 
modifications in the binding kinetics in the physiological setting that is affected by the unique 
environment of RBCs, conformational changes of hemoglobin, and/or 5-HMF binding to other 
proteins, such as RBC membranes.  
 On the other hand, the 5-HMF free concentration was underpredicted in the simulations 
including concurrent RBC metabolism. The two simulation scenarios indicated that 5-HMF 
metabolism may have existed in the matrix, however, not to the extent observed in the metabolic 
studies discussed in Chapter 5. Here, the optimized metabolic rate constant was significantly 
lower than that estimated from the RBC metabolism studies in Chapter 5. This observation 
coincides with the absence of inhibitor activity due to the loss of enzyme viability during the 
study. In addition, the metabolic studies in Chapter 5 were performed in a blood pooled from 
different individuals, while in this study the blood was taken from a single Caucasian female. 
Consequently, the activity of the enzyme might be different in these two studies. This is further 
supported by Table 7-3. As demonstrated in this table, the activity of ALDH enzyme in RBCs 
varies between individual as much as 10 fold. In addition, as stated in Chapter 1, 1 out of 16 
persons had a deficiency in RBCs ALDH enzyme. Hence, this may have contributed to the 
failure of observing significant metabolism in the current study. Moreover, Equation 7-2 assumes 
that the activity of enzymes remains fully functional over the incubation time, which might not 
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be the case. Furthermore, the cofactor for the metabolic enzymes might have diminished during 
the period of the experiment. 
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Table  7-3. Erythrocyte ALDH activity in mU/ml (Goedde 1983) 
 Number of Individuals 
Erythrocyte ALDH Activity 
(mU/ml) Healthy Controls Alcoholics 
Psychiatric Patients 
(Non-Alcoholic) 
0.3 9 41 6 
0.9 29 17 3 
1.5 23 6 13 
2.1 5 1 9 
2.7 1 0 3 
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As shown in Figures 7-10 and 7-11, the fit using the optimized parameters matches 
the observed data for the 2 mM of 5-HMF incubated in whole blood, which validates the 
optimized model parameter estimates. On the other hand, the fit was less perfect for the 0.3 
mM concentration of 5-HMF incubated in whole blood. This discrepancy was explored 
above through the discussion of the rate constant for 5-HMF decline over time.  
The inclusion of albumin binding in the initial conditions of the model assumes that 
a steady-state (equilibrium) was instantaneous. While this might be valid in the case of 2 
mM, this might not be the case with lower concentrations such as 0.3 mM. In addition, in 
the model, the factor correcting for RBCs membrane binding was estimated at 2 mM 
concentration rather than at 0.3 mM.   
Overall, the built model demonstrated a persistence of the adduct concentration in 
the RBCs in comparison to the free concentration of 5-HMF in plasma. Consequently, the 
plasma concentration of 5-HMF does not reflect the concentration of 5-HMF in its 
biophase in contrast to the assumption made to most of the drugs in the market. Due to the 
time-dependency in 5-HMF binding to hemoglobin, there is a lag time between the peak 
plasma concentration and the peak adduct concentration. In addition, the covalent bond in 
the adduct will hinder the clearance of the bound 5-HMF leading to the persistence of the 
pharmacodynamics effects of 5-HMF.    
Since binding and metabolic parameters were not obtained in an in-vivo settings, 
the following factors may contribute to a different behavior of 5-HMF when compared to 
in-vitro studies: 
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1. The unique environment of RBCs, including the presence of organic phosphate 2,3-
diphosphoglycerate (2,3-DG), cationic, and anionic species might affect the 
binding and the metabolic reactions. It was reported that the presence of 2,3-DG, 
CO, CO2, and O2 affected the rate constants for the Schiff base in HbA1c Invalid 
source specified..  
2. Inter-individual variation in hemoglobin concentration.  
3. Genetic variation in the metabolic enzymes.  
4. Sample preparation used in the analysis might disturb the equilibrium of binding 
and metabolism.    
5. Conformational changes of hemoglobin upon oxygenation and deoxygenation, 
which makes the binding site for 5-HMF more or less accessible Invalid source 
specified.. 
6. 5-HMF might be bound to other proteins. Lens crystalline, peripheral nerve 
proteins, and erythrocytes membranes are examples of proteins that are susceptible 
to Schiff base adduct formation with aldehydes Invalid source specified. (Bucala 
1982).  
7. The cofactor steady-state concentration in the physiological setting might be 
different from that used in the conducted-studies.  
Nevertheless, the parameters obtained from the performed studies were able to 
describe 5-HMF behavior in blood. Accordingly, 5-HMF free concentration and that bound 
to its site of action can be acceptably predicted using Equation 7-2.  
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In a human body, 5-HMF is exposed to metabolism by the liver and RBCs. This 
metabolism is not expected to undergo saturation since the determined Km value in hepatic 
cytosol (218 mM) was much higher than the proposed therapeutic concentration (1-2 mM). 
Likewise, the metabolism in the RBCs was not saturated with 5-HMF concentration up to 
142 mM. Consequently, non-linear PK of 5-HMF in the plasma are not expected due to 5-
HMF metabolism. On the other hand, 5-HMF binding to hemoglobin is saturable due to 
the finite binding sites to 5-HMF, which are equivalent to the concentration of Hemoglobin 
dimmers (4.6 mM in blood). Consequently, 5-HMF binding to hemoglobin result in non-
linear PK of 5-HMF in plasma (supra-propotional) at high concentration of 5-HMF. 
  
 353 
 
 
 
 
 
 
 
CHAPTER 8 
8  
OVERALL RESULTS AND CONCLUSIONS 
 
 
In this research project, the available literature on the physiochemical properties, 
pharmacokinetics, and pharmacodynamics of 5-HMF was reviewed. 5-HMF is found 
constitutively in food and is an adulteration product in honey, beer, fruit juice, and glucose 
infusion solutions (Janzowski 2000) (Godfrey 1999). Although 5-HMF was administered 
orally to human in three clinical studies, its PK properties were not described (Prior 2006) 
(Matzi 2007) (M. P. Murkovic 2006). In different species, 5-HMF was shown to be 
extensively metabolized and the metabolites were mainly excreted in urine (Godfrey 1999) 
(Germond 1987). On the other hand, gaps were identified in human pharmacokinetics. 
Consequently, this research project was carried out to explore the differences in 5-HMF 
pharmacokinetics between and among species and to estimate its oral bioavailability.  
An HPLC assay method for the quantitation of 5-HMF in neat solution, human 
plasma, and human RBCs was developed and validated. 5-HMF was detected using UV 
absorbance at 285 nm. The mobile phase was mainly aqueous with more than 90% water 
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in addition to acetic acid, methanol, and tetrahydrofuran. The mobile phase had a flow rate 
of 0.75 ml/minute through C18 guard and analytical columns.  
The experimental conditions needed to investigate 5-HMF metabolism in human 
hepatic cytosol were optimized to determine the metabolic pathways of the oxidative 
metabolism of 5-HMF. NADH production was monitored at 340 nm as an indicator of 5-
HMF oxidative metabolism. In human hepatic cytosol, selective substrates validated the 
presence of active ALDH and ADH enzymes. In addition, selective inhibitors 
demonstrated that 5-HMF was metabolized by ALDH enzyme and to a lesser extent by 
ADH enzyme in human hepatic cytosol.  
In addition to human hepatic cytosol, oxidative metabolism was also demonstrated 
in mouse, rat, and dog hepatic cytosol and was described by Michaelis Menten kinetics. 
The in-vitro metabolic capacities (per mg protein of hepatic cytosol) were relatively similar 
in mouse, rat, and dog hepatic cytosol. On the other hand, affinities were more variable - 
with the highest affinity observed in the dogs and the lowest in humans. Consequently, 
quantitative differences were predicted in the intrinsic clearance (per kg body weight) 
among species with the lowest intrinsic clearance in humans.  
In-vitro-in-vivo extrapolations of 5-HMF metabolism in mouse, rat, dog, and 
human hepatic cytosol were performed and compared with published data. In all animal 
species studied, 5-HMF is predicted to be subject to low hepatic extraction and clearance 
and show high oral bioavailability in-vivo. In-vivo systemic exposure predictions using the 
respective in-vitro-in-vivo extrapolations parameter estimates in mouse and dog were 
reasonable and were within two-fold of those reported for in-vivo exposures. On the other 
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hand, the in-vitro-in-vivo extrapolated t1/2 for humans was more than 30-fold longer than 
the reported plasma t1/2 of the (presumed) primary metabolite, HMFA, after oral 
administration of 5-HMF. This major discrepancy implied the involvement of extrahepatic 
metabolism of 5-HMF in humans.  
In-vitro 5-HMF metabolism was observed in human RBCs. Nevertheless, 
metabolic saturation was not achieved in that system due to experimental limitations. The 
intrinsic clearance was determined from the slope of the velocities vs. the concentration. 
The failure to observe NAD+-dependent oxidation of ethanol and 5-HMF inhibition by 4-
methylpyrazole indicated the absence of ADH enzyme in RBCs.  5-HMF clearance by 
RBCs, estimated through in-vitro-in-vivo extrapolations, was added to the hepatic 
clearance, estimated previously from human hepatic cytosol, resulting in a total 5-HMF 
clearance in human. The in-vitro-in-vivo extrapolated half-life was similar to the reported 
plasma t1/2 of the (presumed) primary metabolite, HMFA, after oral administration of 5-
HMF. This resolved the discrepancy observed in human hepatic cytosol studies.  
Time-dependency was observed in 5-HMF binding to human hemoglobin and to a 
lower extent in 5-HMF binding to serum albumin. The kinetics of this binding indicated a 
fast binding reaction rate with a slow dissociation rate. When 5-HMF binding to 
hemoglobin was compared to glucose binding to hemoglobin, 5-HMF had a faster rate 
constant of Hb-adduct formation than glucose, while it had a slower rate constant of Hb-
adduct degradation. At physiological Hb concentrations in whole blood, 5-HMF is 
expected to show fast association with, but slow dissociation from Hb, resulting in 
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prolonged persistence of the Hb adduct (t1/2eq of 0.7 hrs). Thus, this unique drug-receptor 
interaction may lead to a prolonged in-vivo PD effect. 
When the steady-state concentration-dependent kinetics were investigated, 5-HMF 
showed saturable binding to human hemoglobin and non-saturable binding to serum 
albumin. In the physiological environment, the serum albumin concentration in blood is 
lower than hemoglobin, which makes hemoglobin have a higher capacity and affinity of 
binding to 5-HMF than serum albumin. 
A PK model that combined both hemoglobin and serum albumin binding together 
with RBCs metabolism of 5-HMF to describe its disposition in blood was developed. The 
fit using the optimized parameters matched the observed data for the 2 mM of 5-HMF 
incubated in whole blood, validating by that the optimized model parameters. Accordingly, 
5-HMF free concentration and that bound to its site of action can be acceptably predicted 
using the developed PK model. In addition, the model demonstrated a persistence of the 
adduct concentration in the RBCs in comparison to the free concentration of 5-HMF in 
plasma. Consequently, the plasma concentration of 5-HMF does not reflect the 
concentration of 5-HMF in its biophase due to the time-dependency in 5-HMF binding to 
hemoglobin and the covalent bond in the adduct leading to the persistence of the 
pharmacodynamics effects of 5-HMF.    
Nevertheless, since binding and metabolic studies were not carried-out in an in-vivo 
setting, a discrepancy might be observed in the behavior of 5-HMF in-vivo when compared 
to in-vitro studies findings. 
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As a conclusion, 5-HMF was found to be a low-affinity ALDH/ADH substrate in 
hepatic cytosol and appears to be oxidatively metabolized primarily by ALDH in humans. 
Across animal species, 5-HMF is expected to be a low-hepatic-extraction-ratio drug with 
low hepatic first-pass effect and high oral bioavailability. In addition, 5-HMF is 
metabolized in humans RBCs (presumably by ALDH). The presumed effective 
concentrations of 5-HMF are expected to show fast association with, but slow dissociation 
from its drug target, hemoglobin, which may lead to a prolonged in-vivo PD effect. 
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DATA FOR CONCENTRATION DEPENDENCY KINETICS USING HEPATIC 
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Table A- 1. Ethanol concentration-dependency metabolic curve in human hepatic cytosol. 
Concentration (mM) Velocity (nmol/min/mg) 
0.000 0.112 (0.013) 
0.255 0.256 (0.008) 
0.510 0.363 (0.023) 
1.53 0.496 (0.032) 
3.06 0.613 (0.013) 
6.12 0.708 (0.031) 
12.2 0.736 (0.001) 
24.5 0.835 (0.042) 
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Table A- 2. DN concentration-dependency metabolic curve in human hepatic cytosol. 
Concentration (nM) Velocity (nmol/min/mg) 
0.000 0.083 (0.199) 
3.30 2.03 (0.110) 
8.25 2.07 (0.082) 
24.8 3.21 (1.94) 
66.0 3.46 (0.543) 
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Table A- 3. Acetaldehyde concentration-dependency metabolic curve in human hepatic 
cytosol. 
Concentration (µM) Velocity (nmol/min/mg) 
4.12 1.92 (0.309) 
12.4 2.39 (0.317) 
37.0 2.08 (0.424) 
111 2.62 (1.13) 
333 4.38 (2.24) 
33333 4.41 (0.603) 
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Table A- 4. 5-HMF concentration-dependency metabolic curve in human hepatic cytosol. 
Concentration (mM) Velocity (nmol/min/mg) 
0.000 1.86 (0.622) 
1.50 2.01 (0.155) 
3.01 2.40 (0.340) 
6.02 2.23 (0.050) 
12.0 3.78 (0.723) 
24.1 4.89 (0.297) 
48.1 7.90 (0.584) 
96.3 11.9 (0.918) 
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Table A- 5. 5-HMF concentration-dependency metabolic curve in mouse hepatic cytosol. 
Concentration (mM) Velocity (nmol/min/mg) 
0.000 0.815 (0.511) 
1.50 1.49 (0.284) 
3.01 2.02 (0.357) 
6.02 2.83 (1.13) 
12.0 4.48 (1.98) 
24.1 7.78 (1.12) 
48.1 9.54 (0.633) 
96.3 12.6 (2.83) 
 
 
  
 377 
 
Table A- 6. 5-HMF concentration-dependency metabolic curve in rat hepatic cytosol. 
Concentration (mM) Velocity (nmol/min/mg) 
6 2.49 (0.682) 
12 2.34 (0.788) 
16 7.07 (2.69) 
24 5.67 (0.637) 
32 7.23 (1.71) 
48 10.7 (2.59) 
64 13.8 (1.35) 
96 14.9 (2.13) 
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Table A- 7. 5-HMF concentration-dependency metabolic curve in dog hepatic cytosol. 
Concentration (mM) Velocity (nmol/min/mg) 
0.000 1.36 (1.25) 
1.50 2.28 (0.819) 
3.01 4.31(3.98) 
6.02 4.47 (3.10) 
12.0 4.02 (0.482) 
24.1 8.43 (1.97) 
48.1 9.90 (0.259) 
96.3 13.4 (1.61) 
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Table B- 1. Time-dependency of 5-HMF (0.0000079) binding to hemoglobin (0.000217 
M). 
 Time (hours) Unbound 5-HMF (M) 
0 0.0000065 
2.6 0.0000046 
6.8 0.0000043 
25 0.0000035 
30 0.0000037 
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Table B- 2. Time-dependency of 5-HMF (0.000063 M) binding to hemoglobin (0.000217 
M). 
Time (hours) Unbound 5-HMF  (M) 
0 0.000060 (0.00000002) 
0.40 0.000059 (0.00000043) 
1.2 0.000056 (0.00000025) 
3.0 0.000049 (0.00000005) 
3.9 0.000046 
6.5 0.000043 
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Table B- 3. Time-dependency of 5-HMF (0.000397 M) binding to hemoglobin (0.000217 
M). 
Time (hours) Unbound 5-HMF (M) 
0.03 0.000296 
1.0 0.000264 
3.0 0.000250 
6.0 0.000216 
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Table B- 4. Time-dependency of 5-HMF (0.000037 M) binding to albumin (0.000202 M). 
Time (hours) Unbound 5-HMF (M) 
0.07 0.000034 
0.58 0.000032 
1.3 0.000032 
3.0 0.000031 
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Table B- 5.Time-dependency of 5-HMF (0.0000079 M) binding to albumin (0.000063 M). 
Time (hours) Unbound 5-HMF (M) 
0.0 0.00000696 
2.6 0.00000691 
6.8 0.00000687 
24.9 0.00000691 
30.2 0.00000684 
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Table B- 6.Time-dependency of 5-HMF (0.0000198 M) binding to albumin (0.000063 M). 
Time (hours) Unbound 5-HMF  (M) 
0.0 0.0000197 
0.4 0.0000197 
1.1 0.0000191 
2.8 0.0000189 
5.2 0.0000187 
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Table B- 7. Time-dependency of 5-HMF (0.000150 M) binding to albumin (0.000063 M). 
Time (hours) Unbound 5-HMF  (M) 
0.03 0.000143 
0.97 0.00013 
3.0 0.000128 
6.1 0.000135 
8.7 0.000138 
25 0.000137 
 
 
  
 387 
 
 
 
 
 
 
 
 
APPENDIX C 
C.  
 
  
 
SCIENTIST MODELS 
 
 
  
 388 
 
// In-Vitro 5-HMF Binding to Hemoglobin 
//  Version 1.0 
//  JV, TO, July 29, 2009 
// 
//  Assuming bimolecular, reversible interaction 
//  concentrations in M 
//   k1 in M*hr-1 
//   k-1 in hr-1 
// 
IndVars: T 
DepVars: HMF, Hb, HbHMF 
Params: k1, kmin1, Hb0, HMF0 
// Diff Equations 
HMF'=kmin1*HbHMF-k1*Hb*HMF 
HbHMF'=k1*Hb*HMF-kmin1*HbHMF 
// Mass Balance 
Hb=Hb0-HbHMF 
// IC 
t=0 
HMF=HMF0 
HbHMF=0 
*** 
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// In-Vitro 5-HMF in RBC suspension 
//  Version 1.0 
//  JV, TO, Dec 27, 2009 
// 
//  Assuming bimolecular, reversible interaction 
//  concentrations in M 
//   k1 in M*hr-1 
//   k-1 in hr-1 
//   kmet in hr-1 
//   kmembrane in fraction  
// 
IndVars: T 
DepVars: HMF, Hb, HbHMF, HMFmet 
Params: k1, kmin1, Hb0, HMF0, kmet, kmembrane 
// Diff Equations 
HMF'=kmin1*HbHMF-k1*Hb*HMF-kmet*HMF 
HbHMF'=k1*Hb*HMF-kmin1*HbHMF 
HMFmet'=kmet*HMF 
// Mass Balance 
Hb=Hb0-HbHMF 
// IC 
t=0 
HMF=HMF0-kmembrane*HMF0 
HbHMF=0 
HMFmet=0 
*** 
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// In-Vitro 5-HMF in Blood 
//  Version 1.0 
//  JV, TO, Dec 28, 2009 
// 
//  Assuming bimolecular, reversible interaction 
//  concentrations in M 
//   k1 in M*hr-1 
//   k-1 in hr-1 
//   kmet in hr-1 
//   kmembrane and khsa in fraction 
// 
IndVars: T 
DepVars: HMF, Hb, HbHMF, HMFmet 
Params: k1, kmin1, Hb0, HMF0, kmet, kmembrane, khsa 
// Diff Equations 
HMF'=kmin1*HbHMF-k1*Hb*HMF-kmet*HMF 
HbHMF'=k1*Hb*HMF-kmin1*HbHMF 
HMFmet'=kmet*HMF 
// Mass Balance 
Hb=Hb0-HbHMF 
// IC 
t=0 
HMF=HMF0-kmembrane*HMF0-khsa*HMF0 
HbHMF=0 
HMFmet=0 
*** 
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